Processing 00000000.tx.1: Inhibitory Effects of Tenilsetam on the Maillard Reaction Hiroyuki Shoda, Satoshi Miyata, Bing-Fen Liu, Hiroyuki Yamada, Takeshi Ohara, Kotaro Suzuki, Munetada Oimomi and Masato Kasuga Second Department of Internal Medicine, Kobe University School of Medicine, Kobe, Japan Address all correspondence and requests for reprints to: Satoshi Miyata, M.D., Second Department of Internal Medicine, Kobe University School of Medicine, 75-1 Kusunoki-cho, Chuo-ku, Kobe 650, Japan. 

Phrase: "Inhibitory Effects of Tenilsetam"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   770   C1280500:effects [Qualitative Concept]
   737 E C2348382:Effect [Qualitative Concept]

Phrase: "on the Maillard Reaction Hiroyuki Shoda,"

Phrase: "Satoshi Miyata,"

Phrase: "Bing-Fen Liu,"

Phrase: "Hiroyuki Yamada,"

Phrase: "Takeshi Ohara,"

Phrase: "Kotaro Suzuki,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0998924:suzuki [Fish]

Phrase: "Munetada Oimomi"

Phrase: "and"

Phrase: "Masato Kasuga Second Department of Internal Medicine,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C1704729:Department [Organization]

Phrase: "Kobe University School of Medicine,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0036375:School [Manufactured Object,Organization]

Phrase: "Kobe,"

Phrase: "Japan"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0022341:Japan [Geographic Area]

Phrase: "Address"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0376649:Address [Intellectual Product]
  1000   C1442065:Address [Spatial Concept]

Phrase: "all correspondence"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0282413:Correspondence [Intellectual Product]

Phrase: "and"

Phrase: "requests for reprints"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   882   C0686900:Request for [Functional Concept]
           request
   790   C1272683:Request [Functional Concept]
   790   C1522634:Request [Intellectual Product]
   756   C3273171:Reprint [Intellectual Product]

Phrase: "to"

Phrase: ":"

Phrase: "Satoshi Miyata,"

Phrase: "M.D.,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1512018:M.D. [Intellectual Product]
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Second Department of Internal Medicine,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C1704729:Department [Organization]

Phrase: "Kobe University School of Medicine,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0036375:School [Manufactured Object,Organization]

Phrase: "75-1 Kusunoki-cho,"

Phrase: "Chuo-ku,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1532717:ku [Quantitative Concept]
   861   C1881335:kU [Quantitative Concept]

Phrase: "Kobe 650,"

Phrase: "Japan."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0022341:Japan [Geographic Area]
Processing 00000000.tx.2: E-mail: miyata{at}med.kobe-u.ac.jp  Abstract Top Abstract Introduction Materials and Methods Results Discussion References  It has been hypothesized that advanced Maillard reaction in vivo could explain some of the age- and diabetes-related changes. 

Phrase: "E-mail"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0013849:E-Mail [Intellectual Product]
  1000   C1705961:E-mail [Intellectual Product]
   861   C0024492:Mail [Manufactured Object]
   861   C1538057:MAIL [Gene or Genome]
   861   C1547565:Mail [Idea or Concept]

Phrase: ":"

Phrase: "miyata{at}med.kobe-u.ac.jp  Abstract Top Abstract Introduction Materials"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   787   C0520510:Materials [Substance]

Phrase: "and"

Phrase: "Methods Results Discussion"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0557061:Discussion [Therapeutic or Preventive Procedure]
   827   C2584313:Discussion [Social Behavior]

Phrase: "References"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "It"

Phrase: "has"

Phrase: "been"

Phrase: "hypothesized"

Phrase: "that advanced Maillard reaction"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   901   C0024495:Maillard Reaction [Natural Phenomenon or Process]
   827   C0443286:Reaction [Functional Concept]
   827   C1114821:Reaction [Clinical Attribute]

Phrase: "in vivo"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1515655:In Vivo [Spatial Concept]
           vivo

Phrase: "could"

Phrase: "explain"

Phrase: "some of the age-"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0001779:Age [Organism Attribute]
   770   C0205392:Some [Quantitative Concept]
   770   C3540770:Some [Intellectual Product]

Phrase: "and"

Phrase: "diabetes-related changes."
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   827   C0392747:changes [Functional Concept]
   827   C0443172:changes [Quantitative Concept]
   793 E C1705241:Change [Quantitative Concept]
Processing 00000000.tx.3: Furthermore, involvement of the Maillard reaction with Alzheimers disease has also been suggested, as advanced glycation end products, such as pyrraline and pentosidine, were demonstrated to localize in lesions of the disease. 

Phrase: "Furthermore,"

Phrase: "involvement of the Maillard reaction"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C1314939:Involvement [Functional Concept]

Phrase: "with Alzheimers disease"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0002395:Alzheimers disease [Disease or Syndrome]
   861   C0012634:Disease [Disease or Syndrome]
   805 E C1836721:MALS [Finding]
   805 E C3538764:MALS [Gene or Genome]
   805 E C3540595:MAL [Gene or Genome]

Phrase: "has"

Phrase: "also"

Phrase: "been"

Phrase: "suggested"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1705535:Suggest [Idea or Concept]

Phrase: ","

Phrase: "as"

Phrase: "advanced glycation end products,"
Meta Candidates (Total=11; Excluded=5; Pruned=0; Remaining=6)
  1000   C0162574:Glycation End Products, Advanced [Biologically Active Substance,Organic Chemical]
   812   C0205179:Advanced [Qualitative Concept]
   812   C0444930:End [Spatial Concept]
   812   C0598528:glycation [Phenomenon or Process]
   812   C1514468:Products [Entity]
   812   C2746065:End [Temporal Concept]
   779 E C0725066:Advance [Medical Device]
   779 E C1704444:Product [Quantitative Concept]
   756 E C0205088:Terminal [Temporal Concept]
   756 E C1705314:Terminal [Manufactured Object]
   756 E C1705315:Terminal [Spatial Concept]

Phrase: "such as pyrraline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0209143:pyrraline [Biologically Active Substance,Organic Chemical]

Phrase: "and"

Phrase: "pentosidine,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0070317:pentosidine [Amino Acid, Peptide, or Protein,Pharmacologic Substance]

Phrase: "were"

Phrase: "demonstrated"

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "localize in lesions of the disease."
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   753   C0012634:Disease [Disease or Syndrome]
   753   C0221198:lesions [Finding]
   753   C0392752:localize [Spatial Concept]
   719 E C1546698:Lesion [Intellectual Product]
Processing 00000000.tx.4: Although aminoguanidine has been studied extensively and established as an inhibitor of the Maillard reaction, other candidates have not been investigated thoroughly. 

Phrase: "Although"

Phrase: "aminoguanidine"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0282774:aminoguanidine [Organic Chemical,Pharmacologic Substance]

Phrase: "has"

Phrase: "been"

Phrase: "studied"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C0557651:Study [Manufactured Object]
   966   C2603343:Study [Research Activity]

Phrase: "extensively"

Phrase: "and"

Phrase: "established as an inhibitor of the Maillard reaction,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   770   C0024495:Maillard Reaction [Natural Phenomenon or Process]
   744   C0443211:Established [Qualitative Concept]
   744   C0443286:Reaction [Functional Concept]
   744   C1114821:Reaction [Clinical Attribute]
   744   C1272684:Established [Qualitative Concept]
   744   C1999216:Inhibitor [Qualitative Concept]

Phrase: "other candidates"

Phrase: "have"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "been"

Phrase: "investigated"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1292732:investigated [Functional Concept]

Phrase: "thoroughly."
Processing 00000000.tx.5: In the present study, we examined the inhibitory effect of tenilsetam [()-3-(2-thienyl)-2-piperazinone], an antidementia drug, on the Maillard reaction. 

Phrase: "In the present study,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0150312:Present [Quantitative Concept]
   861   C0449450:Present [Idea or Concept]
   861   C0557651:Study [Manufactured Object]
   861   C2603343:Study [Research Activity]

Phrase: "we"

Phrase: "examined"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0332128:Examined [Finding]

Phrase: "the inhibitory effect of tenilsetam"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C1280500:Effect [Qualitative Concept]
   760   C2348382:Effect [Qualitative Concept]

Phrase: "["

Phrase: "("

Phrase: ")-"

Phrase: "3-"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439086:<3 [Quantitative Concept]
  1000   C2827736:3+ [Quantitative Concept]
  1000   C2981702:3+ [Classification]

Phrase: "(2-thienyl"

Phrase: ")-"

Phrase: "2-piperazinone"

Phrase: "],"

Phrase: "an antidementia drug,"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
  1000   C1276997:Antidementia drug [Pharmacologic Substance]
   861   C0013227:Drug [Pharmacologic Substance]
   861   C1254351:Drug [Pharmacologic Substance]
   805 E C0031336:Pharmaceutical [Biomedical Occupation or Discipline]
   805 E C1135440:pharmaceutical [Therapeutic or Preventive Procedure]
   768 E C0456386:Medicament [Pharmacologic Substance]

Phrase: "on the Maillard reaction."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0024495:Maillard Reaction [Natural Phenomenon or Process]
   861   C0443286:Reaction [Functional Concept]
   861   C1114821:Reaction [Clinical Attribute]
Processing 00000000.tx.6: Tenilsetam inhibited glucose- and fructose-induced polymerization of lysozyme in a concentration-dependent manner in vitro. 

Phrase: "Tenilsetam"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0076093:tenilsetam [Organic Chemical,Pharmacologic Substance]

Phrase: "inhibited"
Meta Candidates (Total=6; Excluded=5; Pruned=0; Remaining=1)
  1000   C0311403:Inhibited [Qualitative Concept]
   928 E C0018790:arrested [Disease or Syndrome]
   928 E C0237477:Arrest [Temporal Concept]
   928 E C0392351:arrest [Governmental or Regulatory Activity]
   928 E C0521111:Retarded [Qualitative Concept]
   907 E C3463820:Inhibiting [Activity]

Phrase: "glucose-"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]

Phrase: "and"

Phrase: "fructose-induced polymerization of lysozyme"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0314672:Polymerisation [Phenomenon or Process]

Phrase: "in a concentration-dependent manner"

Phrase: "in vitro."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0021135:In Vitro [Intellectual Product]
  1000   C1533691:in vitro [Qualitative Concept]
           vitro
  1000   C2827718:In Vitro [Functional Concept]
Processing 00000000.tx.7: Reduced enzymatic digestibility of collagen incubated with 100 mM glucose for 4 weeks was also restored to a control level by coincubation with 100 mM tenilsetam. 

Phrase: "Reduced enzymatic digestibility of collagen"

Phrase: "incubated with 100 mM glucose"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   760   C1439852:Incubated [Laboratory Procedure]

Phrase: "for 4 weeks"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C1442465:4 Weeks [Temporal Concept]
   861   C0439230:weeks [Temporal Concept]
   827 E C0332174:/week [Temporal Concept]

Phrase: "was"

Phrase: "also"

Phrase: "restored to a control level"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   760   C0243148:control [Qualitative Concept]
   760   C0441889:Level [Qualitative Concept]
   760   C0456079:Level [Classification]
   760   C1547707:Level [Geographic Area]
   760   C1550141:Control [Substance]
   760   C1882979:Control [Conceptual Entity]
   760   C2587213:Control [Functional Concept]
   760   C2946261:Level [Pharmacologic Substance]
   760   C3274648:Control [Qualitative Concept]

Phrase: "by coincubation"

Phrase: "with 100 mM tenilsetam."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0076093:tenilsetam [Organic Chemical,Pharmacologic Substance]
Processing 00000000.tx.8: To determine whether tenilsetam inhibits the Maillard reaction in vivo, streptozotocin-induced diabetic rats were treated with tenilsetam (50 mg/kgday). 

Phrase: "To"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "determine"

Phrase: "whether"

Phrase: "tenilsetam"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0076093:tenilsetam [Organic Chemical,Pharmacologic Substance]

Phrase: "inhibits"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   944   C0018790:arrested [Disease or Syndrome]
   944   C0237477:Arrest [Temporal Concept]
   944   C0392351:arrest [Governmental or Regulatory Activity]
   944   C0521111:Retarded [Qualitative Concept]
   916 E C0311403:Inhibited [Qualitative Concept]
   916 E C3463820:Inhibiting [Activity]

Phrase: "the Maillard reaction in vivo, streptozotocin-induced diabetic rats"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   793   C0034693:rats [Mammal]
   793   C0034721:Rats [Mammal]
   793   C0241863:DIABETIC [Finding]

Phrase: "were"

Phrase: "treated with tenilsetam"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   882   C0332293:Treated with [Therapeutic or Preventive Procedure]
           treated
   790   C0076093:tenilsetam [Organic Chemical,Pharmacologic Substance]
   790   C1522326:Treated [Functional Concept]
   756 E C1292734:TREAT [Functional Concept]

Phrase: "(50 mg/kgday"

Phrase: ")."
Processing 00000000.tx.9: Elevated levels of advanced glycation end-product-derived fluorescence and pyrraline in renal cortex and aorta of diabetic rats were suppressed by the administration of tenilsetam for 16 weeks. 

Phrase: "Elevated levels of advanced glycation end-product-derived fluorescence"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   742   C0441889:Levels [Qualitative Concept]
   708 E C0456079:Level [Classification]
   708 E C1547707:Level [Geographic Area]
   708 E C2946261:Level [Pharmacologic Substance]

Phrase: "and"

Phrase: "pyrraline in renal cortex"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0209143:pyrraline [Biologically Active Substance,Organic Chemical]

Phrase: "and"

Phrase: "aorta of diabetic rats"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   802   C1882561:Rat Aorta [Body Part, Organ, or Organ Component]
   770   C0003483:Aorta [Body Part, Organ, or Organ Component]
   770   C1278934:Aorta [Body Part, Organ, or Organ Component]

Phrase: "were"

Phrase: "suppressed by the administration of tenilsetam"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   753   C0001554:Administration [Occupational Activity]
   753   C0076093:tenilsetam [Organic Chemical,Pharmacologic Substance]
   753   C1260953:Suppressed [Functional Concept]
   753   C1533734:Administration [Therapeutic or Preventive Procedure]

Phrase: "for 16 weeks."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0439230:weeks [Temporal Concept]
   827 E C0332174:/week [Temporal Concept]
Processing 00000000.tx.10: These inhibitory effects of this agent on advanced glycation in diabetic rats suggested its potential therapeutic role in controlling diabetic complications.  

Phrase: "These inhibitory effects of this agent"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   753   C1280500:effects [Qualitative Concept]
   719 E C2348382:Effect [Qualitative Concept]

Phrase: "on advanced glycation"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0598528:glycation [Phenomenon or Process]

Phrase: "in diabetic rats"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0034693:rats [Mammal]
   861   C0034721:Rats [Mammal]
   861   C0241863:DIABETIC [Finding]

Phrase: "suggested"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1705535:Suggest [Idea or Concept]

Phrase: "its potential therapeutic role in controlling diabetic complications."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C0035820:Role [Social Behavior]
   744   C1705810:Role [Conceptual Entity]
Processing 00000000.tx.11: Introduction Top Abstract Introduction Materials and Methods Results Discussion References  THE MAILLARD reaction is initiated by the nonenzymatic reaction of reducing sugars with free amino groups on protein to form Amadori product. 

Phrase: "Introduction Top Abstract Introduction Materials"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   804   C0520510:Materials [Substance]

Phrase: "and"

Phrase: "Methods Results Discussion"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0557061:Discussion [Therapeutic or Preventive Procedure]
   827   C2584313:Discussion [Social Behavior]

Phrase: "References"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "THE MAILLARD reaction"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0024495:Maillard Reaction [Natural Phenomenon or Process]
   861   C0443286:Reaction [Functional Concept]
   861   C1114821:Reaction [Clinical Attribute]

Phrase: "is"

Phrase: "initiated by the nonenzymatic reaction of reducing sugars"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   744   C0242209:Sugars [Carbohydrate,Pharmacologic Substance]
   744   C0392756:Reducing [Qualitative Concept]
   744   C0443286:Reaction [Functional Concept]
   744   C1114821:Reaction [Clinical Attribute]
   711 E C0007004:Sugar [Carbohydrate]
   711   C1548602:Initiate [Idea or Concept]
   711   C1704686:Initiate [Functional Concept]

Phrase: "with free amino groups"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   867   C0596072:amino group [Inorganic Chemical]
   827   C0441833:Group [Idea or Concept]
   827   C0687744:group [Population Group]
   827   C1257890:Group [Population Group]
   827   C1552516:Group [Health Care Related Organization]
   827   C1552839:groups [Idea or Concept]
   827   C1705428:Group [Conceptual Entity]
   827   C1705429:Group [Population Group]

Phrase: "on protein to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "form"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0348078:Form [Qualitative Concept]
  1000   C0376315:Form [Manufactured Object]
  1000   C1522492:Form [Functional Concept]

Phrase: "Amadori product."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1514468:product [Entity]
   861   C1704444:Product [Quantitative Concept]
Processing 00000000.tx.12: The Amadori product irreversibly undergoes a variety of dehydration and rearrangement reactions, leading to the formation of advanced glycation end products (AGEs). 

Phrase: "The Amadori product irreversibly"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C1514468:product [Entity]
   827   C1704444:Product [Quantitative Concept]

Phrase: "undergoes"

Phrase: "a variety of dehydration"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C1883525:Variety [Conceptual Entity]
   770   C2346866:Variety [Conceptual Entity]

Phrase: "and"

Phrase: "rearrangement reactions,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0443286:Reaction [Functional Concept]
   827   C1114821:Reaction [Clinical Attribute]

Phrase: "leading to the formation of advanced glycation end products (AGEs)."
Meta Candidates (Total=17; Excluded=6; Pruned=0; Remaining=11)
   818   C0162574:Glycation End Products, Advanced [Biologically Active Substance,Organic Chemical]
   742   C0205179:Advanced [Qualitative Concept]
   742   C0220781:formation [Biologic Function]
   742   C0332152:Leading [Temporal Concept]
   742   C0439634:formation [Spatial Concept]
   742   C0444930:End [Spatial Concept]
   742   C0598528:glycation [Phenomenon or Process]
   742   C1514468:Products [Entity]
   742   C1522492:Formation [Functional Concept]
   742   C1522538:Leading [Functional Concept]
   742   C2746065:End [Temporal Concept]
   708 E C0023175:???lead [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
   708 E C0725066:Advance [Medical Device]
   708 E C1442948:lead [Inorganic Chemical,Pharmacologic Substance]
   708 E C1704444:Product [Quantitative Concept]
   708 E C2348269:Lead [Element, Ion, or Isotope]
   708 E C3275067:LEAD [Therapeutic or Preventive Procedure]
Processing 00000000.tx.13: Accumulation of AGEs has been thought to play a role in the pathogenesis of diabetic complications as well as the aging process (1, 2, 3). 

Phrase: "Accumulation of AGEs"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   716   C0162574:Glycation End Products, Advanced [Biologically Active Substance,Organic Chemical]

Phrase: "has"

Phrase: "been"

Phrase: "thought"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0039869:Thought [Mental Process]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "play"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0032214:Play [Daily or Recreational Activity]
  1000   C0600138:play [Finding]

Phrase: "a role in the pathogenesis of diabetic complications"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C0035820:Role [Social Behavior]
   744   C1705810:Role [Conceptual Entity]

Phrase: "as well as"

Phrase: "the aging process"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1510835:Aging Process [Organism Function]
   861   C1184743:Process [Body Part, Organ, or Organ Component]
   861   C1522240:Process [Phenomenon or Process]

Phrase: "(1,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C2827734:1+ [Quantitative Concept]
  1000   C2981698:1+ [Classification]

Phrase: "2,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0740116:+2 [Quantitative Concept]
  1000   C2827735:2+ [Quantitative Concept]
  1000   C2981700:2+ [Classification]

Phrase: "3"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439086:<3 [Quantitative Concept]
  1000   C2827736:3+ [Quantitative Concept]
  1000   C2981702:3+ [Classification]

Phrase: ")."
Processing 00000000.tx.14: Recent immunochemical studies by several investigators proved the presence of AGEs in vivo (4, 5, 6, 7) as well as Amadori product (8). 

Phrase: "Recent immunochemical studies by several investigators"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   753   C0947630:studies [Laboratory Procedure]
   719 E C0557651:Study [Manufactured Object]
   719 E C2603343:Study [Research Activity]

Phrase: "proved"

Phrase: "the presence of AGEs"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0392148:Presence [Therapeutic or Preventive Procedure]

Phrase: "in vivo"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1515655:In Vivo [Spatial Concept]
           vivo

Phrase: "(4,"

Phrase: "5,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0439084:>5 [Quantitative Concept]
  1000   C0728893:+5 [Quantitative Concept]

Phrase: "6,"

Phrase: "7"

Phrase: ")"

Phrase: "as well as"

Phrase: "Amadori product"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1514468:product [Entity]
   861   C1704444:Product [Quantitative Concept]

Phrase: "(8"

Phrase: ")."
Processing 00000000.tx.15: Although AGEs are known to alter structural and functional properties of proteins (9, 10, 11), the exact pathway leading to the formation of AGEs has not yet been completely identified. 

Phrase: "Although"

Phrase: "AGEs"
Meta Candidates (Total=11; Excluded=5; Pruned=0; Remaining=6)
  1000   C0162574:Glycation End Products, Advanced [Biologically Active Substance,Organic Chemical]
   812   C0205179:Advanced [Qualitative Concept]
   812   C0444930:End [Spatial Concept]
   812   C0598528:glycation [Phenomenon or Process]
   812   C1514468:Products [Entity]
   812   C2746065:End [Temporal Concept]
   779 E C0725066:Advance [Medical Device]
   779 E C1704444:Product [Quantitative Concept]
   756 E C0205088:Terminal [Temporal Concept]
   756 E C1705314:Terminal [Manufactured Object]
   756 E C1705315:Terminal [Spatial Concept]

Phrase: "are"

Phrase: "known"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205309:Known [Qualitative Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "alter"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   916   C0392747:Altered [Functional Concept]

Phrase: "structural"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0678594:Structural [Spatial Concept]

Phrase: "and"

Phrase: "functional properties of proteins"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   770   C0871161:properties [Qualitative Concept]
   770   C1292721:properties [Functional Concept]
   737 E C1882134:Property [Conceptual Entity]
   737 E C2347695:Property [Entity]

Phrase: "(9,"

Phrase: "10,"

Phrase: "11"

Phrase: ")"

Phrase: ","

Phrase: "the exact pathway"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1704259:Pathway [Molecular Function]
   861   C1705987:Pathway [Conceptual Entity]

Phrase: "leading to the formation of AGEs"
Meta Candidates (Total=17; Excluded=6; Pruned=0; Remaining=11)
   818   C0162574:Glycation End Products, Advanced [Biologically Active Substance,Organic Chemical]
   742   C0205179:Advanced [Qualitative Concept]
   742   C0220781:formation [Biologic Function]
   742   C0332152:Leading [Temporal Concept]
   742   C0439634:formation [Spatial Concept]
   742   C0444930:End [Spatial Concept]
   742   C0598528:glycation [Phenomenon or Process]
   742   C1514468:Products [Entity]
   742   C1522492:Formation [Functional Concept]
   742   C1522538:Leading [Functional Concept]
   742   C2746065:End [Temporal Concept]
   708 E C0023175:???lead [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
   708 E C0725066:Advance [Medical Device]
   708 E C1442948:lead [Inorganic Chemical,Pharmacologic Substance]
   708 E C1704444:Product [Quantitative Concept]
   708 E C2348269:Lead [Element, Ion, or Isotope]
   708 E C3275067:LEAD [Therapeutic or Preventive Procedure]

Phrase: "has"

Phrase: "not yet"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1518422:Not [Functional Concept]

Phrase: "been"

Phrase: "completely"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205197:Completely [Qualitative Concept]

Phrase: "identified."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205396:Identified [Qualitative Concept]
  1000   C1550043:Identified [Finding]
  1000   C1551388:Identified [Functional Concept]
Processing 00000000.tx.16: However, despite their complexity, the structures of several AGEs have been described, i.e. those of pyrraline (12), pentosidine (13), crossline (14), and pyrropyridine (15). 

Phrase: "However,"

Phrase: "despite their complexity,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   928   C0439855:Complex [Qualitative Concept]
   928   C1704241:Complex [Chemical Viewed Structurally]

Phrase: "the structures of several AGEs"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   744   C0678594:structures [Spatial Concept]

Phrase: "have"

Phrase: "been"

Phrase: "described"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1552738:described [Idea or Concept]

Phrase: ","

Phrase: "i.e."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0683454:I-E [Diagnostic Procedure,Intellectual Product]
   861   C0021966:I- [Inorganic Chemical]
   861   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "those of pyrraline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0209143:pyrraline [Biologically Active Substance,Organic Chemical]

Phrase: "(12"

Phrase: ")"

Phrase: ","

Phrase: "pentosidine"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0070317:pentosidine [Amino Acid, Peptide, or Protein,Pharmacologic Substance]

Phrase: "(13"

Phrase: ")"

Phrase: ","

Phrase: "crossline"

Phrase: "(14"

Phrase: ")"

Phrase: ","

Phrase: "and"

Phrase: "pyrropyridine"

Phrase: "(15"

Phrase: ")."
Processing 00000000.tx.17: Furthermore, oxidation of Amadori product forms carboxymethyllysine (16). 

Phrase: "Furthermore,"

Phrase: "oxidation of Amadori product"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0030011:Oxidation [Molecular Function]

Phrase: "forms"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0348078:Form [Qualitative Concept]
  1000   C0376315:Form [Manufactured Object]
  1000   C1522492:Form [Functional Concept]

Phrase: "carboxymethyllysine"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0083528:carboxymethyl-lysine [Amino Acid, Peptide, or Protein]

Phrase: "(16"

Phrase: ")."
Processing 00000000.tx.18: Kimura et al. recently suggested that carboxymethyllysine accumulated in human hippocampal neurons with age (17). 

Phrase: "Kimura et al. recently"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0332185:Recently [Temporal Concept]

Phrase: "suggested"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1705535:Suggest [Idea or Concept]

Phrase: "that carboxymethyllysine"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0083528:carboxymethyl-lysine [Amino Acid, Peptide, or Protein]

Phrase: "accumulated in human hippocampal neurons"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0019564:Hippocampal [Body Part, Organ, or Organ Component]
   760   C0027882:Neurons [Cell]
   760   C0086418:Human [Human]

Phrase: "with age (17"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0001779:Age [Organism Attribute]

Phrase: ")."
Processing 00000000.tx.19: Dicarbonyl compounds, including 3-deoxyglucosone (3-DG), are also known to form as reactive intermediates of an advanced stage of the Maillard reaction (18). 

Phrase: "Dicarbonyl compounds,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0205198:Compound [Qualitative Concept]
   827   C1706082:Compound [Chemical]

Phrase: "including"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332257:Including [Functional Concept]
   966 E C1552866:include [Idea or Concept]
   966 E C2700399:Include [Activity]

Phrase: "3-deoxyglucosone (3-DG),"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0047359:3-deoxyglucosone [Carbohydrate]

Phrase: "are"

Phrase: "also"

Phrase: "known"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205309:Known [Qualitative Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "form as reactive intermediates of an advanced stage of the Maillard reaction"
Meta Candidates (Total=15; Excluded=1; Pruned=0; Remaining=14)
   753   C0024495:Maillard Reaction [Natural Phenomenon or Process]
   736   C0205179:Advanced [Qualitative Concept]
   736   C0205332:Reactive [Qualitative Concept]
   736   C0205390:Stage [Temporal Concept]
   736   C0348078:Form [Qualitative Concept]
   736   C0376315:Form [Manufactured Object]
   736   C0443286:Reaction [Functional Concept]
   736   C1114821:Reaction [Clinical Attribute]
   736   C1300072:Stage [Clinical Attribute]
   736   C1306673:Stage [Qualitative Concept]
   736   C1522492:Form [Functional Concept]
   703   C0205103:Intermediate [Spatial Concept]
   703 E C0725066:Advance [Medical Device]
   703   C1550465:intermediate [Idea or Concept]
   703   C2827755:INTERMEDIATE [Laboratory or Test Result]

Phrase: "(18"

Phrase: ")."
Processing 00000000.tx.20: The extent of AGE formation in tissue has been estimated by measuring the fluorescence derived from AGEs at excitation/emission = 370/440 nm (19) and 328/378 nm (20). 

Phrase: "The extent of AGE formation"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0439792:Extent [Spatial Concept]

Phrase: "in tissue"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0040300:Tissue [Tissue]
  1000   C1547928:Tissue [Intellectual Product]

Phrase: "has"

Phrase: "been"

Phrase: "estimated by measuring"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   790   C0444706:measuring [Qualitative Concept]
   790   C0449770:measuring [Quantitative Concept]
   790   C0750572:Estimated [Quantitative Concept]
   756 E C0079809:Measure [Quantitative Concept]
   756 E C0242485:Measure [Functional Concept]

Phrase: "the fluorescence"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0016315:Fluorescence [Natural Phenomenon or Process]
   928 E C0303920:Fluorescent [Indicator, Reagent, or Diagnostic Aid,Organic Chemical]

Phrase: "derived from AGEs"
Meta Candidates (Total=10; Excluded=2; Pruned=0; Remaining=8)
   882   C0162574:Glycation End Products, Advanced [Biologically Active Substance,Organic Chemical]
   753   C0205179:Advanced [Qualitative Concept]
   753   C0444930:End [Spatial Concept]
   753   C0598528:glycation [Phenomenon or Process]
   753   C1441547:Derived [Qualitative Concept]
   753   C1514468:Products [Entity]
   753   C2746065:End [Temporal Concept]
   753   C3245521:derived [Idea or Concept]
   719 E C0725066:Advance [Medical Device]
   719 E C1704444:Product [Quantitative Concept]

Phrase: "at excitation/emission"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0233929:Emission [Body Substance]
   861   C2349995:Emission [Substance]

Phrase: "= 370/440 nm (19"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0312860:NM [Cell Function]

Phrase: ")"

Phrase: "and"

Phrase: "328/378 nm (20"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0312860:NM [Cell Function]

Phrase: ")."
Processing 00000000.tx.21: It has been suggested that inhibition of the Maillard reaction may prevent the progress of diabetic complications and slow the aging process. 

Phrase: "It"

Phrase: "has"

Phrase: "been"

Phrase: "suggested"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1705535:Suggest [Idea or Concept]

Phrase: "that inhibition of the Maillard reaction"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   753   C0021467:Inhibition [Mental Process]
   753   C0021469:Inhibition [Molecular Function]
   753   C1628982:% inhibition [Quantitative Concept]
   753   C3463820:Inhibition [Activity]

Phrase: "may"

Phrase: "prevent"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0309872:PREVENT [Pharmacologic Substance]

Phrase: "the progress of diabetic complications"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C1272688:progress [Functional Concept]
   760   C1280477:Progress [Functional Concept]

Phrase: "and"

Phrase: "slow"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439834:Slow [Qualitative Concept]

Phrase: "the aging process."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1510835:Aging Process [Organism Function]
   861   C1184743:Process [Body Part, Organ, or Organ Component]
   861   C1522240:Process [Phenomenon or Process]
Processing 00000000.tx.22: Since Brownlee et al. focused on a nucleophilic hydrazine compound, aminoguanidine (AG) (21), several lines of evidence now suggest that AG could inhibit the Maillard reaction both in vitro and in vivo (22, 23, 24, 25, 26). 

Phrase: "Since"

Phrase: "Brownlee et al."

Phrase: "focused on a nucleophilic hydrazine compound,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   753   C0020231:Hydrazine [Inorganic Chemical]
   753   C0020233:Hydrazine [Organic Chemical]
   753   C0205198:Compound [Qualitative Concept]
   753   C0205234:Focused [Spatial Concept]
   753   C1285542:focused [Functional Concept]
   753   C1706082:Compound [Chemical]

Phrase: "aminoguanidine (AG)"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0282774:aminoguanidine [Organic Chemical,Pharmacologic Substance]

Phrase: "(21"

Phrase: ")"

Phrase: ","

Phrase: "several lines of evidence now"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   760   C0205132:lines [Spatial Concept]
   726 E C1550648:Line [Substance]
   726 E C1552960:Line [Quantitative Concept]

Phrase: "suggest"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1705535:Suggest [Idea or Concept]

Phrase: "that AG"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0282774:aminoguanidine [Organic Chemical,Pharmacologic Substance]

Phrase: "could"

Phrase: "inhibit"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   944   C0018790:arrested [Disease or Syndrome]
   944   C0237477:Arrest [Temporal Concept]
   944   C0392351:arrest [Governmental or Regulatory Activity]
   944   C0521111:Retarded [Qualitative Concept]
   916 E C0311403:Inhibited [Qualitative Concept]
   916 E C3463820:Inhibiting [Activity]

Phrase: "the Maillard reaction"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0024495:Maillard Reaction [Natural Phenomenon or Process]
   861   C0443286:Reaction [Functional Concept]
   861   C1114821:Reaction [Clinical Attribute]

Phrase: "both in vitro"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0021135:In Vitro [Intellectual Product]
  1000   C1533691:in vitro [Qualitative Concept]
           vitro
  1000   C2827718:In Vitro [Functional Concept]

Phrase: "and"

Phrase: "in vivo"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1515655:In Vivo [Spatial Concept]
           vivo

Phrase: "(22,"

Phrase: "23,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0450348:23 [Quantitative Concept]

Phrase: "24,"

Phrase: "25,"

Phrase: "26"

Phrase: ")."
Processing 00000000.tx.23: The action of AG is probably due to trapping of intermediates of advanced Maillard reaction, such as 3-DG, leading to the inhibition of further progress of the Maillard reaction (27). 

Phrase: "The action of AG"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0441472:Action [Functional Concept]
   770   C3266814:Action [Activity]

Phrase: "is"

Phrase: "probably due to trapping of intermediates of advanced Maillard reaction,"
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
   760   C0024495:Maillard Reaction [Natural Phenomenon or Process]
   760   C0678226:Due to [Functional Concept]
           due
   739   C0205179:Advanced [Qualitative Concept]
   739   C0443286:Reaction [Functional Concept]
   739   C0750492:Probably [Idea or Concept]
   739   C1114821:Reaction [Clinical Attribute]
   739   C3146286:Due [Idea or Concept]
   706   C0205103:Intermediate [Spatial Concept]
   706   C1550465:intermediate [Idea or Concept]
   706   C2827755:INTERMEDIATE [Laboratory or Test Result]

Phrase: "such as 3-DG,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0047359:3-deoxyglucosone [Carbohydrate]

Phrase: "leading to the inhibition of further progress of the Maillard reaction"
Meta Candidates (Total=17; Excluded=5; Pruned=0; Remaining=12)
   756   C0024495:Maillard Reaction [Natural Phenomenon or Process]
   738   C0021467:Inhibition [Mental Process]
   738   C0021469:Inhibition [Molecular Function]
   738   C0332152:Leading [Temporal Concept]
   738   C0443286:Reaction [Functional Concept]
   738   C1114821:Reaction [Clinical Attribute]
   738   C1272688:progress [Functional Concept]
   738   C1280477:Progress [Functional Concept]
   738   C1517331:Further [Spatial Concept]
   738   C1522538:Leading [Functional Concept]
   738   C1628982:% inhibition [Quantitative Concept]
   738   C3463820:Inhibition [Activity]
   704 E C0023175:???lead [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
   704 E C0205108:far [Spatial Concept]
   704 E C1442948:lead [Inorganic Chemical,Pharmacologic Substance]
   704 E C2348269:Lead [Element, Ion, or Isotope]
   704 E C3275067:LEAD [Therapeutic or Preventive Procedure]

Phrase: "(27"

Phrase: ")."
Processing 00000000.tx.24: The roles of other agents as potential inhibitors of the Maillard reaction have not yet been investigated thoroughly. 

Phrase: "The roles of other agents"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   760   C0035820:Roles [Social Behavior]
   726 E C1705810:Role [Conceptual Entity]

Phrase: "as potential inhibitors"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0243077:inhibitors [Chemical Viewed Functionally]
   827 E C1999216:Inhibitor [Qualitative Concept]

Phrase: "of the Maillard reaction"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0024495:Maillard Reaction [Natural Phenomenon or Process]
   861   C0443286:Reaction [Functional Concept]
   861   C1114821:Reaction [Clinical Attribute]

Phrase: "have"

Phrase: "not yet"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1518422:Not [Functional Concept]

Phrase: "been"

Phrase: "investigated"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1292732:investigated [Functional Concept]

Phrase: "thoroughly."
Processing 00000000.tx.25: Tenilsetam [()-3-(2-thienyl)-2-piperazinone] is an antidementia drug used for the treatment of senile dementia and in clinical trials in Alzheimers disease (28, 29, 30, 31, 32). 

Phrase: "Tenilsetam"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0076093:tenilsetam [Organic Chemical,Pharmacologic Substance]

Phrase: "["

Phrase: "("

Phrase: ")-"

Phrase: "3-"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439086:<3 [Quantitative Concept]
  1000   C2827736:3+ [Quantitative Concept]
  1000   C2981702:3+ [Classification]

Phrase: "(2-thienyl"

Phrase: ")-"

Phrase: "2-piperazinone"

Phrase: "]"

Phrase: "is"

Phrase: "an antidementia drug"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
  1000   C1276997:Antidementia drug [Pharmacologic Substance]
   861   C0013227:Drug [Pharmacologic Substance]
   861   C1254351:Drug [Pharmacologic Substance]
   805 E C0031336:Pharmaceutical [Biomedical Occupation or Discipline]
   805 E C1135440:pharmaceutical [Therapeutic or Preventive Procedure]
   768 E C0456386:Medicament [Pharmacologic Substance]

Phrase: "used for the treatment of senile dementia"
Meta Candidates (Total=16; Excluded=3; Pruned=0; Remaining=13)
   778   C0002395:Dementia, Senile [Disease or Syndrome]
   778   C0011268:Senile dementia [Mental or Behavioral Dysfunction]
   757   C1524063:Use of [Functional Concept]
   748   C0011265:dementia [Mental or Behavioral Dysfunction]
   748   C0039798:treatment [Functional Concept]
   748   C0087111:Treatment [Therapeutic or Preventive Procedure]
   748   C0392079:Senile [Finding]
   748   C0497327:Dementia [Mental or Behavioral Dysfunction]
   748   C1273517:used [Finding]
   748   C1522326:Treatment [Functional Concept]
   748   C1533734:Treatment [Therapeutic or Preventive Procedure]
   748   C1705169:Treatment [Conceptual Entity]
   748   C3538994:TREATMENT [Research Activity]
   714 E C0042153:use [Functional Concept]
   714 E C0457083:Use [Functional Concept]
   714 E C1947944:Use [Intellectual Product]

Phrase: "and in clinical trials"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   833   C0008976:Clinical Trials [Research Activity]
           Trial
   833   C1096775:clinical trials [Intellectual Product]
   770   C0205210:Clinical [Qualitative Concept]
   770   C1515981:And [Idea or Concept]

Phrase: "in Alzheimers disease"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0002395:Alzheimers disease [Disease or Syndrome]
   861   C0012634:Disease [Disease or Syndrome]
   805 E C1836721:MALS [Finding]
   805 E C3538764:MALS [Gene or Genome]
   805 E C3540595:MAL [Gene or Genome]

Phrase: "(28,"

Phrase: "29,"

Phrase: "30,"

Phrase: "31,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0450355:31 [Intellectual Product]

Phrase: "32"

Phrase: ")."
Processing 00000000.tx.26: Recently, the involvement of AGE modification in the lesion of Alzheimers disease has been proposed (33, 34). 

Phrase: "Recently,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0332185:Recently [Temporal Concept]

Phrase: "the involvement of AGE modification"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C1314939:Involvement [Functional Concept]

Phrase: "in the lesion"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0221198:Lesion [Finding]
  1000   C1546698:Lesion [Intellectual Product]

Phrase: "of Alzheimers disease"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0002395:Alzheimers disease [Disease or Syndrome]
   861   C0012634:Disease [Disease or Syndrome]
   805 E C1836721:MALS [Finding]
   805 E C3538764:MALS [Gene or Genome]
   805 E C3540595:MAL [Gene or Genome]

Phrase: "has"

Phrase: "been"

Phrase: "proposed"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1441414:PROPOSED [Idea or Concept]
  1000   C1553874:Proposed [Qualitative Concept]
  1000   C1578820:Proposed [Idea or Concept]

Phrase: "(33,"

Phrase: "34"

Phrase: ")."
Processing 00000000.tx.27: Immunohistochemical analysis by Smith et al. 

Phrase: "Immunohistochemical analysis by Smith et al."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   753   C0002778:Analysis [Laboratory Procedure]
   753   C0936012:Analysis [Research Activity]
   753   C1441616:Immunohistochemical [Laboratory Procedure]
   753   C1524024:analysis [Functional Concept]
Processing 00000000.tx.28: (33) demonstrated that pyrraline and pentosidine were localized in lesions of Alzheimers disease. 

Phrase: "(33"

Phrase: ")"

Phrase: "demonstrated"

Phrase: "that pyrraline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0209143:pyrraline [Biologically Active Substance,Organic Chemical]

Phrase: "and"

Phrase: "pentosidine"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0070317:pentosidine [Amino Acid, Peptide, or Protein,Pharmacologic Substance]

Phrase: "were"

Phrase: "localized in lesions of Alzheimers disease."
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   790   C0002395:Alzheimers disease [Disease or Syndrome]
   783   C0277565:Localized disease [Disease or Syndrome]
   767   C1517926:Localized Lesion [Finding]
   753   C0012634:Disease [Disease or Syndrome]
   753   C0221198:lesions [Finding]
   753   C0392752:Localized [Spatial Concept]
   719 E C1546698:Lesion [Intellectual Product]
Processing 00000000.tx.29: In addition, Vitek et al. 

Phrase: "In addition,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1883712:Addition [Functional Concept]
   928 E C1524062:Additional [Functional Concept]

Phrase: "Vitek et al."
Processing 00000000.tx.30: (34) suggested that AGEs contributed to amyloidosis in Alzheimers disease. 

Phrase: "(34"

Phrase: ")"

Phrase: "suggested"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1705535:Suggest [Idea or Concept]

Phrase: "that AGEs"
Meta Candidates (Total=11; Excluded=5; Pruned=0; Remaining=6)
  1000   C0162574:Glycation End Products, Advanced [Biologically Active Substance,Organic Chemical]
   812   C0205179:Advanced [Qualitative Concept]
   812   C0444930:End [Spatial Concept]
   812   C0598528:glycation [Phenomenon or Process]
   812   C1514468:Products [Entity]
   812   C2746065:End [Temporal Concept]
   779 E C0725066:Advance [Medical Device]
   779 E C1704444:Product [Quantitative Concept]
   756 E C0205088:Terminal [Temporal Concept]
   756 E C1705314:Terminal [Manufactured Object]
   756 E C1705315:Terminal [Spatial Concept]

Phrase: "contributed to amyloidosis"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0002726:Amyloidosis [Disease or Syndrome]
   756   C1880177:Contribute [Activity]

Phrase: "in Alzheimers disease."
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0002395:Alzheimers disease [Disease or Syndrome]
   861   C0012634:Disease [Disease or Syndrome]
   805 E C1836721:MALS [Finding]
   805 E C3538764:MALS [Gene or Genome]
   805 E C3540595:MAL [Gene or Genome]
Processing 00000000.tx.31: Considering that senile dementia is an aging process, a positive action of tenilsetam on aging could include inhibition of the Maillard reaction. 

Phrase: "Considering"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0750591:considering [Idea or Concept]

Phrase: "that senile dementia"
Meta Candidates (Total=8; Excluded=3; Pruned=0; Remaining=5)
  1000   C0002395:Dementia, Senile [Disease or Syndrome]
  1000   C0011268:Senile dementia [Mental or Behavioral Dysfunction]
   861   C0011265:dementia [Mental or Behavioral Dysfunction]
   861   C0392079:Senile [Finding]
   861   C0497327:Dementia [Mental or Behavioral Dysfunction]
   805 E C0231337:Old age [Finding]
   805 E C1999167:Old age [Population Group]
   761 E C0860630:dement [Mental or Behavioral Dysfunction]

Phrase: "is"

Phrase: "an aging process,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1510835:Aging Process [Organism Function]
   861   C1184743:Process [Body Part, Organ, or Organ Component]
   861   C1522240:Process [Phenomenon or Process]

Phrase: "a positive action of tenilsetam"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0441472:Action [Functional Concept]
   760   C3266814:Action [Activity]

Phrase: "on aging"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0001811:Ageing [Organism Function]

Phrase: "could"

Phrase: "include"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0332257:include [Functional Concept]
  1000   C1552866:include [Idea or Concept]
  1000   C2700399:Include [Activity]

Phrase: "inhibition of the Maillard reaction."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   760   C0021467:Inhibition [Mental Process]
   760   C0021469:Inhibition [Molecular Function]
   760   C1628982:% inhibition [Quantitative Concept]
   760   C3463820:Inhibition [Activity]
Processing 00000000.tx.32: We, therefore, examined in the present study the effect of tenilsetam on the Maillard reaction in vitro. 

Phrase: "We,"

Phrase: "therefore,"

Phrase: "examined in the present study"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   760   C0150312:Present [Quantitative Concept]
   760   C0332128:Examined [Finding]
   760   C0449450:Present [Idea or Concept]
   760   C0557651:Study [Manufactured Object]
   760   C2603343:Study [Research Activity]

Phrase: "the effect of tenilsetam"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C1280500:Effect [Qualitative Concept]
   770   C2348382:Effect [Qualitative Concept]

Phrase: "on the Maillard reaction"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0024495:Maillard Reaction [Natural Phenomenon or Process]
   861   C0443286:Reaction [Functional Concept]
   861   C1114821:Reaction [Clinical Attribute]

Phrase: "in vitro."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0021135:In Vitro [Intellectual Product]
  1000   C1533691:in vitro [Qualitative Concept]
           vitro
  1000   C2827718:In Vitro [Functional Concept]
Processing 00000000.tx.33: Subsequently, we compared AGE formation in the tissues of diabetic rats with and without administration of tenilsetam. 

Phrase: "Subsequently,"

Phrase: "we"

Phrase: "compared"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1707455:Compared [Activity]

Phrase: "AGE formation in the tissues of diabetic rats"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   744   C0220781:formation [Biologic Function]
   744   C0439634:formation [Spatial Concept]
   744   C1522492:Formation [Functional Concept]

Phrase: "with"

Phrase: "and without administration of tenilsetam."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   760   C0001554:Administration [Occupational Activity]
   760   C0076093:tenilsetam [Organic Chemical,Pharmacologic Substance]
   760   C1515981:And [Idea or Concept]
   760   C1533734:Administration [Therapeutic or Preventive Procedure]
Processing 00000000.tx.34: In addition, the reactivity of tenilsetam to 3-DG was investigated using a specific HPLC assay for 3-DG to compare the action of tenilsetam with that of AG.  

Phrase: "In addition,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1883712:Addition [Functional Concept]
   928 E C1524062:Additional [Functional Concept]

Phrase: "the reactivity of tenilsetam"

Phrase: "to 3-DG"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0047359:3-deoxyglucosone [Carbohydrate]

Phrase: "was"

Phrase: "investigated"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1292732:investigated [Functional Concept]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "a specific HPLC assay for 3-DG to"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   744   C0005507:Assay [Laboratory Procedure]
   744   C0243073:assay [Qualitative Concept]
   744   C1510438:Assay [Laboratory Procedure]

Phrase: "compare"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1707455:Compare [Activity]

Phrase: "the action of tenilsetam"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0441472:Action [Functional Concept]
   770   C3266814:Action [Activity]

Phrase: "with that"

Phrase: "of AG."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0282774:aminoguanidine [Organic Chemical,Pharmacologic Substance]
Processing 00000000.tx.35: Materials and Methods Top Abstract Introduction Materials and Methods Results Discussion References  Reagents and materials Lysozyme (6 x crystallized, from egg white) was purchased from Seikagaku Kogyo Co. 

Phrase: "Materials"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0520510:Materials [Substance]

Phrase: "and"

Phrase: "Methods Top Abstract Introduction Materials"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   804   C0520510:Materials [Substance]

Phrase: "and"

Phrase: "Methods Results Discussion"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0557061:Discussion [Therapeutic or Preventive Procedure]
   827   C2584313:Discussion [Social Behavior]

Phrase: "References"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "Reagents"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0034760:Reagents [Indicator, Reagent, or Diagnostic Aid]

Phrase: "and"

Phrase: "materials Lysozyme"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0026794:Lysosyme [Enzyme,Pharmacologic Substance]
   861   C1416945:LYSOZYME [Gene or Genome]
   861   C3541379:lysozyme [Enzyme,Pharmacologic Substance]

Phrase: "(6 x"

Phrase: "crystallized"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0444626:Crystallized [Chemical Viewed Structurally]

Phrase: ","

Phrase: "from egg white"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0013704:Egg White [Food]
   861   C0007457:White [Population Group]
   861   C0013710:EGG [Food]
   861   C0029974:Egg [Cell]
   861   C0043157:White [Population Group]
   861   C0220938:White [Qualitative Concept]
   861   C1508746:Egg [Organic Chemical,Pharmacologic Substance]

Phrase: ")"

Phrase: "was"

Phrase: "purchased from Seikagaku Kogyo Co."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0869011:purchased [Activity]
Processing 00000000.tx.36: (Tokyo, Japan). 

Phrase: "(Tokyo,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0040371:Tokyo [Geographic Area]

Phrase: "Japan"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0022341:Japan [Geographic Area]

Phrase: ")."
Processing 00000000.tx.37: Type I collagen (from bovine Achilles tendon), collagenase (type VII), AG (hemisulfate salt), and streptozotocin (STZ) were purchased from Sigma Chemical Co. 

Phrase: "Type I collagen"
Meta Candidates (Total=9; Excluded=1; Pruned=0; Remaining=8)
  1000   C0041455:Type 1 Collagen [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   901   C0441729:Type I [Classification]
   827   C0009325:Collagen [Amino Acid, Peptide, or Protein,Biologically Active Substance,Biomedical or Dental Material]
   827   C0021966:I- [Inorganic Chemical]
   827   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C0332307:Type [Qualitative Concept]
   827   C1167364:collagen [Cell Component]
   827   C1547052:*Type [Quantitative Concept]
   755 E C0439689:Collagenous [Qualitative Concept]

Phrase: "("

Phrase: "from bovine Achilles tendon"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   901   C0001074:Achilles Tendon [Body Part, Organ, or Organ Component]
           Achilles
   827   C0039508:Tendon [Body Part, Organ, or Organ Component]
   827   C1280538:Tendon [Body Part, Organ, or Organ Component]

Phrase: ")"

Phrase: ","

Phrase: "collagenase"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0162745:COLLAGENASE [Amino Acid, Peptide, or Protein,Enzyme,Pharmacologic Substance]

Phrase: "(type VII"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0445385:VII [Intellectual Product]

Phrase: ")"

Phrase: ","

Phrase: "AG (hemisulfate salt"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   827   C0036140:Salt [Chemical Viewed Structurally]
   827   C0037494:Salt [Biologically Active Substance,Inorganic Chemical,Pharmacologic Substance]
   827   C0206136:Salt [Food,Inorganic Chemical]
   755 E C1537053:salty [Qualitative Concept]
   727 E C0678584:saltiness [Qualitative Concept]

Phrase: ")"

Phrase: ","

Phrase: "and"

Phrase: "streptozotocin (STZ)"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0038432:Streptozotocin [Antibiotic,Carbohydrate]

Phrase: "were"

Phrase: "purchased from Sigma Chemical Co."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   760   C0220806:Chemical [Chemical]
   760   C0869011:purchased [Activity]
   760   C1719918:Sigma [Intellectual Product]
   760   C3272558:Chemical [Intellectual Product]
Processing 00000000.tx.38: (St. Louis, MO). 

Phrase: "(St. Louis,"

Phrase: "MO"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C3538743:MO [Idea or Concept]

Phrase: ")."
Processing 00000000.tx.39: Tenilsetam was supplied by Cassella (Frankfurt, Germany). 

Phrase: "Tenilsetam"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0076093:tenilsetam [Organic Chemical,Pharmacologic Substance]

Phrase: "was"

Phrase: "supplied by Cassella"
Meta Candidates (Total=6; Excluded=5; Pruned=0; Remaining=1)
   790   C1999230:Supplied [Activity]
   756 E C0243163:supply [Idea or Concept]
   756 E C0699914:supply [Quantitative Concept]
   756 E C1314650:SUPPLY, NOT OTHERWISE SPECIFIED [Medical Device]
   756 E C1561604:supply [Functional Concept]
   756 E C1875802:SUPPLY [Medical Device]

Phrase: "(Frankfurt,"

Phrase: "Germany"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0017480:Germany [Geographic Area]

Phrase: ")."
Processing 00000000.tx.40: 3-DG was supplied by Dr. 

Phrase: "3-DG"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0047359:3-deoxyglucosone [Carbohydrate]

Phrase: "was"

Phrase: "supplied by Dr."
Meta Candidates (Total=10; Excluded=5; Pruned=0; Remaining=5)
   790   C0031831:DR [Professional or Occupational Group]
   790   C1707664:DR [Biomedical or Dental Material]
   790   C1999230:Supplied [Activity]
   790   C2348314:Dr. [Conceptual Entity]
   790   C3540849:DR [Idea or Concept]
   756 E C0243163:supply [Idea or Concept]
   756 E C0699914:supply [Quantitative Concept]
   756 E C1314650:SUPPLY, NOT OTHERWISE SPECIFIED [Medical Device]
   756 E C1561604:supply [Functional Concept]
   756 E C1875802:SUPPLY [Medical Device]
Processing 00000000.tx.41: H. 

Phrase: "H."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]
Processing 00000000.tx.42: Kato (University of Tokyo, Tokyo, Japan); 

Phrase: "Kato"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0721226:Kato [Inorganic Chemical,Pharmacologic Substance]
  1000   C1551914:Kato [Language]

Phrase: "(University of Tokyo,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0040371:Tokyo [Geographic Area]
   827   C0041740:University [Manufactured Object,Organization]

Phrase: "Tokyo,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0040371:Tokyo [Geographic Area]

Phrase: "Japan"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0022341:Japan [Geographic Area]

Phrase: ")"

Phrase: ";"
Processing 00000000.tx.43: the substance was synthesized according to a modified method of Khadem et al. 

Phrase: "the substance"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439861:Substance [Substance]

Phrase: "was"

Phrase: "synthesized according to a modified method of Khadem et al."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   757   C0217843:ET-A [Amino Acid, Peptide, or Protein,Receptor]
   739   C0025663:Method [Intellectual Product]
   739   C0392747:Modified [Functional Concept]
   739   C0449851:Method [Functional Concept]
   739   C0680240:according [Social Behavior]
   739   C0871511:METHOD [Intellectual Product]
   739   C1883254:Synthesized [Activity]
Processing 00000000.tx.44: (35, 36). 

Phrase: "(35,"

Phrase: "36"

Phrase: ")."
Processing 00000000.tx.45: All other chemicals and substances were of analytical reagent grade unless stated otherwise. 

Phrase: "All"

Phrase: "other chemicals"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0220806:Chemicals [Chemical]
   966 E C3272558:Chemical [Intellectual Product]

Phrase: "and"

Phrase: "substances"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439861:Substances [Substance]

Phrase: "were of analytical reagent grade"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   760   C0034760:Reagent [Indicator, Reagent, or Diagnostic Aid]
   760   C0441800:Grade [Classification]
   760   C0919553:Grade [Classification]
   760   C0936012:Analytical [Research Activity]
   760   C3244287:grade [Finding]

Phrase: "unless"

Phrase: "stated"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C1301808:stated [Geographic Area]
  1000   C1442792:Stated [Functional Concept]
   966 E C3148680:State [Geographic Area]

Phrase: "otherwise."
Processing 00000000.tx.46: Lysozyme polymerization We incubated 10 mg/ml lysozyme solution with 100 mM glucose, fructose, or 10 mM 3-DG in the presence and absence of tenilsetam (10 or 100 mM) for 28 days in 0.1 M sodium phosphate buffer (PB; pH 7.4) at 37 C. 

Phrase: "Lysozyme polymerization"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0314672:Polymerisation [Phenomenon or Process]

Phrase: "We"

Phrase: "incubated"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1439852:Incubated [Laboratory Procedure]

Phrase: "10 mg/ml lysozyme solution with 100 mM glucose,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   742   C0037633:Solution [Substance]
   742   C0525069:Solution [Biomedical or Dental Material]

Phrase: "fructose,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0016745:Fructose [Carbohydrate,Pharmacologic Substance]

Phrase: "or"

Phrase: "10 mM 3-DG in the presence"

Phrase: "and"

Phrase: "absence of tenilsetam"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   790   C0332197:absence [Quantitative Concept]
   790   C1689985:Absence [Anatomical Abnormality]
   718 E C2699517:ABSENT [Finding]

Phrase: "(10"

Phrase: "or"

Phrase: "100 mM) for 28 days"

Phrase: "in 0.1 M sodium phosphate buffer"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C3256935:sodium phosphate buffer [Pharmacologic Substance]
   827   C0991865:Phosphate Buffer [Indicator, Reagent, or Diagnostic Aid,Pharmacologic Substance]
   799   C0006353:Buffer [Indicator, Reagent, or Diagnostic Aid,Pharmacologic Substance]

Phrase: "(PB"

Phrase: "; pH 7.4"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   913   C2678549:PH-4 [Gene or Genome]
   901   C1882074:pH 7 [Qualitative Concept]
   827   C0020283:[pH] [Quantitative Concept]
   827   C0450407:ph+ [Finding]
   827   C0450408:ph++ [Finding]
   827   C0450409:ph+++ [Finding]

Phrase: ")"

Phrase: "at 37 C."
Processing 00000000.tx.47: The samples were later dialyzed against distilled water to remove excess sugars and tenilsetam. 

Phrase: "The samples"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C0370003:Sample [Substance]
   966   C2347026:Sample [Conceptual Entity]

Phrase: "were"

Phrase: "later"

Phrase: "dialyzed against distilled water to"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   806   C0790233:Distilled water [Inorganic Chemical,Pharmacologic Substance]
   760   C0043047:Water [Inorganic Chemical,Pharmacologic Substance]
   760   C0599638:WATER [Substance]
   760   C0681549:distilled [Occupational Activity]
   760   C1550678:Water [Inorganic Chemical]

Phrase: "remove"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0849355:remove [Qualitative Concept]
  1000   C1883720:Remove [Activity]
  1000   C3244314:remove [Functional Concept]

Phrase: "excess sugars"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0242209:Sugars [Carbohydrate,Pharmacologic Substance]
   827 E C0007004:Sugar [Carbohydrate]

Phrase: "and"

Phrase: "tenilsetam."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0076093:tenilsetam [Organic Chemical,Pharmacologic Substance]
Processing 00000000.tx.48: All samples were then evaporated to dryness after determining the concentrations of proteins according to the method of Bradford (37). 

Phrase: "All samples"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C0370003:Sample [Substance]
   966   C2347026:Sample [Conceptual Entity]

Phrase: "were"

Phrase: "then"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883708:Then [Temporal Concept]

Phrase: "evaporated"

Phrase: "to dryness after determining"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1512080:Dryness [Qualitative Concept]

Phrase: "the concentrations of proteins"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   786   C0427716:Protein concentration [Laboratory Procedure]
   786   C1304757:Protein concentration [Laboratory or Test Result]
   770   C0086045:Concentrations [Mental Process]
   737 E C1446561:Concentration [Quantitative Concept]

Phrase: "according to the method"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0025663:Method [Intellectual Product]
  1000   C0449851:Method [Functional Concept]
  1000   C0871511:METHOD [Intellectual Product]

Phrase: "of Bradford"

Phrase: "(37"

Phrase: ")."
Processing 00000000.tx.49: Samples were reconstituted in a sample buffer of 50 mM Tris-HCl, 10% (vol/vol) glycerol, 2% (wt/vol) SDS, and 5% (vol/vol) -mercaptoethanol (pH 6.8) at a protein concentration of 1 mg/ml, then boiled for 4 min at 95 C and subjected to SDS-PAGE, conducted on a 15% separating gel (38). 

Phrase: "Samples"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C0370003:Sample [Substance]
   966   C2347026:Sample [Conceptual Entity]

Phrase: "were"

Phrase: "reconstituted in a sample buffer of 50 mM Tris-HCl,"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   757   C0041175:Tris Buffer [Organic Chemical,Pharmacologic Substance]
           TRIS
   739   C0006353:Buffer [Indicator, Reagent, or Diagnostic Aid,Pharmacologic Substance]
   739   C0077281:Tris [Hazardous or Poisonous Substance,Organophosphorus Compound]
   739   C0370003:Sample [Substance]
   739   C0814229:TRI [Intellectual Product]
   739   C2347026:Sample [Conceptual Entity]

Phrase: "10%"

Phrase: "(vol/vol) glycerol,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0017861:Glycerol [Biologically Active Substance,Organic Chemical,Pharmacologic Substance]

Phrase: "2%"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0740116:+2 [Quantitative Concept]
  1000   C2827735:2+ [Quantitative Concept]
  1000   C2981700:2+ [Classification]

Phrase: "(wt/vol) SDS,"

Phrase: "and"

Phrase: "5%"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0439084:>5 [Quantitative Concept]
  1000   C0728893:+5 [Quantitative Concept]

Phrase: "(vol/vol) -mercaptoethanol"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0025402:Mercaptoethanol [Organic Chemical]

Phrase: "(pH 6.8"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   827   C0020283:[pH] [Quantitative Concept]
   827   C0450407:ph+ [Finding]
   827   C0450408:ph++ [Finding]
   827   C0450409:ph+++ [Finding]

Phrase: ")"

Phrase: "at a protein concentration"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
  1000   C0427716:Protein concentration [Laboratory Procedure]
  1000   C1304757:Protein concentration [Laboratory or Test Result]
   861   C0086045:Concentration [Mental Process]
   861   C1446561:Concentration [Quantitative Concept]
   789 E C1880165:Concentrated [Biomedical or Dental Material]

Phrase: "of 1 mg/ml,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   901   C0439294:mg ml [Quantitative Concept]
   827   C0439526:/mL [Quantitative Concept]

Phrase: "then"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883708:Then [Temporal Concept]

Phrase: "boiled for 4 min"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0702093:/min [Temporal Concept]
   737   C0242301:Boil [Disease or Syndrome]
   737   C1546559:Boil [Intellectual Product]

Phrase: "at 95 C"

Phrase: "and"

Phrase: "subjected to SDS-PAGE,"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   833   C0600209:SDS-PAGE [Laboratory Procedure,Research Activity]
   770   C1704732:Page [Intellectual Product]
   737   C0681850:Subject [Group]
   737   C1550501:{Subject} [Idea or Concept]
   737   C1706203:Subject [Idea or Concept]
   737   C2349001:Subject [Human]
   737   C2697811:Subject [Functional Concept]

Phrase: "conducted on a 15% separating gel"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   753   C0017243:Gel [Biomedical or Dental Material]
   753   C0443299:separating [Spatial Concept]
   753   C1382104:Gel [Substance]
   719   C0004927:Conduct [Individual Behavior]

Phrase: "(38"

Phrase: ")."
Processing 00000000.tx.50: An electrophoresis calibration kit for low molecular mass proteins (Pharmacia Co., Piscataway, NJ) was used as a molecular mass marker. 

Phrase: "An electrophoresis calibration kit for low molecular mass proteins"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   742   C0812225:KIT [Medical Device]
   742   C1150635:KIT [Molecular Function]
   742   C1705212:Kit [Medical Device]
   742   C1705213:KIT [Medical Device]
   742   C3273202:Kit [Manufactured Object]

Phrase: "(Pharmacia Co.,"

Phrase: "Piscataway,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1551491:Piscataway [Population Group]

Phrase: "NJ"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0027971:NJ [Geographic Area]

Phrase: ")"

Phrase: "was"

Phrase: "used as a molecular mass marker."
Meta Candidates (Total=11; Excluded=3; Pruned=0; Remaining=8)
   790   C3152252:Molecular Mass [Quantitative Concept]
           Mass
   783   C0005516:Molecular Marker [Clinical Attribute]
           Marker
   753   C0577559:Mass [Finding]
   753   C1273517:used [Finding]
   753   C1306372:*Mass [Quantitative Concept]
   753   C1521991:Molecular [Qualitative Concept]
   719 E C0042153:use [Functional Concept]
   719 E C0457083:Use [Functional Concept]
   719 E C1947944:Use [Intellectual Product]
Processing 00000000.tx.51: Gels were stained with Coomassie brilliant blue R-250 (Nacalai Tesque Co., Kyoto, Japan) and destained with 40% methanol-10% acetic acid. 

Phrase: "Gels"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0017243:Gels [Biomedical or Dental Material]
   966 E C1382104:Gel [Substance]

Phrase: "were"

Phrase: "stained with Coomassie brilliant blue R-250"
Meta Candidates (Total=11; Excluded=1; Pruned=0; Remaining=10)
   853   C0056271:Coomassie brilliant blue R [Organic Chemical]
           Coomassie blue R 250
   814   C0056270:coomassie Brilliant Blue [Indicator, Reagent, or Diagnostic Aid,Organic Chemical,Pharmacologic Substance]
   778   C0054051:brilliant blue [Indicator, Reagent, or Diagnostic Aid,Organic Chemical]
   774   C0056269:Coomassie blue [Organic Chemical,Pharmacologic Substance]
   748   C0205090:R- [Spatial Concept]
   748   C0684010:R. [Professional or Occupational Group]
   748   C1260957:Blue [Qualitative Concept]
   748   C2603358:R' [Clinical Attribute]
   748   C2986582:Stained [Qualitative Concept]
   714 E C0038128:Stain [Indicator, Reagent, or Diagnostic Aid]

Phrase: "(Nacalai Tesque Co.,"

Phrase: "Kyoto,"

Phrase: "Japan"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0022341:Japan [Geographic Area]

Phrase: ")"

Phrase: "and"

Phrase: "destained with 40% methanol-10% acetic acid."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   778   C0000983:Acetic Acid [Indicator, Reagent, or Diagnostic Aid,Organic Chemical,Pharmacologic Substance]
   778   C0000985:Acetic acid [Organic Chemical]
   748   C0001128:Acid [Chemical]
   748   C0001963:Methanol [Hazardous or Poisonous Substance,Organic Chemical,Pharmacologic Substance]
   748   C0202406:Acid [Laboratory Procedure]
   748   C0439509:/40 [Temporal Concept]
   748   C0981805:ACETIC [Organic Chemical,Pharmacologic Substance]
Processing 00000000.tx.52: Measurement of collagen digestibility We incubated type I collagen solution (10 mg/ml) with 100 mM glucose or fructose in the presence or absence of 10 or 100 mM tenilsetam in PB for 28 days at 37 C. 

Phrase: "Measurement of collagen digestibility"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0242485:Measurement [Functional Concept]

Phrase: "We"

Phrase: "incubated"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1439852:Incubated [Laboratory Procedure]

Phrase: "type I collagen solution"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   812   C0037633:Solution [Substance]
   812   C0525069:Solution [Biomedical or Dental Material]
   756   C0041455:Type 1 Collagen [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "(10 mg/"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0439269:mg% [Quantitative Concept]
   861   C1960952:mg % [Quantitative Concept]
   861   C2346927:Mg++ [Element, Ion, or Isotope,Pharmacologic Substance]

Phrase: "ml) with 100 mM glucose"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0439526:/mL [Quantitative Concept]

Phrase: "or"

Phrase: "fructose in the presence"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0016745:Fructose [Carbohydrate,Pharmacologic Substance]

Phrase: "or"

Phrase: "absence of 10"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   790   C0332197:absence [Quantitative Concept]
   790   C1689985:Absence [Anatomical Abnormality]
   718 E C2699517:ABSENT [Finding]

Phrase: "or"

Phrase: "100 mM tenilsetam in PB"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0076093:tenilsetam [Organic Chemical,Pharmacologic Substance]

Phrase: "for 28 days"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   861   C0439228:days [Temporal Concept]
   827 E C0332173:/day [Temporal Concept]
   827 E C0439505:/day [Temporal Concept]

Phrase: "at 37 C."
Processing 00000000.tx.53: Collagen was also incubated with buffer alone as a control. 

Phrase: "Collagen"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0009325:Collagen [Amino Acid, Peptide, or Protein,Biologically Active Substance,Biomedical or Dental Material]
  1000   C1167364:collagen [Cell Component]
   928 E C0439689:Collagenous [Qualitative Concept]

Phrase: "was"

Phrase: "also"

Phrase: "incubated with buffer"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0006353:Buffer [Indicator, Reagent, or Diagnostic Aid,Pharmacologic Substance]
   790   C1439852:Incubated [Laboratory Procedure]

Phrase: "alone as a control."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0205171:Alone [Quantitative Concept]
   770   C0439044:alone [Finding]
   770   C0679994:alone [Group Attribute]
Processing 00000000.tx.54: All samples were then dialyzed against distilled water and digested with an appropriate volume of type VII collagenase in 0.02 M HEPES buffer (pH 7.5) containing 0.1 M CaCl2 for 48 h at 37 C. 

Phrase: "All samples"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C0370003:Sample [Substance]
   966   C2347026:Sample [Conceptual Entity]

Phrase: "were"

Phrase: "then"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883708:Then [Temporal Concept]

Phrase: "dialyzed against distilled water"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   833   C0790233:Distilled water [Inorganic Chemical,Pharmacologic Substance]
   770   C0043047:Water [Inorganic Chemical,Pharmacologic Substance]
   770   C0599638:WATER [Substance]
   770   C0681549:distilled [Occupational Activity]
   770   C1550678:Water [Inorganic Chemical]

Phrase: "and"

Phrase: "digested with an appropriate volume of type VII collagenase"
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   742   C0162745:COLLAGENASE [Amino Acid, Peptide, or Protein,Enzyme,Pharmacologic Substance]
   742   C0332307:Type [Qualitative Concept]
   742   C0445385:VII [Intellectual Product]
   742   C0449468:*Volume [Quantitative Concept]
   742   C0868946:digested [Physiologic Function]
   742   C1547052:*Type [Quantitative Concept]
   742   C1548787:Appropriate [Qualitative Concept]
   742   C1690016:% volume [Qualitative Concept]
   742   C1705102:Volume [Intellectual Product]
   742   C2700258:Volume [Laboratory Procedure]

Phrase: "in 0.02 M HEPES buffer"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   804   C0006353:Buffer [Indicator, Reagent, or Diagnostic Aid,Pharmacologic Substance]

Phrase: "(pH 7.5"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   901   C1882074:pH 7 [Qualitative Concept]
   827   C0020283:[pH] [Quantitative Concept]
   827   C0450407:ph+ [Finding]
   827   C0450408:ph++ [Finding]
   827   C0450409:ph+++ [Finding]

Phrase: ")"

Phrase: "containing"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0332256:Containing [Functional Concept]
  1000   C2700400:Containing [Activity]

Phrase: "0.1 M CaCl2 for 48 h"

Phrase: "at 37 C."
Processing 00000000.tx.55: Soluble and insoluble fractions were separated by centrifugation at 8000 x g for 10 min. 

Phrase: "Soluble"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1749467:soluble [Cell Component]
  1000   C1948047:Soluble [Qualitative Concept]

Phrase: "and"

Phrase: "insoluble fractions"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C1264633:Fractions [Quantitative Concept]
   827 E C1554103:Fraction [Idea or Concept]

Phrase: "were"

Phrase: "separated by centrifugation"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   790   C0007703:Centrifugation [Laboratory Procedure]
   790   C0086972:Separated [Finding]
   790   C0443299:separated [Spatial Concept]
   790   C0687118:Separated [Functional Concept]

Phrase: "at 8000 x g"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0439267:g% [Quantitative Concept]

Phrase: "for 10 min."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0456692:/10 min [Temporal Concept]
   861   C0702093:/min [Temporal Concept]
Processing 00000000.tx.56: Each fraction was acid hydrolyzed in 6 N HCl for 24 h at 110 C. 

Phrase: "Each fraction"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1264633:Fraction [Quantitative Concept]
  1000   C1554103:Fraction [Idea or Concept]

Phrase: "was"

Phrase: "acid"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0001128:Acid [Chemical]
  1000   C0202406:Acid [Laboratory Procedure]

Phrase: "hydrolyzed in 6 N HCl"

Phrase: "for 24 h"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "at 110 C."
Processing 00000000.tx.57: Finally, the amount of collagen in each fraction was estimated by the hydroxyproline assay of Stegmann and Stalder (39), and digestibility was calculated as the ratio of collagen in the soluble fraction to the total collagen content. 

Phrase: "Finally,"

Phrase: "the amount of collagen"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1265611:Amount [Quantitative Concept]

Phrase: "in each fraction"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1264633:Fraction [Quantitative Concept]
  1000   C1554103:Fraction [Idea or Concept]

Phrase: "was"

Phrase: "estimated by the hydroxyproline assay of Stegmann"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   748   C0005507:Assay [Laboratory Procedure]
   748   C0020388:Hydroxyproline [Amino Acid, Peptide, or Protein,Biologically Active Substance,Pharmacologic Substance]
   748   C0243073:assay [Qualitative Concept]
   748   C0750572:Estimated [Quantitative Concept]
   748   C1510438:Assay [Laboratory Procedure]

Phrase: "and"

Phrase: "Stalder"

Phrase: "(39"

Phrase: ")"

Phrase: ","

Phrase: "and"

Phrase: "digestibility"

Phrase: "was"

Phrase: "calculated as the ratio of collagen"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   753   C0009325:Collagen [Amino Acid, Peptide, or Protein,Biologically Active Substance,Biomedical or Dental Material]
   753   C0444686:Calculated [Functional Concept]
   753   C0456603:Ratio [Quantitative Concept]
   753   C1167364:collagen [Cell Component]
   753   C1441506:Calculated [Activity]
   753   C1443182:Calculated [Laboratory Procedure]
   753   C1547037:Ratio [Intellectual Product]

Phrase: "in the soluble fraction"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1264633:Fraction [Quantitative Concept]
   861   C1554103:Fraction [Idea or Concept]

Phrase: "to the total collagen content."
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   827   C0009325:Collagen [Amino Acid, Peptide, or Protein,Biologically Active Substance,Biomedical or Dental Material]
   827   C0423896:Content [Mental Process]
   827   C0456205:Content [Conceptual Entity]
   827   C1167364:collagen [Cell Component]
   755 E C0439689:Collagenous [Qualitative Concept]
Processing 00000000.tx.58: In addition, we examined whether the glucose concentration, comparable to blood glucose level in nontreated diabetic subjects, still had the suppressive effect on collagen digestibility. 

Phrase: "In addition,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1883712:Addition [Functional Concept]
   928 E C1524062:Additional [Functional Concept]

Phrase: "we"

Phrase: "examined"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0332128:Examined [Finding]

Phrase: "whether"

Phrase: "the glucose concentration,"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
  1000   C0427743:Glucose concentration [Laboratory Procedure]
  1000   C1287281:Glucose concentration [Laboratory or Test Result]
   861   C0086045:Concentration [Mental Process]
   861   C1446561:Concentration [Quantitative Concept]
   789 E C1880165:Concentrated [Biomedical or Dental Material]

Phrase: "comparable to blood glucose level"

Phrase: "in nontreated diabetic subjects,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   793   C0681850:Subject [Group]
   793   C1550501:{Subject} [Idea or Concept]
   793   C1706203:Subject [Idea or Concept]
   793   C2349001:Subject [Human]
   793   C2697811:Subject [Functional Concept]

Phrase: "still"

Phrase: "had"

Phrase: "the suppressive effect on collagen digestibility."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C1280500:Effect [Qualitative Concept]
   753   C2348382:Effect [Qualitative Concept]
Processing 00000000.tx.59: Collagen was incubated with 30 mM glucose in the presence or absence of tenilsetam for 28 days, followed by estimation of digestibility as described above. 

Phrase: "Collagen"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0009325:Collagen [Amino Acid, Peptide, or Protein,Biologically Active Substance,Biomedical or Dental Material]
  1000   C1167364:collagen [Cell Component]
   928 E C0439689:Collagenous [Qualitative Concept]

Phrase: "was"

Phrase: "incubated with 30 mM glucose"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   760   C1439852:Incubated [Laboratory Procedure]

Phrase: "in the presence"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0392148:Presence [Therapeutic or Preventive Procedure]
   928 E C0150312:Present [Quantitative Concept]
   928 E C0449450:Present [Idea or Concept]

Phrase: "or"

Phrase: "absence of tenilsetam"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   790   C0332197:absence [Quantitative Concept]
   790   C1689985:Absence [Anatomical Abnormality]
   718 E C2699517:ABSENT [Finding]

Phrase: "for 28 days,"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   861   C0439228:days [Temporal Concept]
   827 E C0332173:/day [Temporal Concept]
   827 E C0439505:/day [Temporal Concept]

Phrase: "followed by estimation of digestibility"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   806   C0332283:Followed by [Temporal Concept]
           followed
   760   C0680844:estimation [Mental Process]
   760   C0681916:Estimation [Quantitative Concept]
   760   C0750572:Estimation [Quantitative Concept]
   726 E C1719822:Follow [Intellectual Product]

Phrase: "as described above."
Processing 00000000.tx.60: The data were expressed as the mean  SD of three samples. 

Phrase: "The data"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1511726:Data [Idea or Concept]
  1000   C3245479:data [Medical Device]

Phrase: "were"

Phrase: "expressed as the mean  SD of three samples."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   750   C2348143:Sample Mean [Quantitative Concept]
           Mean
   744   C0205449:Three [Quantitative Concept]
   744   C0444504:Mean [Quantitative Concept]
   744   C2347634:Mean [Quantitative Concept]
   711   C0370003:Sample [Substance]
   711   C2347026:Sample [Conceptual Entity]
Processing 00000000.tx.61: Animals Male Sprague-Dawley rats (46 weeks old, 120150 g BW) were randomly subdivided into three groups: group A, controls (n = 10); 

Phrase: "Animals Male Sprague-Dawley rats"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   884   C0034715:Rats, Sprague-Dawley [Mammal]
   840   C2699239:Sprague-Dawley [Mammal]
   804   C0034693:rats [Mammal]
   804   C0034721:Rats [Mammal]

Phrase: "(46 weeks old,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0580836:Old [Temporal Concept]

Phrase: "120150 g BW)"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0005910:BW [Organism Attribute]
   827   C0006041:BW [Geographic Area]
   827   C2986891:BW [Idea or Concept]

Phrase: "were"

Phrase: "randomly"

Phrase: "subdivided into three groups"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   770   C0205449:Three [Quantitative Concept]
   770   C0441833:Group [Idea or Concept]
   770   C0687744:group [Population Group]
   770   C1257890:Group [Population Group]
   770   C1552516:Group [Health Care Related Organization]
   770   C1552839:groups [Idea or Concept]
   770   C1705428:Group [Conceptual Entity]
   770   C1705429:Group [Population Group]

Phrase: ":"

Phrase: "group A,"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0441835:Group A [Classification]
   861   C0441833:Group [Idea or Concept]
   861   C0687744:group [Population Group]
   861   C1257890:Group [Population Group]
   861   C1552516:Group [Health Care Related Organization]
   861   C1705428:Group [Conceptual Entity]
   861   C1705429:Group [Population Group]

Phrase: "controls"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   966   C0243148:control [Qualitative Concept]
   966   C1550141:Control [Substance]
   966   C1882979:Control [Conceptual Entity]
   966   C2587213:Control [Functional Concept]
   966   C3274648:Control [Qualitative Concept]

Phrase: "(n = 10"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441922:N+ [Intellectual Product]
   861   C1553036:[n] [Quantitative Concept]

Phrase: ")"

Phrase: ";"
Processing 00000000.tx.62: group B, STZ-induced diabetic rats (n = 8); 

Phrase: "group B,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   861   C0441833:Group [Idea or Concept]
   861   C0687744:group [Population Group]
   861   C1257890:Group [Population Group]
   861   C1552516:Group [Health Care Related Organization]
   861   C1705428:Group [Conceptual Entity]
   861   C1705429:Group [Population Group]

Phrase: "STZ-induced diabetic rats"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   812   C0034693:rats [Mammal]
   812   C0034721:Rats [Mammal]
   812   C0241863:DIABETIC [Finding]

Phrase: "(n = 8"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441922:N+ [Intellectual Product]
   861   C1553036:[n] [Quantitative Concept]

Phrase: ")"

Phrase: ";"
Processing 00000000.tx.63: and group C, tenilsetam-treated diabetic rats (n = 9). 

Phrase: "and"

Phrase: "group C,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0441837:Group C [Classification]

Phrase: "tenilsetam-treated diabetic rats"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   812   C0034693:rats [Mammal]
   812   C0034721:Rats [Mammal]
   812   C0241863:DIABETIC [Finding]

Phrase: "(n = 9"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441922:N+ [Intellectual Product]
   861   C1553036:[n] [Quantitative Concept]

Phrase: ")."
Processing 00000000.tx.64: Diabetes was induced by a single iv injection of STZ (65 mg/kg BW) freshly dissolved in 200 l sterile citrate buffer (pH 4.5). 

Phrase: "Diabetes"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0011847:Diabetes [Disease or Syndrome]
  1000   C0011849:Diabetes [Disease or Syndrome]

Phrase: "was"

Phrase: "induced by a single iv injection of STZ"
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   770   C0021494:IV injection [Functional Concept]
   744   C0021485:injection [Therapeutic or Preventive Procedure]
   744   C0037179:Single [Population Group]
   744   C0038432:Streptozotocin [Antibiotic,Carbohydrate]
   744   C0087136:single [Finding]
   744   C0205171:Single [Quantitative Concept]
   744   C0205263:Induced [Functional Concept]
   744   C1272883:Injection [Biomedical or Dental Material]
   744   C1533685:Injection [Therapeutic or Preventive Procedure]
   744   C1828121:Injection [Functional Concept]

Phrase: "(65 mg/kg BW) freshly"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   804   C0005910:BW [Organism Attribute]
   804   C0006041:BW [Geographic Area]
   804   C2986891:BW [Idea or Concept]

Phrase: "dissolved in 200 l sterile citrate buffer"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   778   C3256468:citrate buffer [Pharmacologic Substance]
   748   C0006353:Buffer [Indicator, Reagent, or Diagnostic Aid,Pharmacologic Substance]
   748   C0008857:Citrate [Organic Chemical]
   748   C0232920:Sterile [Qualitative Concept]
   748   C0376259:Citrate [Organic Chemical,Pharmacologic Substance]
   748   C0678108:Sterile [Pathologic Function]
   714   C1549535:Dissolve [Functional Concept]

Phrase: "(pH 4.5"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   901   C2678549:PH-4 [Gene or Genome]
   827   C0020283:[pH] [Quantitative Concept]
   827   C0450407:ph+ [Finding]
   827   C0450408:ph++ [Finding]
   827   C0450409:ph+++ [Finding]

Phrase: ")."
Processing 00000000.tx.65: Only animals with plasma glucose levels over 20 mM after 1 week of injection were included in the study. 

Phrase: "Only animals with plasma glucose levels"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0003062:Animals [Animal]

Phrase: "over 20 mM"

Phrase: "after 1 week"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1442452:1 Week [Temporal Concept]
   861   C0332174:/week [Temporal Concept]
   861   C0439230:week [Temporal Concept]

Phrase: "of injection"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0021485:injection [Therapeutic or Preventive Procedure]
  1000   C1272883:Injection [Biomedical or Dental Material]
  1000   C1533685:Injection [Therapeutic or Preventive Procedure]
  1000   C1828121:Injection [Functional Concept]

Phrase: "were"

Phrase: "included in the study."
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   770   C0332257:included [Functional Concept]
   770   C0557651:Study [Manufactured Object]
   770   C2603343:Study [Research Activity]
   770   C3538986:INCLUDED [Gene or Genome]
   737 E C1552866:include [Idea or Concept]
   737 E C2700399:Include [Activity]
Processing 00000000.tx.66: Control rats were sham injected with the citrate buffer. 

Phrase: "Control rats"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   861   C0034693:rats [Mammal]
   861   C0034721:Rats [Mammal]
   861   C0243148:control [Qualitative Concept]
   861   C1550141:Control [Substance]
   861   C1882979:Control [Conceptual Entity]
   861   C2587213:Control [Functional Concept]
   861   C3274648:Control [Qualitative Concept]

Phrase: "were"

Phrase: "sham"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0068899:S-HAM [Therapeutic or Preventive Procedure]
  1000   C0073980:SHAM [Organic Chemical,Pharmacologic Substance]

Phrase: "injected with the citrate buffer."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   806   C3256468:citrate buffer [Pharmacologic Substance]
   760   C0006353:Buffer [Indicator, Reagent, or Diagnostic Aid,Pharmacologic Substance]
   760   C0008857:Citrate [Organic Chemical]
   760   C0376259:Citrate [Organic Chemical,Pharmacologic Substance]
   726   C1720154:Inject [Functional Concept]
Processing 00000000.tx.67: Animals were provided with water ad libitum and fed standard laboratory chow. 

Phrase: "Animals"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0003062:Animals [Animal]

Phrase: "were"

Phrase: "provided with water"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   790   C0043047:Water [Inorganic Chemical,Pharmacologic Substance]
   790   C0599638:WATER [Substance]
   790   C1550678:Water [Inorganic Chemical]
   790   C1999230:Provided [Activity]
   718 E C0443350:Watery [Qualitative Concept]

Phrase: "ad libitum"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1879743:ad libitum [Qualitative Concept]

Phrase: "and"

Phrase: "fed standard laboratory chow."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0324335:chow [Mammal]
Processing 00000000.tx.68: Group C rats were administered tenilsetam (50 mg/kgday) orally using a catheter for 16 weeks. 

Phrase: "Group C rats"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0034693:rats [Mammal]
   827   C0034721:Rats [Mammal]
   734   C0441837:Group C [Classification]

Phrase: "were"

Phrase: "administered"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1521801:Administered [Functional Concept]
   966 E C1621583:Administer [Functional Concept]

Phrase: "tenilsetam"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0076093:tenilsetam [Organic Chemical,Pharmacologic Substance]

Phrase: "(50 mg/kgday"

Phrase: ")"

Phrase: "orally"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0442027:Orally [Spatial Concept]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "a catheter for 16 weeks."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0085590:Catheter [Medical Device]
   760   C1704454:Catheter [Medical Device]
Processing 00000000.tx.69: Principles of laboratory animal care were followed. 

Phrase: "Principles of laboratory animal care"

Phrase: "were"

Phrase: "followed."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0332283:followed [Temporal Concept]
   966 E C1719822:Follow [Intellectual Product]
Processing 00000000.tx.70: Plasma glucose level was determined by glucose oxidase method (40), whereas glycated hemoglobin (Hb) was assayed using a boronate affinity chromatography with Gly-Affin-Ghb (Seikagaku Kogyo Co., Tokyo, Japan). 

Phrase: "Plasma glucose level"
Meta Candidates (Total=12; Excluded=0; Pruned=0; Remaining=12)
  1000   C0455280:plasma glucose level [Laboratory or Test Result]
           plasma glucose
   901   C0202042:Plasma glucose [Laboratory Procedure]
   901   C0337438:glucose level [Laboratory Procedure]
   901   C0428548:Glucose level [Laboratory or Test Result]
   827   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   827   C0032105:Plasma [Body Substance]
   827   C0441889:Level [Qualitative Concept]
   827   C0456079:Level [Classification]
   827   C1547707:Level [Geographic Area]
   827   C1550098:Plasma, NOS (not otherwise specified) [Body Substance]
   827   C2946261:Level [Pharmacologic Substance]

Phrase: "was"

Phrase: "determined by glucose oxidase method"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   806   C0017735:GLUCOSE OXIDASE [Amino Acid, Peptide, or Protein,Enzyme]
   760   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   760   C0025663:Method [Intellectual Product]
   760   C0242417:Oxidase [Amino Acid, Peptide, or Protein,Enzyme]
   760   C0449851:Method [Functional Concept]
   760   C0871511:METHOD [Intellectual Product]

Phrase: "(40"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439509:/40 [Temporal Concept]

Phrase: ")"

Phrase: ","

Phrase: "whereas"

Phrase: "glycated hemoglobin (Hb)"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0017853:Glycated haemoglobin [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   861   C0019046:Haemoglobin [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "was"

Phrase: "assayed"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C0005507:Assay [Laboratory Procedure]
   966   C0243073:assay [Qualitative Concept]
   966   C1510438:Assay [Laboratory Procedure]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "a boronate affinity chromatography"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   901   C0008551:Chromatography, Affinity [Laboratory Procedure]
   827   C0008550:Chromatography [Laboratory Procedure]
   827   C1510827:Affinity [Natural Phenomenon or Process]
   727 E C0302647:chromatograph [Medical Device]

Phrase: "with Gly-Affin-Ghb (Seikagaku Kogyo Co.,"

Phrase: "Tokyo,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0040371:Tokyo [Geographic Area]

Phrase: "Japan"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0022341:Japan [Geographic Area]

Phrase: ")."
Processing 00000000.tx.71: Tissue preparation After 16 weeks of treatment, the animals were killed under ether anesthesia. 

Phrase: "Tissue preparation After 16 weeks of treatment,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   778   C0200728:Tissue Preparation [Laboratory Procedure]
   748   C0455052:Preparation [Health Care Activity]
   748   C1521827:Preparation [Functional Concept]

Phrase: "the animals"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0003062:Animals [Animal]

Phrase: "were"

Phrase: "killed under ether anesthesia."
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   770   C0002903:Anesthesia [Therapeutic or Preventive Procedure]
   770   C0002930:Anaesthesia [Biomedical Occupation or Discipline]
   770   C0014994:Ether [Organic Chemical,Pharmacologic Substance]
   770   C0014996:Ether, NOS [Organic Chemical,Pharmacologic Substance]
   770   C0162388:killed [Social Behavior]
   770   C1161324:ether [Organic Chemical,Pharmacologic Substance]
   761   C3495432:Anaesthetic ether [Organic Chemical,Pharmacologic Substance]
   737 E C0681205:Kill [Idea or Concept]
   737 E C1550555:kill [Functional Concept]
Processing 00000000.tx.72: The tissue preparation was carried out by the modified method of Monnier et al. 

Phrase: "The tissue preparation"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0200728:Tissue Preparation [Laboratory Procedure]
   861   C0455052:Preparation [Health Care Activity]
   861   C1521827:Preparation [Functional Concept]

Phrase: "was"

Phrase: "carried"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0206243:carried [Activity]
  1000   C0699809:carried [Finding]

Phrase: "out by the modified method of Monnier et al."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   762   C0205349:Modified By [Qualitative Concept]
   742   C0025663:Method [Intellectual Product]
   742   C0392747:Modified [Functional Concept]
   742   C0439787:Out [Spatial Concept]
   742   C0449851:Method [Functional Concept]
   742   C0849355:Out [Qualitative Concept]
   742   C0871511:METHOD [Intellectual Product]
Processing 00000000.tx.73: (3). 

Phrase: "(3"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439086:<3 [Quantitative Concept]
  1000   C2827736:3+ [Quantitative Concept]
  1000   C2981702:3+ [Classification]

Phrase: ")."
Processing 00000000.tx.74: Briefly, the renal cortex and aorta from each animal were dissected, minced with a blade, and washed in cold PBS, followed by delipidation using 5 ml chloroform-ethanol (2:1, vol/vol) with gentle shaking overnight at room temperature. 

Phrase: "Briefly,"

Phrase: "the renal cortex"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0022655:Renal cortex [Body Part, Organ, or Organ Component]
   861   C0007776:Cortex [Body Part, Organ, or Organ Component]
   861   C0022646:Renal [Body Part, Organ, or Organ Component]
   861   C1176472:Cortex [Body Part, Organ, or Organ Component]
   861   C2700441:Cortex [Plant]

Phrase: "and"

Phrase: "aorta from each animal"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0003483:Aorta [Body Part, Organ, or Organ Component]
   770   C1278934:Aorta [Body Part, Organ, or Organ Component]

Phrase: "were"

Phrase: "dissected"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205239:dissected [Functional Concept]

Phrase: ","

Phrase: "minced with a blade,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0179323:blade [Medical Device]
   770   C2700402:Blade [Plant]
   770   C2948008:Blade [Pharmacologic Substance]

Phrase: "and"

Phrase: "washed in cold PBS,"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   770   C0009264:Cold [Natural Phenomenon or Process]
   770   C0009443:Cold [Disease or Syndrome]
   770   C0234192:Cold [Physiologic Function]
   770   C1548982:Washed [Idea or Concept]
   770   C1720830:PBS [Disease or Syndrome]
   770   C1823521:PBS [Gene or Genome]
   737 E C0441648:Wash [Activity]

Phrase: "followed by delipidation"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   882   C0332283:Followed by [Temporal Concept]
           followed
   756 E C1719822:Follow [Intellectual Product]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "5 ml chloroform-ethanol"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0001962:Ethanol [Organic Chemical]

Phrase: "(2"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0740116:+2 [Quantitative Concept]
  1000   C2827735:2+ [Quantitative Concept]
  1000   C2981700:2+ [Classification]

Phrase: ":"

Phrase: "1,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C2827734:1+ [Quantitative Concept]
  1000   C2981698:1+ [Classification]

Phrase: "vol/vol) with gentle shaking"

Phrase: "overnight at room temperature."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0439583:Overnight [Temporal Concept]
Processing 00000000.tx.75: Two milliliters of methanol and 0.5 ml water were added in the middle of this period. 

Phrase: "Two milliliters of methanol"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0439242:milliliter [Quantitative Concept]

Phrase: "and"

Phrase: "0.5 ml water"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   812   C0043047:Water [Inorganic Chemical,Pharmacologic Substance]
   812   C0599638:WATER [Substance]
   812   C1550678:Water [Inorganic Chemical]
   741 E C0443350:Watery [Qualitative Concept]

Phrase: "were"

Phrase: "added in the middle of this period."
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   748   C0439531:/period [Temporal Concept]
   748   C0444598:Middle [Spatial Concept]
   748   C0549183:middle [Spatial Concept]
   748   C1524062:Added [Functional Concept]
   748   C1552826:middle [Idea or Concept]
   748   C1948053:Period [Temporal Concept]
   714 E C1883712:Add [Functional Concept]
Processing 00000000.tx.76: The sample was centrifuged at 1500 x g for 10 min at 4 C, and the supernatant was removed by aspiration. 

Phrase: "The sample"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0370003:Sample [Substance]
  1000   C2347026:Sample [Conceptual Entity]

Phrase: "was"

Phrase: "centrifuged at 1500 x g"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0439267:g% [Quantitative Concept]
   726   C0179834:centrifuge [Medical Device]

Phrase: "for 10 min"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0456692:/10 min [Temporal Concept]
   861   C0702093:/min [Temporal Concept]

Phrase: "at 4 C,"

Phrase: "and"

Phrase: "the supernatant"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1550101:Supernatant [Body Substance]

Phrase: "was"

Phrase: "removed by aspiration."
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   790   C0220787:Aspiration [Health Care Activity]
   790   C0349707:Aspiration [Therapeutic or Preventive Procedure]
   790   C0700198:Aspiration [Pathologic Function]
   790   C0849355:Removed [Qualitative Concept]
   790   C2827071:Aspiration [Finding]
   756 E C1883720:Remove [Activity]
   756 E C3244314:remove [Functional Concept]
Processing 00000000.tx.77: The pellet was consecutively washed twice with 5 ml methanol, three times with distilled water, and twice with 0.02 M HEPES buffer (pH 7.5) containing 0.1 M CaCl2 (buffer A). 

Phrase: "The pellet"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0441436:Pellet [Manufactured Object]
  1000   C0993610:Pellet [Biomedical or Dental Material]
  1000   C1998480:Pellet [Quantitative Concept]

Phrase: "was"

Phrase: "consecutively"

Phrase: "washed"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1548982:Washed [Idea or Concept]
   966 E C0441648:Wash [Activity]

Phrase: "twice with 5 ml methanol,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   760   C0001963:Methanol [Hazardous or Poisonous Substance,Organic Chemical,Pharmacologic Substance]
   760   C0439526:/mL [Quantitative Concept]
   760   C1720725:Twice [Intellectual Product]
   760   C1948050:Twice [Quantitative Concept]

Phrase: "three times with distilled water,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   760   C0040223:times [Temporal Concept]
   760   C1632851:Times [Quantitative Concept]
   726 E C3541383:Time [Temporal Concept]

Phrase: "and"

Phrase: "twice with 0.02 M HEPES buffer"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   748   C0006353:Buffer [Indicator, Reagent, or Diagnostic Aid,Pharmacologic Substance]
   748   C0019215:HEPES [Indicator, Reagent, or Diagnostic Aid,Organic Chemical]
   748   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   748   C0441923:M+ [Intellectual Product]
   748   C1720725:Twice [Intellectual Product]
   748   C1948050:Twice [Quantitative Concept]

Phrase: "(pH 7.5"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   901   C1882074:pH 7 [Qualitative Concept]
   827   C0020283:[pH] [Quantitative Concept]
   827   C0450407:ph+ [Finding]
   827   C0450408:ph++ [Finding]
   827   C0450409:ph+++ [Finding]

Phrase: ")"

Phrase: "containing"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0332256:Containing [Functional Concept]
  1000   C2700400:Containing [Activity]

Phrase: "0.1 M CaCl2"

Phrase: "(buffer A"

Phrase: ")."
Processing 00000000.tx.78: The buffer was then removed, and the pellet was resuspended in 2 ml buffer A containing 400 U type VII collagenase. 

Phrase: "The buffer"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0006353:Buffer [Indicator, Reagent, or Diagnostic Aid,Pharmacologic Substance]

Phrase: "was"

Phrase: "then"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883708:Then [Temporal Concept]

Phrase: "removed"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0849355:Removed [Qualitative Concept]
   966 E C1883720:Remove [Activity]
   966 E C3244314:remove [Functional Concept]

Phrase: ","

Phrase: "and"

Phrase: "the pellet"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0441436:Pellet [Manufactured Object]
  1000   C0993610:Pellet [Biomedical or Dental Material]
  1000   C1998480:Pellet [Quantitative Concept]

Phrase: "was"

Phrase: "resuspended in 2 ml buffer"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0006353:Buffer [Indicator, Reagent, or Diagnostic Aid,Pharmacologic Substance]
   760   C0439526:/mL [Quantitative Concept]

Phrase: "A containing 400 U type VII collagenase."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   799   C0162745:COLLAGENASE [Amino Acid, Peptide, or Protein,Enzyme,Pharmacologic Substance]
Processing 00000000.tx.79: Two microliters of toluene were added as a preservative. 

Phrase: "Two microliters of toluene"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0439243:microliter [Quantitative Concept]

Phrase: "were"

Phrase: "added as a preservative."
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   770   C0033086:Preservative [Biomedical or Dental Material]
   770   C1524062:Added [Functional Concept]
   737 E C1883712:Add [Functional Concept]
Processing 00000000.tx.80: The enzymatic digestion was thoroughly performed under constant gentle shaking at 37 C for 60 h. 

Phrase: "The enzymatic digestion"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   861   C0012238:Digestion [Organism Function]
   861   C2349986:Digestion [Research Activity]
   805 E C0443277:Peptic [Functional Concept]

Phrase: "was"

Phrase: "thoroughly"

Phrase: "performed under constant gentle shaking"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   760   C0040822:Shaking [Sign or Symptom]
   760   C0720654:Gentle [Organic Chemical,Pharmacologic Substance]
   760   C0884358:Performed [Functional Concept]
   760   C1547014:*Constant [Quantitative Concept]
   760   C1948059:Constant [Qualitative Concept]
   726 E C1883023:Shake [Activity]
   726 E C2947996:Perform [Pharmacologic Substance]

Phrase: "at 37 C"

Phrase: "for 60 h."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]
Processing 00000000.tx.81: After centrifugation at 8000 x g for 10 min at 4 C, the collagen content in collagenase-soluble and insoluble fractions from each sample was estimated using the hydroxyproline assay as described previously (39). 

Phrase: "After centrifugation"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0007703:Centrifugation [Laboratory Procedure]

Phrase: "at 8000 x g"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0439267:g% [Quantitative Concept]

Phrase: "for 10 min"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0456692:/10 min [Temporal Concept]
   861   C0702093:/min [Temporal Concept]

Phrase: "at 4 C,"

Phrase: "the collagen content in collagenase-soluble"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   753   C0009325:Collagen [Amino Acid, Peptide, or Protein,Biologically Active Substance,Biomedical or Dental Material]
   753   C0423896:Content [Mental Process]
   753   C0456205:Content [Conceptual Entity]
   753   C1167364:collagen [Cell Component]

Phrase: "and"

Phrase: "insoluble fractions from each sample"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   760   C1264633:Fractions [Quantitative Concept]
   726 E C1554103:Fraction [Idea or Concept]

Phrase: "was"

Phrase: "estimated"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0750572:Estimated [Quantitative Concept]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "the hydroxyproline assay"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0005507:Assay [Laboratory Procedure]
   861   C0243073:assay [Qualitative Concept]
   861   C1510438:Assay [Laboratory Procedure]

Phrase: "as"

Phrase: "described"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1552738:described [Idea or Concept]

Phrase: "previously"

Phrase: "(39"

Phrase: ")."
Processing 00000000.tx.82: Thus, it appeared that more than 95% of each tissue collagen was solubilized. 

Phrase: "Thus,"

Phrase: "it"

Phrase: "appeared"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0700364:APPEAR [Qualitative Concept]

Phrase: "that more than 95% of each tissue collagen"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   744   C0009325:Collagen [Amino Acid, Peptide, or Protein,Biologically Active Substance,Biomedical or Dental Material]
   744   C0040300:Tissue [Tissue]
   744   C1167364:collagen [Cell Component]
   744   C1547928:Tissue [Intellectual Product]

Phrase: "was"

Phrase: "solubilized."
Processing 00000000.tx.83: The soluble fraction of each sample was subsequently used to measure collagen-linked fluorescence and the level of pyrraline. 

Phrase: "The soluble fraction of each sample"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C1264633:Fraction of [Quantitative Concept]
           Fraction
   753   C1554103:Fraction [Idea or Concept]

Phrase: "was"

Phrase: "subsequently"

Phrase: "used"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1273517:used [Finding]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "measure"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0079809:Measure [Quantitative Concept]
  1000   C0242485:Measure [Functional Concept]

Phrase: "collagen-linked fluorescence"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   827   C0016315:Fluorescence [Natural Phenomenon or Process]
   755 E C0303920:Fluorescent [Indicator, Reagent, or Diagnostic Aid,Organic Chemical]

Phrase: "and"

Phrase: "the level of pyrraline."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0441889:Level [Qualitative Concept]
   770   C0456079:Level [Classification]
   770   C1547707:Level [Geographic Area]
   770   C2946261:Level [Pharmacologic Substance]
Processing 00000000.tx.84: Collagenase alone was incubated under the same conditions mentioned above as a blank. 

Phrase: "Collagenase"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0162745:COLLAGENASE [Amino Acid, Peptide, or Protein,Enzyme,Pharmacologic Substance]

Phrase: "alone"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205171:Alone [Quantitative Concept]
  1000   C0439044:alone [Finding]
  1000   C0679994:alone [Group Attribute]

Phrase: "was"

Phrase: "incubated under the same conditions"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   760   C0445247:Same [Qualitative Concept]
   760   C1439852:Incubated [Laboratory Procedure]
   726   C0012634:condition [Disease or Syndrome]
   726   C0348080:Condition [Qualitative Concept]
   726   C1705253:Condition [Conceptual Entity]

Phrase: "mentioned"

Phrase: "above as a blank."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C1282910:Above [Spatial Concept]
   770   C1552828:above [Idea or Concept]
Processing 00000000.tx.85: Fluorescence measurement The collagen concentration of each digested tissue sample was adjusted to 3 mg/ml in HEPES buffer solution for fluorescence measurement. 

Phrase: "Fluorescence measurement"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0242485:Measurement [Functional Concept]

Phrase: "The collagen concentration of each digested tissue sample"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C0086045:Concentration [Mental Process]
   744   C1446561:Concentration [Quantitative Concept]

Phrase: "was"

Phrase: "adjusted to 3 mg/ml"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   806   C0439294:mg ml [Quantitative Concept]
   760   C0439269:mg% [Quantitative Concept]
   760   C0439526:/mL [Quantitative Concept]
   760   C0456081:Adjusted [Functional Concept]
   760   C1960952:mg % [Quantitative Concept]
   760   C2346927:Mg++ [Element, Ion, or Isotope,Pharmacologic Substance]

Phrase: "in HEPES buffer solution"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0006353:Buffer [Indicator, Reagent, or Diagnostic Aid,Pharmacologic Substance]
   827   C0037633:Solution [Substance]
   827   C0525069:Solution [Biomedical or Dental Material]

Phrase: "for fluorescence measurement."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0242485:Measurement [Functional Concept]
Processing 00000000.tx.86: Fluorescence intensity was measured in duplicate with excitation/emission at 370/440 nm and 328/378 nm on the Hitachi F-4010 fluorescence spectrophotometer (Hitachi, Tokyo, Japan). 

Phrase: "Fluorescence intensity"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   861   C0016315:Fluorescence [Natural Phenomenon or Process]
   861   C0522510:Intensity [Qualitative Concept]
   789 E C0303920:Fluorescent [Indicator, Reagent, or Diagnostic Aid,Organic Chemical]

Phrase: "was"

Phrase: "measured in duplicate"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   790   C0205173:Duplicate [Functional Concept]
   790   C0444706:Measured [Qualitative Concept]
   790   C3539942:Duplicate [Intellectual Product]
   790   C3541902:MEASURED [Diagnostic Procedure]
   756 E C0079809:Measure [Quantitative Concept]
   756 E C0242485:Measure [Functional Concept]

Phrase: "with excitation/emission"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0233929:Emission [Body Substance]
   861   C2349995:Emission [Substance]

Phrase: "at 370/440 nm"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0312860:NM [Cell Function]

Phrase: "and"

Phrase: "328/378 nm on the Hitachi F-4010 fluorescence spectrophotometer"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   739   C0312860:NM [Cell Function]

Phrase: "(Hitachi,"

Phrase: "Tokyo,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0040371:Tokyo [Geographic Area]

Phrase: "Japan"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0022341:Japan [Geographic Area]

Phrase: ")."
Processing 00000000.tx.87: Fluorescence values were expressed as arbitrary units (AU) per mg collagen. 

Phrase: "Fluorescence values"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0042295:Values [Qualitative Concept]
   827 E C1522609:Value [Quantitative Concept]

Phrase: "were"

Phrase: "expressed as arbitrary units (AU)"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   799   C0439183:Arbitrary unit [Quantitative Concept]
   770   C0439148:Units [Quantitative Concept]
   770   C1264693:*Arbitrary [Quantitative Concept]
   770   C1519795:Units [Quantitative Concept]
   737 E C1704753:Unit [Manufactured Object]
   737 E C1880519:Unit [Quantitative Concept]

Phrase: "per mg collagen."
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   861   C0009325:Collagen [Amino Acid, Peptide, or Protein,Biologically Active Substance,Biomedical or Dental Material]
   861   C1167364:collagen [Cell Component]
   789 E C0439689:Collagenous [Qualitative Concept]
Processing 00000000.tx.88: Enzyme-linked immunosorbent assay (ELISA) for pyrraline Pyrraline levels of collagenase-digested renal cortex and aorta were assayed as described previously (41). 

Phrase: "Enzyme-linked immunosorbent assay (ELISA) for pyrraline Pyrraline levels"
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
   833   C0014441:Enzyme-Linked Immunosorbent Assay [Laboratory Procedure]
   767   C0014440:enzyme levels [Laboratory Procedure]
   767   C1287349:enzyme levels [Laboratory or Test Result]
   767   C2717977:Enzyme Assay [Laboratory Procedure]
   744   C0005507:Assay [Laboratory Procedure]
   744   C0014442:Enzyme [Enzyme,Organic Chemical]
   744   C0021075:immunosorbent [Indicator, Reagent, or Diagnostic Aid]
   744   C0243073:assay [Qualitative Concept]
   744   C1510438:Assay [Laboratory Procedure]
   711   C1517892:Link [Intellectual Product]
   711   C1704666:Link [Intellectual Product]

Phrase: "of collagenase-digested renal cortex"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   861   C0022655:Renal cortex [Body Part, Organ, or Organ Component]
   812   C0007776:Cortex [Body Part, Organ, or Organ Component]
   812   C0022646:Renal [Body Part, Organ, or Organ Component]
   812   C1176472:Cortex [Body Part, Organ, or Organ Component]
   812   C2700441:Cortex [Plant]

Phrase: "and"

Phrase: "aorta"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0003483:Aorta [Body Part, Organ, or Organ Component]
  1000   C1278934:Aorta [Body Part, Organ, or Organ Component]

Phrase: "were"

Phrase: "assayed"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C0005507:Assay [Laboratory Procedure]
   966   C0243073:assay [Qualitative Concept]
   966   C1510438:Assay [Laboratory Procedure]

Phrase: "as"

Phrase: "described"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1552738:described [Idea or Concept]

Phrase: "previously"

Phrase: "(41"

Phrase: ")."
Processing 00000000.tx.89: Briefly, the concentration of collagenase-digested tissues was adjusted to 3 mg collagen/ml in HEPES buffer solution. 

Phrase: "Briefly,"

Phrase: "the concentration of collagenase-digested tissues"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0086045:Concentration [Mental Process]
   753   C1446561:Concentration [Quantitative Concept]

Phrase: "was"

Phrase: "adjusted to 3 mg collagen/ml"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   783   C0439294:mg ml [Quantitative Concept]
   753   C0009325:Collagen [Amino Acid, Peptide, or Protein,Biologically Active Substance,Biomedical or Dental Material]
   753   C0439269:mg% [Quantitative Concept]
   753   C0439526:/mL [Quantitative Concept]
   753   C0456081:Adjusted [Functional Concept]
   753   C1167364:collagen [Cell Component]
   753   C1960952:mg % [Quantitative Concept]
   753   C2346927:Mg++ [Element, Ion, or Isotope,Pharmacologic Substance]

Phrase: "in HEPES buffer solution."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0006353:Buffer [Indicator, Reagent, or Diagnostic Aid,Pharmacologic Substance]
   827   C0037633:Solution [Substance]
   827   C0525069:Solution [Biomedical or Dental Material]
Processing 00000000.tx.90: They were preincubated with the same volume of 3000 times diluted monoclonal antibody against pyrraline for 3 h at 37 C and then applied to a well of a microtiter plate coated with BSA conjugated with caproyl pyrraline. 

Phrase: "They"

Phrase: "were"

Phrase: "preincubated with the same volume of 3000 times"
Meta Candidates (Total=8; Excluded=1; Pruned=0; Remaining=7)
   744   C0040223:times [Temporal Concept]
   744   C0445247:Same [Qualitative Concept]
   744   C0449468:*Volume [Quantitative Concept]
   744   C1632851:Times [Quantitative Concept]
   744   C1690016:% volume [Qualitative Concept]
   744   C1705102:Volume [Intellectual Product]
   744   C2700258:Volume [Laboratory Procedure]
   711 E C3541383:Time [Temporal Concept]

Phrase: "diluted"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C1720119:Dilute [Functional Concept]
   966   C1948037:Dilute [Functional Concept]

Phrase: "monoclonal antibody against pyrraline"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   833   C0003250:Monoclonal antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   770   C0003241:Antibody [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   770   C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   770   C0746619:monoclonal [Finding]

Phrase: "for 3 h"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0041119:3 H [Element, Ion, or Isotope]
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "at 37 C"

Phrase: "and"

Phrase: "then"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883708:Then [Temporal Concept]

Phrase: "applied to a well of a microtiter plate"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   770   C1709027:Microtiter Plate [Research Device]
   744   C0005971:Plate [Medical Device]
   744   C0185125:Applied [Health Care Activity]
   744   C0205170:Well [Qualitative Concept]
   744   C1139930:plate [Medical Device]
   744   C3146287:Well [Manufactured Object]
   744   C3537155:Plate [Manufactured Object]
   711 E C1632850:Apply [Functional Concept]
   711 E C1879355:Apply [Functional Concept]

Phrase: "coated with BSA"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   790   C1522408:Coated [Qualitative Concept]
   756 E C0453946:Coat [Manufactured Object]
   756 E C2987482:Coat [Body Part, Organ, or Organ Component]

Phrase: "conjugated with caproyl pyrraline."
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   770   C0209143:pyrraline [Biologically Active Substance,Organic Chemical]
   770   C0522529:Conjugated [Spatial Concept]
   737 E C0301869:Conjugate [Immunologic Factor]
Processing 00000000.tx.91: After incubation for 1 h under gentle shaking, the well was washed three times with 0.1% ovalbumin (grade V, Sigma) in PBS and incubated with 1000 times diluted goat antimouse IgG conjugated with alkaline phosphatase (Boehringer Mannheim, Mannheim, Germany) for 1 h at room temperature. 

Phrase: "After incubation"

Phrase: "for 1 h"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0700308:1 H [Element, Ion, or Isotope]
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "under gentle shaking,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0040822:Shaking [Sign or Symptom]
   827 E C1883023:Shake [Activity]

Phrase: "the well"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0205170:Well [Qualitative Concept]
  1000   C3146287:Well [Manufactured Object]

Phrase: "was"

Phrase: "washed"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1548982:Washed [Idea or Concept]
   966 E C0441648:Wash [Activity]

Phrase: "three times with 0.1% ovalbumin"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   753   C0040223:times [Temporal Concept]
   753   C1632851:Times [Quantitative Concept]
   719 E C3541383:Time [Temporal Concept]

Phrase: "(grade V,"

Phrase: "Sigma"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1719918:Sigma [Intellectual Product]

Phrase: ")"

Phrase: "in PBS"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1720830:PBS [Disease or Syndrome]
  1000   C1823521:PBS [Gene or Genome]

Phrase: "and"

Phrase: "incubated with 1000 times"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   770   C0040223:times [Temporal Concept]
   770   C1439852:Incubated [Laboratory Procedure]
   770   C1632851:Times [Quantitative Concept]
   737 E C3541383:Time [Temporal Concept]

Phrase: "diluted"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C1720119:Dilute [Functional Concept]
   966   C1948037:Dilute [Functional Concept]

Phrase: "goat antimouse IgG"

Phrase: "conjugated with alkaline phosphatase"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   833   C0002059:Alkaline Phosphatase [Amino Acid, Peptide, or Protein,Enzyme]
   833   C1318717:Alkaline phosphatase [Indicator, Reagent, or Diagnostic Aid,Organic Chemical]
   770   C0031678:Phosphatase [Amino Acid, Peptide, or Protein,Enzyme]
   770   C0522529:Conjugated [Spatial Concept]
   770   C1149880:phosphatase [Molecular Function]
   770   C1979842:Alkaline [Qualitative Concept]
   737 E C0301869:Conjugate [Immunologic Factor]

Phrase: "(Boehringer Mannheim,"

Phrase: "Mannheim,"

Phrase: "Germany"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0017480:Germany [Geographic Area]

Phrase: ")"

Phrase: "for 1 h"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0700308:1 H [Element, Ion, or Isotope]
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "at room temperature."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C2348236:ROOM TEMPERATURE [Qualitative Concept]
   861   C0005903:temperature [Organism Attribute]
   861   C0039476:*Temperature [Quantitative Concept]
   861   C1547703:Room [Spatial Concept]
Processing 00000000.tx.92: After washing as described above, 100 l p-nitrophenyl phosphate (Sigma) substrate solution were added, and gentle shaking was maintained to develop coloration. 

Phrase: "After washing"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0441648:Washing [Activity]

Phrase: "as"

Phrase: "described above, 100 l p-nitrophenyl phosphate"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   818   C0068854:nitrophenylphosphate [Organophosphorus Compound,Pharmacologic Substance]
   795   C0031603:Phosphate [Inorganic Chemical,Pharmacologic Substance]
   795   C0031701:phosphate [Organophosphorus Compound]
   795   C1601799:PHOSPHATE [Inorganic Chemical,Pharmacologic Substance]

Phrase: "(Sigma"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1719918:Sigma [Intellectual Product]

Phrase: ")"

Phrase: "substrate solution"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0037633:Solution [Substance]
   861   C0525069:Solution [Biomedical or Dental Material]

Phrase: "were"

Phrase: "added"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1524062:Added [Functional Concept]
   966 E C1883712:Add [Functional Concept]

Phrase: ","

Phrase: "and"

Phrase: "gentle shaking"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0040822:Shaking [Sign or Symptom]
   827 E C1883023:Shake [Activity]

Phrase: "was"

Phrase: "maintained"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1314677:Maintained [Functional Concept]
   966 E C0024501:Maintain [Activity]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "develop"

Phrase: "coloration."
Processing 00000000.tx.93: Absorbance at 405 nm of each well was measured by ELISA reader (Bio-Rad, Richmond, CA). 

Phrase: "Absorbance at 405 nm of each well"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C1268822:Absorbance [Clinical Attribute]
   748   C2825050:Absorbance [Phenomenon or Process]

Phrase: "was"

Phrase: "measured by ELISA reader"
Meta Candidates (Total=15; Excluded=2; Pruned=0; Remaining=13)
   853   C0014441:Enzyme-Linked Immunosorbent Assay [Laboratory Procedure]
   774   C2717977:Enzyme Assay [Laboratory Procedure]
   748   C0005507:Assay [Laboratory Procedure]
   748   C0014442:Enzyme [Enzyme,Organic Chemical]
   748   C0021075:immunosorbent [Indicator, Reagent, or Diagnostic Aid]
   748   C0243073:assay [Qualitative Concept]
   748   C0444706:Measured [Qualitative Concept]
   748   C1510438:Assay [Laboratory Procedure]
   748   C1514743:Reader [Professional or Occupational Group]
   748   C1706461:Reader [Manufactured Object]
   748   C3541902:MEASURED [Diagnostic Procedure]
   714 E C0079809:Measure [Quantitative Concept]
   714 E C0242485:Measure [Functional Concept]
   714   C1517892:Link [Intellectual Product]
   714   C1704666:Link [Intellectual Product]

Phrase: "(Bio-Rad,"

Phrase: "Richmond,"

Phrase: "CA)."
Processing 00000000.tx.94: Quantitation was performed in duplicate, with lysyl pyrraline as a standard. 

Phrase: "Quantitation"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1709793:Quantitation [Quantitative Concept]

Phrase: "was"

Phrase: "performed in duplicate,"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   790   C0205173:Duplicate [Functional Concept]
   790   C0884358:Performed [Functional Concept]
   790   C3539942:Duplicate [Intellectual Product]
   756 E C2947996:Perform [Pharmacologic Substance]

Phrase: "with lysyl pyrraline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0209143:pyrraline [Biologically Active Substance,Organic Chemical]

Phrase: "as a standard."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1442989:Standard [Qualitative Concept]
  1000   C2828392:Standard [Intellectual Product]
Processing 00000000.tx.95: Reactivity of tenilsetam to 3-DG 3-DG, a highly reactive intermediate of the Maillard reaction, is suggested to also be a precursor of AGEs such as pyrraline and pentosidine. 

Phrase: "Reactivity of tenilsetam"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   718   C0205332:Reactive [Qualitative Concept]

Phrase: "to 3-DG 3-DG,"

Phrase: "a highly reactive intermediate of the Maillard reaction,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   744   C0205103:Intermediate [Spatial Concept]
   744   C1550465:intermediate [Idea or Concept]
   744   C2827755:INTERMEDIATE [Laboratory or Test Result]

Phrase: "is"

Phrase: "suggested"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1705535:Suggest [Idea or Concept]

Phrase: "to also"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1883351:To [Qualitative Concept]

Phrase: "be"

Phrase: "a precursor of AGEs"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C1709634:Precursor [Idea or Concept]

Phrase: "such as pyrraline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0209143:pyrraline [Biologically Active Substance,Organic Chemical]

Phrase: "and"

Phrase: "pentosidine."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0070317:pentosidine [Amino Acid, Peptide, or Protein,Pharmacologic Substance]
Processing 00000000.tx.96: A 50-M concentration of 3-DG was incubated in the presence or absence of 5 mM tenilsetam in PB (pH 7.4) at 37 C. 

Phrase: "A 50-M concentration of 3-DG"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C0086045:Concentration [Mental Process]
   748   C1446561:Concentration [Quantitative Concept]

Phrase: "was"

Phrase: "incubated in the presence"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0392148:Presence [Therapeutic or Preventive Procedure]
   770   C1439852:Incubated [Laboratory Procedure]

Phrase: "or"

Phrase: "absence of 5 mM tenilsetam"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0332197:absence [Quantitative Concept]
   760   C1689985:Absence [Anatomical Abnormality]

Phrase: "in PB (pH 7.4"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   875   C2678549:PH-4 [Gene or Genome]
   861   C1882074:pH 7 [Qualitative Concept]
   812   C0020283:[pH] [Quantitative Concept]
   812   C0450407:ph+ [Finding]
   812   C0450408:ph++ [Finding]
   812   C0450409:ph+++ [Finding]

Phrase: ")"

Phrase: "at 37 C."
Processing 00000000.tx.97: AG was also incubated with 3-DG under the same conditions as those used for tenilsetam. 

Phrase: "AG"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0282774:aminoguanidine [Organic Chemical,Pharmacologic Substance]

Phrase: "was"

Phrase: "also"

Phrase: "incubated with 3-DG"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1439852:Incubated [Laboratory Procedure]

Phrase: "under the same conditions"
Meta Candidates (Total=7; Excluded=4; Pruned=0; Remaining=3)
   827   C0012634:condition [Disease or Syndrome]
   827   C0348080:Condition [Qualitative Concept]
   827   C1705253:Condition [Conceptual Entity]
   777 E C0009647:Conditioned [Mental Process]
   777 E C1701901:Conditional [Qualitative Concept]
   777 E C1963686:Conditional [Functional Concept]
   755 E C1519605:Conditionality [Conceptual Entity]

Phrase: "as those"

Phrase: "used for tenilsetam."
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   790   C0076093:tenilsetam [Organic Chemical,Pharmacologic Substance]
   790   C1273517:used [Finding]
   756 E C0042153:use [Functional Concept]
   756 E C0457083:Use [Functional Concept]
   756 E C1947944:Use [Intellectual Product]
Processing 00000000.tx.98: Incubated samples were obtained periodically to measure the level of the remaining 3-DG by HPLC as described previously (42). 

Phrase: "Incubated samples"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0370003:Sample [Substance]
   827   C2347026:Sample [Conceptual Entity]

Phrase: "were"

Phrase: "obtained"
Meta Candidates (Total=8; Excluded=7; Pruned=0; Remaining=1)
  1000   C1301820:Obtained [Functional Concept]
   966 E C1706701:Obtain [Activity]
   928 E C1517378:Gain [Quantitative Concept]
   907 E C0205217:Increased [Quantitative Concept]
   907 E C0439661:Acquired [Temporal Concept]
   907 E C0442805:Increase [Functional Concept]
   907 E C0442808:Increasing [Functional Concept]
   907 E C3245488:acquired [Intellectual Product]

Phrase: "periodically to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0332182:Periodically [Temporal Concept]

Phrase: "measure"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0079809:Measure [Quantitative Concept]
  1000   C0242485:Measure [Functional Concept]

Phrase: "the level of the remaining 3-DG"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   774   C0456949:Level 3 [Intellectual Product]
   748   C0441889:Level [Qualitative Concept]
   748   C0456079:Level [Classification]
   748   C1547707:Level [Geographic Area]
   748   C2946261:Level [Pharmacologic Substance]

Phrase: "by HPLC"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0008562:HPLC [Laboratory Procedure]

Phrase: "as"

Phrase: "described"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1552738:described [Idea or Concept]

Phrase: "previously"

Phrase: "(42"

Phrase: ")."
Processing 00000000.tx.99: Briefly, an aliquot of the sample was incubated overnight with 100 l 0.1% 2,3-diaminonaphthalene (Aldrich Chemical Co., Milwaukee, WI) at 4 C in the presence of 50 l 0.05% 3,4-hexanedione (Tokyo Kasei Organic Chemicals, Tokyo, Japan) as an internal standard. 

Phrase: "Briefly,"

Phrase: "an aliquot of the sample"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C1510844:Aliquot [Quantitative Concept]

Phrase: "was"

Phrase: "incubated"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1439852:Incubated [Laboratory Procedure]

Phrase: "overnight with 100 l 0.1% 2,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0439583:Overnight [Temporal Concept]

Phrase: "3-diaminonaphthalene"

Phrase: "(Aldrich Chemical Co.,"

Phrase: "Milwaukee,"

Phrase: "WI) at 4 C in"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0043193:WI [Geographic Area]

Phrase: "the presence of 50 l 0.05% 3,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   744   C0392148:Presence [Therapeutic or Preventive Procedure]

Phrase: "4-hexanedione"

Phrase: "(Tokyo Kasei Organic Chemicals,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   861   C0029224:Organic Chemicals [Organic Chemical]
   812   C0220806:Chemicals [Chemical]
   779 E C3272558:Chemical [Intellectual Product]

Phrase: "Tokyo,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0040371:Tokyo [Geographic Area]

Phrase: "Japan"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0022341:Japan [Geographic Area]

Phrase: ")"

Phrase: "as an internal standard."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   861   C0205102:Internal [Spatial Concept]
   861   C1442989:Standard [Qualitative Concept]
   861   C1553872:Internal [Intellectual Product]
   861   C1619620:Internal [Intellectual Product]
   861   C2828392:Standard [Intellectual Product]
Processing 00000000.tx.100: The reaction mixture was extracted using 4 ml ethyl acetate, followed by evaporation to dryness. 

Phrase: "The reaction mixture"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439962:Mixture [Substance]

Phrase: "was"

Phrase: "extracted"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0185115:Extracted [Therapeutic or Preventive Procedure]
  1000   C3541890:EXTRACTED [Finding]
   966 E C2828366:Extract [Substance]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "4 ml ethyl acetate,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0059747:ethyl acetate [Organic Chemical,Pharmacologic Substance]
   812   C0000975:Acetate [Organic Chemical,Pharmacologic Substance]

Phrase: "followed by evaporation to dryness."
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   806   C0332283:Followed by [Temporal Concept]
           followed
   760   C0596539:evaporation [Natural Phenomenon or Process]
   760   C1512080:Dryness [Qualitative Concept]
   726 E C1719822:Follow [Intellectual Product]
Processing 00000000.tx.101: The dried extract was reconstituted with 200 l methanol and applied to HPLC. 

Phrase: "The dried extract"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2828366:Extract [Substance]

Phrase: "was"

Phrase: "reconstituted with 200 l methanol"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0001963:Methanol [Hazardous or Poisonous Substance,Organic Chemical,Pharmacologic Substance]

Phrase: "and"

Phrase: "applied to HPLC."
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   790   C0008562:HPLC [Laboratory Procedure]
   790   C0185125:Applied [Health Care Activity]
   756 E C1632850:Apply [Functional Concept]
   756 E C1879355:Apply [Functional Concept]
Processing 00000000.tx.102: Conversion of 3-DG to a stable compound, 2-(2,3,4-trihydroxy butyl)-benzo[g]quinoxaline, was accomplished by reaction with 2,3-diaminonaphthalene as mentioned above. 

Phrase: "Conversion of 3-DG"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0439836:Conversion [Functional Concept]

Phrase: "to a stable compound,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0205198:Compound [Qualitative Concept]
   861   C1706082:Compound [Chemical]

Phrase: "2-"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0740116:+2 [Quantitative Concept]
  1000   C2827735:2+ [Quantitative Concept]
  1000   C2981700:2+ [Classification]

Phrase: "(2,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0740116:+2 [Quantitative Concept]
  1000   C2827735:2+ [Quantitative Concept]
  1000   C2981700:2+ [Classification]

Phrase: "3,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439086:<3 [Quantitative Concept]
  1000   C2827736:3+ [Quantitative Concept]
  1000   C2981702:3+ [Classification]

Phrase: "4-trihydroxy butyl"

Phrase: ")-"

Phrase: "benzo"

Phrase: "[g]quinoxaline,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0178820:Quinoxaline [Organic Chemical]

Phrase: "was"

Phrase: "accomplished by reaction"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0443286:Reaction [Functional Concept]
   790   C1114821:Reaction [Clinical Attribute]

Phrase: "with 2,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0740116:+2 [Quantitative Concept]
  1000   C2827735:2+ [Quantitative Concept]
  1000   C2981700:2+ [Classification]

Phrase: "3-diaminonaphthalene as mentioned above."
Processing 00000000.tx.103: The derivative had a characteristic UV spectrum, which was determined at 268 nm using HPLC. 

Phrase: "The derivative"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1527240:Derivative [Functional Concept]

Phrase: "had"

Phrase: "a characteristic UV spectrum,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C1883073:Spectrum [Quantitative Concept]
   827   C2827424:Spectrum [Conceptual Entity]

Phrase: "which"

Phrase: "was"

Phrase: "determined at 268 nm"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0312860:NM [Cell Function]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "HPLC."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0008562:HPLC [Laboratory Procedure]
Processing 00000000.tx.104: A peak height ratio of a 3-DG-derived peak to an internal standard peak was calculated. 

Phrase: "A peak height ratio of a 3-DG-derived peak"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   739   C0456603:Ratio [Quantitative Concept]
   739   C1547037:Ratio [Intellectual Product]

Phrase: "to an internal standard peak"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0444505:Peak [Quantitative Concept]

Phrase: "was"

Phrase: "calculated."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0444686:Calculated [Functional Concept]
  1000   C1441506:Calculated [Activity]
  1000   C1443182:Calculated [Laboratory Procedure]
Processing 00000000.tx.105: Quantitation of 3-DG was performed by comparing the peak height ratio with that of authentic 3-DG. 

Phrase: "Quantitation of 3-DG"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1709793:Quantitation [Quantitative Concept]

Phrase: "was"

Phrase: "performed by comparing"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   882   C1550369:Performed By [Qualitative Concept]
   790   C0884358:Performed [Functional Concept]
   756   C1707455:Compare [Activity]
   756 E C2947996:Perform [Pharmacologic Substance]

Phrase: "the peak height ratio with that of authentic 3-DG."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   739   C0456603:Ratio [Quantitative Concept]
   739   C1547037:Ratio [Intellectual Product]
Processing 00000000.tx.106: Statistical analysis Data were expressed as the mean  SD. 

Phrase: "Statistical analysis Data"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   913   C2828391:statistical data [Quantitative Concept]
   827   C1511726:Data [Idea or Concept]
   827   C3245479:data [Medical Device]
   734   C0871424:statistical analysis [Research Activity]

Phrase: "were"

Phrase: "expressed as the mean  SD."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0444504:Mean [Quantitative Concept]
   760   C2347634:Mean [Quantitative Concept]
   760   C2348143:Mean [Quantitative Concept]
Processing 00000000.tx.107: Welch and Students t tests were used for statistical analysis. 

Phrase: "Welch"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0043114:Welsh [Population Group]

Phrase: "and"

Phrase: "Students t tests"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   827   C0022885:Tests [Laboratory Procedure]
   827   C0038492:Students [Professional or Occupational Group]
   827   C0392366:Tests [Intellectual Product]
   793 E C0039593:Test [Functional Concept]
   793 E C1551041:student [Idea or Concept]
   793 E C1552573:student [Intellectual Product]

Phrase: "were"

Phrase: "used for statistical analysis."
Meta Candidates (Total=9; Excluded=3; Pruned=0; Remaining=6)
   833   C0871424:statistical analysis [Research Activity]
   770   C0002778:Analysis [Laboratory Procedure]
   770   C0038215:Statistical [Occupation or Discipline]
   770   C0936012:Analysis [Research Activity]
   770   C1273517:used [Finding]
   770   C1524024:analysis [Functional Concept]
   737 E C0042153:use [Functional Concept]
   737 E C0457083:Use [Functional Concept]
   737 E C1947944:Use [Intellectual Product]
Processing 00000000.tx.108: P < 0.05 denoted statistical significance.  

Phrase: "P < 0.05"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C2603361:P' [Clinical Attribute]

Phrase: "denoted"

Phrase: "statistical significance."
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
  1000   C0237881:Statistical Significance [Quantitative Concept]
           Significance
  1000   C1709380:Statistical Significance [Quantitative Concept]
   861   C0038215:Statistical [Occupation or Discipline]
   861   C0750502:Significance [Idea or Concept]
   789 E C1546944:Significant [Qualitative Concept]
Processing 00000000.tx.109: Results Top Abstract Introduction Materials and Methods Results Discussion References  Effect of tenilsetam on lysozyme polymerization The rates of lysozyme polymerization induced by glucose, fructose, and 3-DG were analyzed by SDS-PAGE (Fig. 1). 

Phrase: "Results"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1274040:Result [Functional Concept]
  1000   C1546471:Result [Idea or Concept]
  1000   C2825142:Result [Finding]

Phrase: "Top Abstract Introduction Materials"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0520510:Materials [Substance]

Phrase: "and"

Phrase: "Methods Results Discussion"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0557061:Discussion [Therapeutic or Preventive Procedure]
   827   C2584313:Discussion [Social Behavior]

Phrase: "References"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "Effect of tenilsetam"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C1280500:Effect [Qualitative Concept]
   790   C2348382:Effect [Qualitative Concept]

Phrase: "on lysozyme polymerization"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0314672:Polymerisation [Phenomenon or Process]

Phrase: "The rates of lysozyme polymerization"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   726   C0871208:Rate [Activity]
   726   C1521828:Rate [Quantitative Concept]

Phrase: "induced by glucose,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   790   C0205263:Induced [Functional Concept]

Phrase: "fructose,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0016745:Fructose [Carbohydrate,Pharmacologic Substance]

Phrase: "and"

Phrase: "3-DG"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0047359:3-deoxyglucosone [Carbohydrate]

Phrase: "were"

Phrase: "analyzed by SDS-PAGE (Fig. 1"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   790   C0600209:SDS-PAGE [Laboratory Procedure,Research Activity]
   783   C1538566:PAGE-1 [Gene or Genome]
   753   C0349966:Fig [Food]
   753   C0936012:Analyzed [Research Activity]
   753   C1337208:FIG [Food]
   753   C1704732:Page [Intellectual Product]

Phrase: ")."
Processing 00000000.tx.110: Lysozyme incubated with 100 mM glucose showed dimer formation. 

Phrase: "Lysozyme"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0026794:Lysosyme [Enzyme,Pharmacologic Substance]
  1000   C1416945:LYSOZYME [Gene or Genome]
  1000   C3541379:lysozyme [Enzyme,Pharmacologic Substance]

Phrase: "incubated with 100 mM glucose"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   760   C1439852:Incubated [Laboratory Procedure]

Phrase: "showed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "dimer formation."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0220781:formation [Biologic Function]
   861   C0439634:formation [Spatial Concept]
   861   C1522492:Formation [Functional Concept]
Processing 00000000.tx.111: Tenilsetam suppressed dimer formation in a dose-dependent manner (Fig. 1A). 

Phrase: "Tenilsetam suppressed dimer formation in a dose-dependent manner"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   742   C0220781:formation [Biologic Function]
   742   C0439634:formation [Spatial Concept]
   742   C1522492:Formation [Functional Concept]

Phrase: "(Fig. 1A"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0450344:1A [Intellectual Product]
   861   C1553633:1a [Medical Device]

Phrase: ")."
Processing 00000000.tx.112: The same amount of fructose polymerized lysozyme more efficiently than glucose, yielding a dimer and a trimer. 

Phrase: "The same amount of fructose polymerized lysozyme more efficiently"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   742   C1265611:Amount [Quantitative Concept]

Phrase: "than glucose,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]

Phrase: "yielding"

Phrase: "a dimer"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0596448:dimer [Chemical Viewed Structurally]

Phrase: "and"

Phrase: "a trimer."
Processing 00000000.tx.113: Formation of the latter was inhibited by 10 mM tenilsetam, whereas dimer formation was significantly suppressed by 100 mM tenilsetam (Fig. 1B). 

Phrase: "Formation of the latter"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0220781:formation [Biologic Function]
   770   C0439634:formation [Spatial Concept]
   770   C1522492:Formation [Functional Concept]

Phrase: "was"

Phrase: "inhibited by 10 mM tenilsetam,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0076093:tenilsetam [Organic Chemical,Pharmacologic Substance]
   760   C0311403:Inhibited [Qualitative Concept]

Phrase: "whereas"

Phrase: "dimer formation"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0220781:formation [Biologic Function]
   861   C0439634:formation [Spatial Concept]
   861   C1522492:Formation [Functional Concept]

Phrase: "was"

Phrase: "significantly"

Phrase: "suppressed by 100 mM tenilsetam"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0076093:tenilsetam [Organic Chemical,Pharmacologic Substance]
   760   C1260953:Suppressed [Functional Concept]

Phrase: "(Fig. 1B"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0450345:1B [Intellectual Product]

Phrase: ")."
Processing 00000000.tx.114: 3-DG caused dimer and trimer formation of the lysozyme when used at an even lower concentration. 

Phrase: "3-DG"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0047359:3-deoxyglucosone [Carbohydrate]

Phrase: "caused"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C0015127:cause [Functional Concept]
   966   C1524003:Cause [Conceptual Entity]

Phrase: "dimer"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0596448:dimer [Chemical Viewed Structurally]

Phrase: "and"

Phrase: "trimer formation of the lysozyme"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0220781:formation [Biologic Function]
   760   C0439634:formation [Spatial Concept]
   760   C1522492:Formation [Functional Concept]

Phrase: "when"

Phrase: "used at an even lower concentration."
Meta Candidates (Total=9; Excluded=3; Pruned=0; Remaining=6)
   753   C0086045:Concentration [Mental Process]
   753   C0441994:Lower [Spatial Concept]
   753   C1273517:used [Finding]
   753   C1446561:Concentration [Quantitative Concept]
   753   C1548802:Lower [Body Location or Region]
   753   C2003888:Lower [Activity]
   719 E C0042153:use [Functional Concept]
   719 E C0457083:Use [Functional Concept]
   719 E C1947944:Use [Intellectual Product]
Processing 00000000.tx.115: The polymer formation was also inhibited by coincubation with tenilsetam in a dose-dependent manner (Fig. 1C). 

Phrase: "The polymer formation"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0220781:formation [Biologic Function]
   861   C0439634:formation [Spatial Concept]
   861   C1522492:Formation [Functional Concept]

Phrase: "was"

Phrase: "also"

Phrase: "inhibited by coincubation"
Meta Candidates (Total=5; Excluded=4; Pruned=0; Remaining=1)
   790   C0311403:Inhibited [Qualitative Concept]
   718 E C0018790:arrested [Disease or Syndrome]
   718 E C0237477:Arrest [Temporal Concept]
   718 E C0392351:arrest [Governmental or Regulatory Activity]
   718 E C0521111:Retarded [Qualitative Concept]

Phrase: "with tenilsetam"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0076093:tenilsetam [Organic Chemical,Pharmacologic Substance]

Phrase: "in a dose-dependent manner"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   734   C1512045:Dose-dependent [Quantitative Concept]

Phrase: "(Fig. 1C"

Phrase: ")."
Processing 00000000.tx.116: View larger version (60K): [in this window] [in a new window]  Figure 1. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "larger version"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0333052:Version [Functional Concept]
   861   C2607870:Version [Spatial Concept]

Phrase: "(60K"

Phrase: ")"

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  Figure 1."
Processing 00000000.tx.117: SDS-PAGE of lysozyme incubated with glucose, fructose, or 3-DG in the presence and absence of tenilsetam. 

Phrase: "SDS-PAGE of lysozyme"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   833   C0600209:SDS-PAGE [Laboratory Procedure,Research Activity]
   770   C1704732:Page [Intellectual Product]

Phrase: "incubated with glucose,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   790   C1439852:Incubated [Laboratory Procedure]

Phrase: "fructose,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0016745:Fructose [Carbohydrate,Pharmacologic Substance]

Phrase: "or"

Phrase: "3-DG in the presence"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   806   C0047359:3-deoxyglucosone [Carbohydrate]

Phrase: "and"

Phrase: "absence of tenilsetam."
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   790   C0332197:absence [Quantitative Concept]
   790   C1689985:Absence [Anatomical Abnormality]
   718 E C2699517:ABSENT [Finding]
Processing 00000000.tx.118: Effect of tenilsetam on glucose (A)-, fructose (B)-, or 3-DG (C)-induced polymerization of lysozyme was investigated. 

Phrase: "Effect of tenilsetam"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C1280500:Effect [Qualitative Concept]
   790   C2348382:Effect [Qualitative Concept]

Phrase: "on glucose"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]

Phrase: "(A)-,"

Phrase: "fructose"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0016745:Fructose [Carbohydrate,Pharmacologic Substance]

Phrase: "(B)-,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]

Phrase: "or"

Phrase: "3-DG"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0047359:3-deoxyglucosone [Carbohydrate]

Phrase: "(C)-induced polymerization of lysozyme"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0314672:Polymerisation [Phenomenon or Process]

Phrase: "was"

Phrase: "investigated."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1292732:investigated [Functional Concept]
Processing 00000000.tx.119: Lysozyme solution (10 mg/ml) was incubated with 100 mM glucose or fructose or with 10 mM 3-DG in the presence and absence of tenilsetam for 28 days in 0.1 M PB (pH 7.4) at 37 C as described below. 

Phrase: "Lysozyme solution"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0037633:Solution [Substance]
   861   C0525069:Solution [Biomedical or Dental Material]

Phrase: "(10 mg/"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0439269:mg% [Quantitative Concept]
   861   C1960952:mg % [Quantitative Concept]
   861   C2346927:Mg++ [Element, Ion, or Isotope,Pharmacologic Substance]

Phrase: "ml)"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439526:/mL [Quantitative Concept]

Phrase: "was"

Phrase: "incubated with 100 mM glucose"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   760   C1439852:Incubated [Laboratory Procedure]

Phrase: "or"

Phrase: "fructose"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0016745:Fructose [Carbohydrate,Pharmacologic Substance]

Phrase: "or with 10 mM 3-DG"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   783   C1883310:10^3 [Quantitative Concept]

Phrase: "in the presence"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0392148:Presence [Therapeutic or Preventive Procedure]
   928 E C0150312:Present [Quantitative Concept]
   928 E C0449450:Present [Idea or Concept]

Phrase: "and"

Phrase: "absence of tenilsetam"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   790   C0332197:absence [Quantitative Concept]
   790   C1689985:Absence [Anatomical Abnormality]
   718 E C2699517:ABSENT [Finding]

Phrase: "for 28 days"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   861   C0439228:days [Temporal Concept]
   827 E C0332173:/day [Temporal Concept]
   827 E C0439505:/day [Temporal Concept]

Phrase: "in 0.1 M PB (pH 7.4"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   845   C0950275:M 7 [Organic Chemical,Pharmacologic Substance]
   829   C2678549:PH-4 [Gene or Genome]
   818   C1882074:pH 7 [Qualitative Concept]
   795   C0020283:[pH] [Quantitative Concept]
   795   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   795   C0441923:M+ [Intellectual Product]
   795   C0450407:ph+ [Finding]
   795   C0450408:ph++ [Finding]
   795   C0450409:ph+++ [Finding]

Phrase: ")"

Phrase: "at 37 C"

Phrase: "as"

Phrase: "described below."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   833   C1552738:described [Idea or Concept]
Processing 00000000.tx.120: Each sample was applied to SDS-PAGE, conducted on a 15% separating gel. 

Phrase: "Each sample"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0370003:Sample [Substance]
  1000   C2347026:Sample [Conceptual Entity]

Phrase: "was"

Phrase: "applied to SDS-PAGE,"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   833   C0600209:SDS-PAGE [Laboratory Procedure,Research Activity]
   770   C0185125:Applied [Health Care Activity]
   770   C1704732:Page [Intellectual Product]
   737 E C1632850:Apply [Functional Concept]
   737 E C1879355:Apply [Functional Concept]

Phrase: "conducted on a 15% separating gel."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   753   C0017243:Gel [Biomedical or Dental Material]
   753   C0443299:separating [Spatial Concept]
   753   C1382104:Gel [Substance]
   719   C0004927:Conduct [Individual Behavior]
Processing 00000000.tx.121: The rate of polymerization was suppressed by tenilsetam. 

Phrase: "The rate of polymerization"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0871208:Rate [Activity]
   770   C1521828:Rate [Quantitative Concept]

Phrase: "was"

Phrase: "suppressed by tenilsetam."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0076093:tenilsetam [Organic Chemical,Pharmacologic Substance]
   790   C1260953:Suppressed [Functional Concept]
Processing 00000000.tx.122: MW, Standard proteins (molecular mass in kilodaltons, listed on the left). 

Phrase: "MW,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0024548:MW [Geographic Area]
  1000   C0026385:mw [Quantitative Concept]
  1000   C0556966:mW [Quantitative Concept]

Phrase: "Standard proteins"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0033684:Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "(molecular mass in kilodaltons,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   833   C3152252:Molecular Mass [Quantitative Concept]
           Mass
   770   C0577559:Mass [Finding]
   770   C1306372:*Mass [Quantitative Concept]

Phrase: "listed on the left"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0205091:Left [Spatial Concept]
   770   C1552822:left [Functional Concept]
   737   C0745732:List [Conceptual Entity]
   737   C3272378:LIST [Intellectual Product]

Phrase: ")."
Processing 00000000.tx.123: Ly, Lysozyme alone. 

Phrase: "Ly,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0023634:LY [Geographic Area]

Phrase: "Lysozyme"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0026794:Lysosyme [Enzyme,Pharmacologic Substance]
  1000   C1416945:LYSOZYME [Gene or Genome]
  1000   C3541379:lysozyme [Enzyme,Pharmacologic Substance]

Phrase: "alone."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205171:Alone [Quantitative Concept]
  1000   C0439044:alone [Finding]
  1000   C0679994:alone [Group Attribute]
Processing 00000000.tx.124: A: a, Lysozyme plus glucose; 

Phrase: "A"

Phrase: ":"

Phrase: "a,"

Phrase: "Lysozyme plus glucose"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]

Phrase: ";"
Processing 00000000.tx.125: b, lysozyme, glucose, and 10 mM tenilsetam; 

Phrase: "b,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]

Phrase: "lysozyme,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0026794:Lysosyme [Enzyme,Pharmacologic Substance]
  1000   C1416945:LYSOZYME [Gene or Genome]
  1000   C3541379:lysozyme [Enzyme,Pharmacologic Substance]

Phrase: "glucose,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]

Phrase: "and"

Phrase: "10 mM tenilsetam"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0076093:tenilsetam [Organic Chemical,Pharmacologic Substance]

Phrase: ";"
Processing 00000000.tx.126: c, lysozyme, glucose, and 100 mM tenilsetam. 

Phrase: "c,"

Phrase: "lysozyme,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0026794:Lysosyme [Enzyme,Pharmacologic Substance]
  1000   C1416945:LYSOZYME [Gene or Genome]
  1000   C3541379:lysozyme [Enzyme,Pharmacologic Substance]

Phrase: "glucose,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]

Phrase: "and"

Phrase: "100 mM tenilsetam."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0076093:tenilsetam [Organic Chemical,Pharmacologic Substance]
Processing 00000000.tx.127: B: d, lysozyme plus fructose; 

Phrase: "B"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]

Phrase: ":"

Phrase: "d,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0073187:D NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "lysozyme plus fructose"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0016745:Fructose [Carbohydrate,Pharmacologic Substance]

Phrase: ";"
Processing 00000000.tx.128: e, lysozyme, fructose, and 10 mM tenilsetam; 

Phrase: "e,"

Phrase: "lysozyme,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0026794:Lysosyme [Enzyme,Pharmacologic Substance]
  1000   C1416945:LYSOZYME [Gene or Genome]
  1000   C3541379:lysozyme [Enzyme,Pharmacologic Substance]

Phrase: "fructose,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0016745:Fructose [Carbohydrate,Pharmacologic Substance]

Phrase: "and"

Phrase: "10 mM tenilsetam"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0076093:tenilsetam [Organic Chemical,Pharmacologic Substance]

Phrase: ";"
Processing 00000000.tx.129: f, lysozyme, fructose, and 100 mM tenilsetam. 

Phrase: "f,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
  1000   C0439133:(f) [Intellectual Product]
  1000   C1553038:[f] [Quantitative Concept]

Phrase: "lysozyme,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0026794:Lysosyme [Enzyme,Pharmacologic Substance]
  1000   C1416945:LYSOZYME [Gene or Genome]
  1000   C3541379:lysozyme [Enzyme,Pharmacologic Substance]

Phrase: "fructose,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0016745:Fructose [Carbohydrate,Pharmacologic Substance]

Phrase: "and"

Phrase: "100 mM tenilsetam."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0076093:tenilsetam [Organic Chemical,Pharmacologic Substance]
Processing 00000000.tx.130: C: g, lysozyme plus 3-DG; 

Phrase: "C"

Phrase: ":"

Phrase: "g,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439267:g% [Quantitative Concept]

Phrase: "lysozyme plus 3-DG"

Phrase: ";"
Processing 00000000.tx.131: h, lysozyme, 3-DG, and 10 mM tenilsetam; 

Phrase: "h,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0033727:H+ [Element, Ion, or Isotope]
  1000   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
  1000   C0441932:H+ [Classification]
  1000   C0564385:/h [Quantitative Concept]

Phrase: "lysozyme,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0026794:Lysosyme [Enzyme,Pharmacologic Substance]
  1000   C1416945:LYSOZYME [Gene or Genome]
  1000   C3541379:lysozyme [Enzyme,Pharmacologic Substance]

Phrase: "3-DG,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0047359:3-deoxyglucosone [Carbohydrate]

Phrase: "and"

Phrase: "10 mM tenilsetam"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0076093:tenilsetam [Organic Chemical,Pharmacologic Substance]

Phrase: ";"
Processing 00000000.tx.132: i, lysozyme, 3-DG, and 100 mM tenilsetam.  

Phrase: "i,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0021966:I- [Inorganic Chemical]
  1000   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "lysozyme,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0026794:Lysosyme [Enzyme,Pharmacologic Substance]
  1000   C1416945:LYSOZYME [Gene or Genome]
  1000   C3541379:lysozyme [Enzyme,Pharmacologic Substance]

Phrase: "3-DG,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0047359:3-deoxyglucosone [Carbohydrate]

Phrase: "and"

Phrase: "100 mM tenilsetam."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0076093:tenilsetam [Organic Chemical,Pharmacologic Substance]
Processing 00000000.tx.133: Effect of tenilsetam on collagen digestibility The amount of digested collagen reached 77.9  3.2% of the original total content when the collagen was incubated under the control conditions (buffer alone). 

Phrase: "Effect of tenilsetam"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C1280500:Effect [Qualitative Concept]
   790   C2348382:Effect [Qualitative Concept]

Phrase: "on collagen digestibility"

Phrase: "The amount of digested collagen"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C1265611:Amount [Quantitative Concept]

Phrase: "reached"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C2584321:Reach [Organism Function]

Phrase: "77.9  3.2% of the original total content"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   742   C0205313:Original [Idea or Concept]
   742   C0423896:Content [Mental Process]
   742   C0439175:% total [Quantitative Concept]
   742   C0439810:Total [Qualitative Concept]
   742   C0456205:Content [Conceptual Entity]
   742   C2347409:Original [Occupational Activity]

Phrase: "when"

Phrase: "the collagen"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0009325:Collagen [Amino Acid, Peptide, or Protein,Biologically Active Substance,Biomedical or Dental Material]
  1000   C1167364:collagen [Cell Component]
   928 E C0439689:Collagenous [Qualitative Concept]

Phrase: "was"

Phrase: "incubated under the control conditions"
Meta Candidates (Total=14; Excluded=5; Pruned=0; Remaining=9)
   760   C0243148:control [Qualitative Concept]
   760   C1439852:Incubated [Laboratory Procedure]
   760   C1550141:Control [Substance]
   760   C1882979:Control [Conceptual Entity]
   760   C2587213:Control [Functional Concept]
   760   C3274648:Control [Qualitative Concept]
   726   C0012634:condition [Disease or Syndrome]
   726   C0348080:Condition [Qualitative Concept]
   726   C1705253:Condition [Conceptual Entity]
   704 E C0040607:Training [Educational Activity]
   704 E C0220931:Training [Educational Activity]
   704 E C0336809:Train [Manufactured Object]
   704 E C1552514:Train [Manufactured Object]
   704 E C2673163:training [Qualitative Concept]

Phrase: "(buffer"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0006353:Buffer [Indicator, Reagent, or Diagnostic Aid,Pharmacologic Substance]

Phrase: "alone"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205171:Alone [Quantitative Concept]
  1000   C0439044:alone [Finding]
  1000   C0679994:alone [Group Attribute]

Phrase: ")."
Processing 00000000.tx.134: The mean value was used as 100% to compare digestibility under other conditions. 

Phrase: "The mean value"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0444504:Mean [Quantitative Concept]
   861   C1522609:Value [Quantitative Concept]
   861   C2347634:Mean [Quantitative Concept]
   861   C2348143:Mean [Quantitative Concept]

Phrase: "was"

Phrase: "used as 100% to"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   770   C1273517:used [Finding]
   737 E C0042153:use [Functional Concept]
   737 E C0457083:Use [Functional Concept]
   737 E C1947944:Use [Intellectual Product]

Phrase: "compare"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1707455:Compare [Activity]

Phrase: "digestibility under other conditions."
Processing 00000000.tx.135: Incubation with 100 mM glucose significantly (P < 0.005) reduced collagen digestibility to 74.1  4.9% compared with the control value. 

Phrase: "Incubation with 100 mM glucose significantly"

Phrase: "(P < 0.005"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C2603361:P' [Clinical Attribute]

Phrase: ")"

Phrase: "reduced collagen digestibility to 74.1  4.9%"

Phrase: "compared with the control value."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   760   C0243148:control [Qualitative Concept]
   760   C1522609:Value [Quantitative Concept]
   760   C1550141:Control [Substance]
   760   C1707455:Compared [Activity]
   760   C1882979:Control [Conceptual Entity]
   760   C2587213:Control [Functional Concept]
   760   C3274648:Control [Qualitative Concept]
Processing 00000000.tx.136: The digestibility of collagen was significantly recovered to 93.1  8.6% with 10 mM tenilsetam and to 99.0  2.1% with 100 mM (P < 0.05 and P < 0.005 vs. glucose alone, respectively). 

Phrase: "The digestibility of collagen"

Phrase: "was"

Phrase: "significantly"

Phrase: "recovered to 93.1  8.6%"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   753   C0521108:recovered [Qualitative Concept]
   719 E C2004454:recover [Organism Function]

Phrase: "with 10 mM tenilsetam"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0076093:tenilsetam [Organic Chemical,Pharmacologic Substance]

Phrase: "and to 99.0  2.1%"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C1515981:And [Idea or Concept]

Phrase: "with 100 mM (P < 0.05"

Phrase: "and"

Phrase: "P < 0.005"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C2603361:P' [Clinical Attribute]

Phrase: "vs. glucose alone, respectively"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   827   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   827   C0205171:Alone [Quantitative Concept]
   827   C0439044:alone [Finding]
   827   C0679994:alone [Group Attribute]

Phrase: ")."
Processing 00000000.tx.137: The rate of collagen digestibility was further decreased by fructose (39.1  2.6% of control; P < 0.001). 

Phrase: "The rate of collagen digestibility"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0871208:Rate [Activity]
   760   C1521828:Rate [Quantitative Concept]

Phrase: "was"

Phrase: "further"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1517331:Further [Spatial Concept]
   966 E C0205108:far [Spatial Concept]

Phrase: "decreased by fructose"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   858   C1291099:Decreased fructose [Finding]
   790   C0016745:Fructose [Carbohydrate,Pharmacologic Substance]
   790   C0205216:Decreased [Quantitative Concept]
   790   C0392756:Decreased [Qualitative Concept]
   790   C0442797:decreased [Qualitative Concept]
   756 E C0547047:Decrease [Quantitative Concept]

Phrase: "(39.1  2.6% of control"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   753   C0243148:control [Qualitative Concept]
   753   C1550141:Control [Substance]
   753   C1882979:Control [Conceptual Entity]
   753   C2587213:Control [Functional Concept]
   753   C3274648:Control [Qualitative Concept]

Phrase: "; P < 0.001"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C2603361:P' [Clinical Attribute]

Phrase: ")."
Processing 00000000.tx.138: The reduction in digestibility was recovered to 61.4  4.6% with 10 mM tenilsetam (P < 0.005 vs. fructose alone) and 76.2  6.6% with 100 mM tenilsetam (P < 0.001 vs. fructose alone; Fig. 2). 

Phrase: "The reduction in digestibility"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0301630:Reduction [Natural Phenomenon or Process]
   770   C0392756:Reduction [Qualitative Concept]
   770   C0441610:Reduction [Therapeutic or Preventive Procedure]

Phrase: "was"

Phrase: "recovered to 61.4  4.6%"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   753   C0521108:recovered [Qualitative Concept]
   719 E C2004454:recover [Organism Function]

Phrase: "with 10 mM tenilsetam"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0076093:tenilsetam [Organic Chemical,Pharmacologic Substance]

Phrase: "(P < 0.005"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C2603361:P' [Clinical Attribute]

Phrase: "vs. fructose"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0016745:Fructose [Carbohydrate,Pharmacologic Substance]

Phrase: "alone"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205171:Alone [Quantitative Concept]
  1000   C0439044:alone [Finding]
  1000   C0679994:alone [Group Attribute]

Phrase: ")"

Phrase: "and"

Phrase: "76.2  6.6% with 100 mM tenilsetam"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   744   C0076093:tenilsetam [Organic Chemical,Pharmacologic Substance]

Phrase: "(P < 0.001"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C2603361:P' [Clinical Attribute]

Phrase: "vs. fructose"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0016745:Fructose [Carbohydrate,Pharmacologic Substance]

Phrase: "alone"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205171:Alone [Quantitative Concept]
  1000   C0439044:alone [Finding]
  1000   C0679994:alone [Group Attribute]

Phrase: "; Fig. 2"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0349966:Fig [Food]
   861   C1337208:FIG [Food]

Phrase: ")."
Processing 00000000.tx.139: View larger version (37K): [in this window] [in a new window]  Figure 2. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "larger version"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0333052:Version [Functional Concept]
   861   C2607870:Version [Spatial Concept]

Phrase: "(37K"

Phrase: ")"

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  Figure 2."
Processing 00000000.tx.140: Enzymatic digestibility of collagen incubated with glucose or fructose in the presence and absence of tenilsetam. 

Phrase: "Enzymatic digestibility of collagen"

Phrase: "incubated with glucose"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   790   C1439852:Incubated [Laboratory Procedure]

Phrase: "or"

Phrase: "fructose in the presence"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0016745:Fructose [Carbohydrate,Pharmacologic Substance]

Phrase: "and"

Phrase: "absence of tenilsetam."
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   790   C0332197:absence [Quantitative Concept]
   790   C1689985:Absence [Anatomical Abnormality]
   718 E C2699517:ABSENT [Finding]
Processing 00000000.tx.141: The collagen concentration was 10 mg/ml in 0.1 M PB. 

Phrase: "The collagen concentration"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   861   C0086045:Concentration [Mental Process]
   861   C1446561:Concentration [Quantitative Concept]
   789 E C1880165:Concentrated [Biomedical or Dental Material]

Phrase: "was"

Phrase: "10 mg/ml in 0.1 M PB."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0439294:mg ml [Quantitative Concept]
   744   C0439526:/mL [Quantitative Concept]
Processing 00000000.tx.142: Incubation was performed with 100 mM glucose or fructose in the presence and absence of tenilsetam at 37 C for 4 weeks. 

Phrase: "Incubation"

Phrase: "was"

Phrase: "performed with 100 mM glucose"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   760   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   760   C0884358:Performed [Functional Concept]
   726 E C2947996:Perform [Pharmacologic Substance]

Phrase: "or"

Phrase: "fructose in the presence"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0016745:Fructose [Carbohydrate,Pharmacologic Substance]

Phrase: "and"

Phrase: "absence of tenilsetam"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   790   C0332197:absence [Quantitative Concept]
   790   C1689985:Absence [Anatomical Abnormality]
   718 E C2699517:ABSENT [Finding]

Phrase: "at 37 C"

Phrase: "for 4 weeks."
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C1442465:4 Weeks [Temporal Concept]
   861   C0439230:weeks [Temporal Concept]
   827 E C0332174:/week [Temporal Concept]
Processing 00000000.tx.143: Each sample was digested by type VII collagenase, and the digestibility was expressed as a percentage of the digestibility of collagen incubated with PB alone. 

Phrase: "Each sample"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0370003:Sample [Substance]
  1000   C2347026:Sample [Conceptual Entity]

Phrase: "was"

Phrase: "digested by type VII collagenase,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   760   C0162745:COLLAGENASE [Amino Acid, Peptide, or Protein,Enzyme,Pharmacologic Substance]
   760   C0332307:Type [Qualitative Concept]
   760   C0445385:VII [Intellectual Product]
   760   C0868946:digested [Physiologic Function]
   760   C1547052:*Type [Quantitative Concept]

Phrase: "and"

Phrase: "the digestibility"

Phrase: "was"

Phrase: "expressed as a percentage of the digestibility of collagen"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   742   C0009325:Collagen [Amino Acid, Peptide, or Protein,Biologically Active Substance,Biomedical or Dental Material]
   742   C0439165:Percentage [Quantitative Concept]
   742   C1167364:collagen [Cell Component]
   742   C1549488:Percentage [Idea or Concept]
   742   C1561533:Percentage [Idea or Concept]

Phrase: "incubated with PB"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C1439852:Incubated [Laboratory Procedure]

Phrase: "alone."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205171:Alone [Quantitative Concept]
  1000   C0439044:alone [Finding]
  1000   C0679994:alone [Group Attribute]
Processing 00000000.tx.144: The digestibility of collagen was significantly reduced by the incubation with glucose and fructose (P < 0.005 and P < 0.001, respectively). 

Phrase: "The digestibility of collagen"

Phrase: "was"

Phrase: "significantly"

Phrase: "reduced by the incubation"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0392756:Reduced [Qualitative Concept]

Phrase: "with glucose"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]

Phrase: "and"

Phrase: "fructose"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0016745:Fructose [Carbohydrate,Pharmacologic Substance]

Phrase: "(P < 0.005"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C2603361:P' [Clinical Attribute]

Phrase: "and"

Phrase: "P < 0.001,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C2603361:P' [Clinical Attribute]

Phrase: "respectively"

Phrase: ")."
Processing 00000000.tx.145: The reduced digestibility of collagen was normalized by the coincubation with tenilsetam in a dose-dependent manner. 

Phrase: "The reduced digestibility of collagen"

Phrase: "was"

Phrase: "normalized by the coincubation"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1882115:Normalized [Research Activity]

Phrase: "with tenilsetam"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0076093:tenilsetam [Organic Chemical,Pharmacologic Substance]

Phrase: "in a dose-dependent manner."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   734   C1512045:Dose-dependent [Quantitative Concept]
Processing 00000000.tx.146: Data are the mean  SD (n = 3). 

Phrase: "Data"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1511726:Data [Idea or Concept]
  1000   C3245479:data [Medical Device]

Phrase: "are"

Phrase: "the mean  SD (n = 3"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   812   C0444504:Mean [Quantitative Concept]
   812   C2347634:Mean [Quantitative Concept]
   812   C2348143:Mean [Quantitative Concept]

Phrase: ")."
Processing 00000000.tx.147: a, Collagen alone; 

Phrase: "a,"

Phrase: "Collagen"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0009325:Collagen [Amino Acid, Peptide, or Protein,Biologically Active Substance,Biomedical or Dental Material]
  1000   C1167364:collagen [Cell Component]
   928 E C0439689:Collagenous [Qualitative Concept]

Phrase: "alone"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205171:Alone [Quantitative Concept]
  1000   C0439044:alone [Finding]
  1000   C0679994:alone [Group Attribute]

Phrase: ";"
Processing 00000000.tx.148: b, collagen and glucose; 

Phrase: "b,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2347469:/B [Quantitative Concept]

Phrase: "collagen"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0009325:Collagen [Amino Acid, Peptide, or Protein,Biologically Active Substance,Biomedical or Dental Material]
  1000   C1167364:collagen [Cell Component]
   928 E C0439689:Collagenous [Qualitative Concept]

Phrase: "and"

Phrase: "glucose"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]

Phrase: ";"
Processing 00000000.tx.149: c, collagen, glucose, and 10 mM tenilsetam; 

Phrase: "c,"

Phrase: "collagen,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0009325:Collagen [Amino Acid, Peptide, or Protein,Biologically Active Substance,Biomedical or Dental Material]
  1000   C1167364:collagen [Cell Component]
   928 E C0439689:Collagenous [Qualitative Concept]

Phrase: "glucose,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]

Phrase: "and"

Phrase: "10 mM tenilsetam"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0076093:tenilsetam [Organic Chemical,Pharmacologic Substance]

Phrase: ";"
Processing 00000000.tx.150: d, collagen, glucose, and 100 mM tenilsetam; 

Phrase: "d,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0073187:D NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "collagen,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0009325:Collagen [Amino Acid, Peptide, or Protein,Biologically Active Substance,Biomedical or Dental Material]
  1000   C1167364:collagen [Cell Component]
   928 E C0439689:Collagenous [Qualitative Concept]

Phrase: "glucose,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]

Phrase: "and"

Phrase: "100 mM tenilsetam"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0076093:tenilsetam [Organic Chemical,Pharmacologic Substance]

Phrase: ";"
Processing 00000000.tx.151: e, collagen plus fructose; 

Phrase: "e,"

Phrase: "collagen plus fructose"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0016745:Fructose [Carbohydrate,Pharmacologic Substance]

Phrase: ";"
Processing 00000000.tx.152: f, collagen, fructose, and 10 mM tenilsetam; 

Phrase: "f,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
  1000   C0439133:(f) [Intellectual Product]
  1000   C1553038:[f] [Quantitative Concept]

Phrase: "collagen,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0009325:Collagen [Amino Acid, Peptide, or Protein,Biologically Active Substance,Biomedical or Dental Material]
  1000   C1167364:collagen [Cell Component]
   928 E C0439689:Collagenous [Qualitative Concept]

Phrase: "fructose,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0016745:Fructose [Carbohydrate,Pharmacologic Substance]

Phrase: "and"

Phrase: "10 mM tenilsetam"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0076093:tenilsetam [Organic Chemical,Pharmacologic Substance]

Phrase: ";"
Processing 00000000.tx.153: g, collagen, fructose, and 100 mM tenilsetam. 

Phrase: "g,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439267:g% [Quantitative Concept]

Phrase: "collagen,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0009325:Collagen [Amino Acid, Peptide, or Protein,Biologically Active Substance,Biomedical or Dental Material]
  1000   C1167364:collagen [Cell Component]
   928 E C0439689:Collagenous [Qualitative Concept]

Phrase: "fructose,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0016745:Fructose [Carbohydrate,Pharmacologic Substance]

Phrase: "and"

Phrase: "100 mM tenilsetam."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0076093:tenilsetam [Organic Chemical,Pharmacologic Substance]
Processing 00000000.tx.154: *, P < 0.05; 

Phrase: "*,"

Phrase: "P < 0.05"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C2603361:P' [Clinical Attribute]

Phrase: ";"
Processing 00000000.tx.155: **, P < 0.005; 

Phrase: "*"

Phrase: "*,"

Phrase: "P < 0.005"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C2603361:P' [Clinical Attribute]

Phrase: ";"
Processing 00000000.tx.156: ***, P < 0.001 (vs. collagen incubated with the corresponding sugar alone).  

Phrase: "*"

Phrase: "*"

Phrase: "*,"

Phrase: "P < 0.001"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C2603361:P' [Clinical Attribute]

Phrase: "("

Phrase: "vs. collagen"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0009325:Collagen [Amino Acid, Peptide, or Protein,Biologically Active Substance,Biomedical or Dental Material]
  1000   C1167364:collagen [Cell Component]
   928 E C0439689:Collagenous [Qualitative Concept]

Phrase: "incubated with the corresponding sugar"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0007004:Sugar [Carbohydrate]
   760   C0242209:Sugar [Carbohydrate,Pharmacologic Substance]
   760   C1439852:Incubated [Laboratory Procedure]

Phrase: "alone"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205171:Alone [Quantitative Concept]
  1000   C0439044:alone [Finding]
  1000   C0679994:alone [Group Attribute]

Phrase: ")."
Processing 00000000.tx.157: When collagen was incubated with glucose at a diabetic blood sugar level such as 30 mM, the decrease in digestibility was still significant (P < 0.05) compared with the control value, as shown in Table 1. 

Phrase: "When"

Phrase: "collagen"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0009325:Collagen [Amino Acid, Peptide, or Protein,Biologically Active Substance,Biomedical or Dental Material]
  1000   C1167364:collagen [Cell Component]
   928 E C0439689:Collagenous [Qualitative Concept]

Phrase: "was"

Phrase: "incubated with glucose"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   790   C1439852:Incubated [Laboratory Procedure]

Phrase: "at a diabetic blood sugar level"
Meta Candidates (Total=19; Excluded=7; Pruned=0; Remaining=12)
   923   C0392201:Blood sugar level [Laboratory Procedure]
   923   C0428554:blood sugar level [Laboratory or Test Result]
   861   C0005802:Blood Sugar [Carbohydrate]
   812   C0005767:Blood [Tissue]
   812   C0005768:blood [Body Substance]
   812   C0007004:Sugar [Carbohydrate]
   812   C0229664:Blood [Body Substance]
   812   C0242209:Sugar [Carbohydrate,Pharmacologic Substance]
   812   C0441889:Level [Qualitative Concept]
   812   C0456079:Level [Classification]
   812   C1547707:Level [Geographic Area]
   812   C2946261:Level [Pharmacologic Substance]
   741 E C0333275:Bloody [Qualitative Concept]
   729 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   729 E C0392895:Bloods [Population Group]
   729 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   729 E C1511228:VESSEL, BLOOD [Tissue]
   712 E C1558950:VASCULAR [Finding]
   712 E C1801960:Vascular [Qualitative Concept]

Phrase: "such as 30 mM,"

Phrase: "the decrease in digestibility"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0392756:Decrease [Qualitative Concept]
   770   C0547047:Decrease [Quantitative Concept]

Phrase: "was"

Phrase: "still significant"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0237881:significant [Quantitative Concept]
   861   C0750502:Significant [Idea or Concept]
   861   C1546944:Significant [Qualitative Concept]

Phrase: "(P < 0.05"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C2603361:P' [Clinical Attribute]

Phrase: ")"

Phrase: "compared with the control value,"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   760   C0243148:control [Qualitative Concept]
   760   C1522609:Value [Quantitative Concept]
   760   C1550141:Control [Substance]
   760   C1707455:Compared [Activity]
   760   C1882979:Control [Conceptual Entity]
   760   C2587213:Control [Functional Concept]
   760   C3274648:Control [Qualitative Concept]

Phrase: "as"

Phrase: "shown in Table 1."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0039224:Table [Manufactured Object]
   770   C1706073:Table [Medical Device]
   770   C1706074:Table [Intellectual Product]
   737   C1547282:Show [Intellectual Product]
Processing 00000000.tx.158: Even 10 mM tenilsetam efficiently recovered the decreased digestibility, whereas 100 mM tenilsetam almost completely restored it to the control level. 

Phrase: "Even 10 mM tenilsetam efficiently"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   804   C0076093:tenilsetam [Organic Chemical,Pharmacologic Substance]

Phrase: "recovered"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0521108:recovered [Qualitative Concept]
   966 E C2004454:recover [Organism Function]

Phrase: "the decreased digestibility,"

Phrase: "whereas"

Phrase: "100 mM tenilsetam almost completely"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   804   C0076093:tenilsetam [Organic Chemical,Pharmacologic Substance]
   804   C0205197:Completely [Qualitative Concept]

Phrase: "restored"

Phrase: "it to the control level."
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   760   C0243148:control [Qualitative Concept]
   760   C0441889:Level [Qualitative Concept]
   760   C0456079:Level [Classification]
   760   C1547707:Level [Geographic Area]
   760   C1550141:Control [Substance]
   760   C1882979:Control [Conceptual Entity]
   760   C2587213:Control [Functional Concept]
   760   C2946261:Level [Pharmacologic Substance]
   760   C3274648:Control [Qualitative Concept]
Processing 00000000.tx.159: View this table: [in this window] [in a new window]  Table 1. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "this table"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0039224:Table [Manufactured Object]
  1000   C1706073:Table [Medical Device]
  1000   C1706074:Table [Intellectual Product]

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  Table 1."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039224:Table [Manufactured Object]
   861   C1706073:Table [Medical Device]
   861   C1706074:Table [Intellectual Product]
Processing 00000000.tx.160: Effect of tenilsetam on the digestibility of collagen incubated with 30 mM glucose  In vivo studies Table 2 shows the profile of animals in the present study. 

Phrase: "Effect of tenilsetam"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C1280500:Effect [Qualitative Concept]
   790   C2348382:Effect [Qualitative Concept]

Phrase: "on the digestibility"

Phrase: "of collagen"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0009325:Collagen [Amino Acid, Peptide, or Protein,Biologically Active Substance,Biomedical or Dental Material]
  1000   C1167364:collagen [Cell Component]
   928 E C0439689:Collagenous [Qualitative Concept]

Phrase: "incubated with 30 mM glucose"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   760   C1439852:Incubated [Laboratory Procedure]

Phrase: "In vivo"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1515655:In Vivo [Spatial Concept]
           vivo

Phrase: "studies"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557651:Study [Manufactured Object]
  1000   C0947630:studies [Laboratory Procedure]
  1000   C2603343:Study [Research Activity]

Phrase: "Table 2"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039224:Table [Manufactured Object]
   861   C1706073:Table [Medical Device]
   861   C1706074:Table [Intellectual Product]

Phrase: "shows"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1547282:Show [Intellectual Product]

Phrase: "the profile of animals"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C1979963:Profile [Laboratory Procedure]
   770   C2003903:Profile [Functional Concept]

Phrase: "in the present study."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0150312:Present [Quantitative Concept]
   861   C0449450:Present [Idea or Concept]
   861   C0557651:Study [Manufactured Object]
   861   C2603343:Study [Research Activity]
Processing 00000000.tx.161: Although the increase in body weight was suppressed in diabetic rats (groups B and C), the administration of tenilsetam did not influence body weight. 

Phrase: "Although"

Phrase: "the increase in body weight"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   797   C0043094:WEIGHT INCREASE [Finding]
   760   C0442805:Increase [Functional Concept]

Phrase: "was"

Phrase: "suppressed in diabetic rats"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0034693:rats [Mammal]
   770   C0034721:Rats [Mammal]
   770   C0241863:DIABETIC [Finding]
   770   C1260953:Suppressed [Functional Concept]

Phrase: "(groups B"

Phrase: "and"

Phrase: "C),"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1553033:[c] [Quantitative Concept]

Phrase: "the administration of tenilsetam"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0001554:Administration [Occupational Activity]
   770   C1533734:Administration [Therapeutic or Preventive Procedure]

Phrase: "did"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "influence"

Phrase: "body weight."
Meta Candidates (Total=10; Excluded=1; Pruned=0; Remaining=9)
  1000   C0005910:Body Weight [Organism Attribute]
           weight
  1000   C1305866:body weight [Diagnostic Procedure]
           weight
   861   C0043100:Weight [Quantitative Concept]
   861   C0242821:body [Human]
   861   C0460148:Body [Anatomical Structure]
   861   C1268086:Body [Anatomical Structure]
   861   C1705104:Weight [Idea or Concept]
   777 E C1995017:Bodies [Cell Component]
Processing 00000000.tx.162: In the 16th week, the mean levels of plasma glucose and glycated Hb were significantly higher in groups B and C compared with the control values (P < 0.01). 

Phrase: "In the 16th week,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0332174:/week [Temporal Concept]
   861   C0439230:week [Temporal Concept]

Phrase: "the mean levels of plasma glucose"
Meta Candidates (Total=7; Excluded=4; Pruned=0; Remaining=3)
   814   C0455280:glucose levels plasma [Laboratory or Test Result]
   783   C0428548:glucose levels [Laboratory or Test Result]
   767 E C0337438:glucose level [Laboratory Procedure]
   753   C0441889:Levels [Qualitative Concept]
   719 E C0456079:Level [Classification]
   719 E C1547707:Level [Geographic Area]
   719 E C2946261:Level [Pharmacologic Substance]

Phrase: "and"

Phrase: "glycated Hb"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0017853:Glycated haemoglobin [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   861   C0019046:Haemoglobin [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "were"

Phrase: "significantly higher in groups B"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   726   C0205250:High [Qualitative Concept]
   726   C1299351:High [Qualitative Concept]
   726   C2700149:HIGH [Intellectual Product]

Phrase: "and"

Phrase: "C"

Phrase: "compared with the control values"
Meta Candidates (Total=8; Excluded=1; Pruned=0; Remaining=7)
   760   C0042295:Values [Qualitative Concept]
   760   C0243148:control [Qualitative Concept]
   760   C1550141:Control [Substance]
   760   C1707455:Compared [Activity]
   760   C1882979:Control [Conceptual Entity]
   760   C2587213:Control [Functional Concept]
   760   C3274648:Control [Qualitative Concept]
   726 E C1522609:Value [Quantitative Concept]

Phrase: "(P < 0.01"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C2603361:P' [Clinical Attribute]

Phrase: ")."
Processing 00000000.tx.163: However, no differences in plasma glucose and glycated Hb levels between nontreated and tenilsetam-treated diabetic rats were observed. 

Phrase: "However,"

Phrase: "no differences in plasma glucose"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   726   C1705241:*Difference [Quantitative Concept]
   726   C1705242:Difference [Qualitative Concept]

Phrase: "and"

Phrase: "glycated Hb levels between nontreated"
Meta Candidates (Total=8; Excluded=3; Pruned=0; Remaining=5)
   806   C0017853:Glycated haemoglobin [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   806   C0019029:haemoglobin levels [Laboratory or Test Result]
   806   C1314664:haemoglobin levels [Laboratory Procedure]
   760   C0019046:Haemoglobin [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   760   C0441889:Levels [Qualitative Concept]
   726 E C0456079:Level [Classification]
   726 E C1547707:Level [Geographic Area]
   726 E C2946261:Level [Pharmacologic Substance]

Phrase: "and"

Phrase: "tenilsetam-treated diabetic rats"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   812   C0034693:rats [Mammal]
   812   C0034721:Rats [Mammal]
   812   C0241863:DIABETIC [Finding]

Phrase: "were"

Phrase: "observed."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1441672:Observed [Functional Concept]
Processing 00000000.tx.164: View this table: [in this window] [in a new window]  Table 2. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "this table"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0039224:Table [Manufactured Object]
  1000   C1706073:Table [Medical Device]
  1000   C1706074:Table [Intellectual Product]

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  Table 2."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039224:Table [Manufactured Object]
   861   C1706073:Table [Medical Device]
   861   C1706074:Table [Intellectual Product]
Processing 00000000.tx.165: Characteristics of rats used in the present experiment  After 16 weeks of diabetes, control rats did not exhibit abnormalities in the lens, whereas five of eight diabetic rats developed signs of lens opacity. 

Phrase: "Characteristics of rats"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C1521970:Characteristics [Qualitative Concept]

Phrase: "used in the present experiment"
Meta Candidates (Total=8; Excluded=3; Pruned=0; Remaining=5)
   760   C0150312:Present [Quantitative Concept]
   760   C0449450:Present [Idea or Concept]
   760   C0681814:Experiment [Research Activity]
   760   C1273517:used [Finding]
   760   C1706386:Experiment [Conceptual Entity]
   726 E C0042153:use [Functional Concept]
   726 E C0457083:Use [Functional Concept]
   726 E C1947944:Use [Intellectual Product]

Phrase: "After 16 weeks"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0439230:weeks [Temporal Concept]
   827 E C0332174:/week [Temporal Concept]

Phrase: "of diabetes,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0011847:Diabetes [Disease or Syndrome]
  1000   C0011849:Diabetes [Disease or Syndrome]

Phrase: "control rats"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   861   C0034693:rats [Mammal]
   861   C0034721:Rats [Mammal]
   861   C0243148:control [Qualitative Concept]
   861   C1550141:Control [Substance]
   861   C1882979:Control [Conceptual Entity]
   861   C2587213:Control [Functional Concept]
   861   C3274648:Control [Qualitative Concept]

Phrase: "did"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "exhibit"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0015272:Exhibit [Intellectual Product]

Phrase: "abnormalities in the lens,"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   819   C0549651:LENSE ABNORMALITIES [Pathologic Function]
   770   C0000768:Abnormalities [Congenital Abnormality]
   770   C0000769:abnormalities [Functional Concept]
   737 E C1704258:Abnormality [Finding]

Phrase: "whereas"

Phrase: "five of eight diabetic rats"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   760   C0034693:rats [Mammal]
   760   C0034721:Rats [Mammal]
   760   C0205451:Five [Quantitative Concept]
   760   C0205454:Eight [Quantitative Concept]
   760   C0241863:DIABETIC [Finding]

Phrase: "developed"

Phrase: "signs of lens opacity."
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   770   C0220912:signs [Functional Concept]
   770   C0220913:signs [Manufactured Object]
   770   C0311392:SIGNS [Finding]
   737 E C1547188:Sign [Idea or Concept]
Processing 00000000.tx.166: In contrast, only one of nine tenilsetam-treated diabetic rats developed lens opacity. 

Phrase: "In contrast,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1979874:Contrast [Qualitative Concept]

Phrase: "only one of nine tenilsetam-treated diabetic rats"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   744   C0205447:One [Quantitative Concept]

Phrase: "developed"

Phrase: "lens opacity."
Meta Candidates (Total=10; Excluded=2; Pruned=0; Remaining=8)
  1000   C0086543:lens opacity [Anatomical Abnormality]
  1000   C1510497:Lens opacity [Disease or Syndrome]
   861   C0023317:Lens [Body Part, Organ, or Organ Component]
   861   C0023318:Lens [Medical Device]
   861   C0029053:Opacity [Finding]
   861   C0996842:Lens [Plant]
   861   C1265876:Opacity [Pathologic Function]
   861   C1278892:Lens [Body Part, Organ, or Organ Component]
   789 E C1261286:Opaque [Qualitative Concept]
   789 E C1882150:OPAQUE [Phenomenon or Process]
Processing 00000000.tx.167: Fluorescence intensity of renal cortex and aorta After 16 weeks of diabetes, the fluorescence intensity (excitation, 370 nm; emission, 440 nm) of the renal cortex in diabetic rats was significantly higher than that in the control group (25.3  2.9 vs. 18.8  5.6 AU/mg collagen; P < 0.01). 

Phrase: "Fluorescence intensity of renal cortex"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0016315:Fluorescence [Natural Phenomenon or Process]
   760   C0522510:Intensity [Qualitative Concept]

Phrase: "and"

Phrase: "aorta After 16 weeks of diabetes,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0003483:Aorta [Body Part, Organ, or Organ Component]
   753   C1278934:Aorta [Body Part, Organ, or Organ Component]

Phrase: "the fluorescence intensity"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   861   C0016315:Fluorescence [Natural Phenomenon or Process]
   861   C0522510:Intensity [Qualitative Concept]
   789 E C0303920:Fluorescent [Indicator, Reagent, or Diagnostic Aid,Organic Chemical]

Phrase: "(excitation,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0549255:Excitation [Activity]

Phrase: "370 nm"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0312860:NM [Cell Function]

Phrase: "; emission,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0233929:Emission [Body Substance]
  1000   C2349995:Emission [Substance]

Phrase: "440 nm) of the renal cortex"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0312860:NM [Cell Function]

Phrase: "in diabetic rats"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0034693:rats [Mammal]
   861   C0034721:Rats [Mammal]
   861   C0241863:DIABETIC [Finding]

Phrase: "was"

Phrase: "significantly higher than that"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   737   C0205250:High [Qualitative Concept]
   737   C1299351:High [Qualitative Concept]
   737   C2700149:HIGH [Intellectual Product]

Phrase: "in the control group"
Meta Candidates (Total=12; Excluded=0; Pruned=0; Remaining=12)
  1000   C0009932:Control Group [Group]
   861   C0243148:control [Qualitative Concept]
   861   C0441833:Group [Idea or Concept]
   861   C0687744:group [Population Group]
   861   C1257890:Group [Population Group]
   861   C1550141:Control [Substance]
   861   C1552516:Group [Health Care Related Organization]
   861   C1705428:Group [Conceptual Entity]
   861   C1705429:Group [Population Group]
   861   C1882979:Control [Conceptual Entity]
   861   C2587213:Control [Functional Concept]
   861   C3274648:Control [Qualitative Concept]

Phrase: "(25.3  2.9"

Phrase: "vs. 18.8  5.6 AU/mg collagen"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   793   C0009325:Collagen [Amino Acid, Peptide, or Protein,Biologically Active Substance,Biomedical or Dental Material]
   793   C1167364:collagen [Cell Component]
   721 E C0439689:Collagenous [Qualitative Concept]

Phrase: "; P < 0.01"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C2603361:P' [Clinical Attribute]

Phrase: ")."
Processing 00000000.tx.168: Fluorescence intensity returned to the control level with tenilsetam treatment (19.5  2.3 AU/mg collagen), as shown in Fig. 

Phrase: "Fluorescence intensity"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   861   C0016315:Fluorescence [Natural Phenomenon or Process]
   861   C0522510:Intensity [Qualitative Concept]
   789 E C0303920:Fluorescent [Indicator, Reagent, or Diagnostic Aid,Organic Chemical]

Phrase: "returned to the control level"
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
   790   C0332156:Return to [Qualitative Concept]
           Return
   760   C0243148:control [Qualitative Concept]
   760   C0441889:Level [Qualitative Concept]
   760   C0456079:Level [Classification]
   760   C1547707:Level [Geographic Area]
   760   C1550141:Control [Substance]
   760   C1882979:Control [Conceptual Entity]
   760   C2587213:Control [Functional Concept]
   760   C2946261:Level [Pharmacologic Substance]
   760   C3274648:Control [Qualitative Concept]

Phrase: "with tenilsetam treatment"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   861   C0039798:treatment [Functional Concept]
   861   C0087111:Treatment [Therapeutic or Preventive Procedure]
   861   C1522326:Treatment [Functional Concept]
   861   C1533734:Treatment [Therapeutic or Preventive Procedure]
   861   C1705169:Treatment [Conceptual Entity]
   861   C3538994:TREATMENT [Research Activity]

Phrase: "(19.5  2.3 AU/mg collagen"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   793   C0009325:Collagen [Amino Acid, Peptide, or Protein,Biologically Active Substance,Biomedical or Dental Material]
   793   C1167364:collagen [Cell Component]
   721 E C0439689:Collagenous [Qualitative Concept]

Phrase: ")"

Phrase: ","

Phrase: "as"

Phrase: "shown in Fig."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0349966:Fig [Food]
   790   C1337208:FIG [Food]
   756   C1547282:Show [Intellectual Product]
Processing 00000000.tx.169: 3. 

Phrase: "3."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439086:<3 [Quantitative Concept]
  1000   C2827736:3+ [Quantitative Concept]
  1000   C2981702:3+ [Classification]
Processing 00000000.tx.170: The other fluorescence intensity (excitation, 328 nm; emission, 378 nm) characteristic for pentosidine increased significantly in the renal cortex of diabetic rats compared with the control value (60.5  13.5 vs. 44.5  11.6 AU/mg collagen; P < 0.01; Fig. 3). 

Phrase: "The"

Phrase: "other fluorescence intensity"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   861   C0016315:Fluorescence [Natural Phenomenon or Process]
   861   C0522510:Intensity [Qualitative Concept]
   789 E C0303920:Fluorescent [Indicator, Reagent, or Diagnostic Aid,Organic Chemical]

Phrase: "(excitation,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0549255:Excitation [Activity]

Phrase: "328 nm"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0312860:NM [Cell Function]

Phrase: "; emission,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0233929:Emission [Body Substance]
  1000   C2349995:Emission [Substance]

Phrase: "378 nm)"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0312860:NM [Cell Function]

Phrase: "characteristic for pentosidine"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C1521970:Characteristic [Qualitative Concept]

Phrase: "increased"
Meta Candidates (Total=8; Excluded=6; Pruned=0; Remaining=2)
  1000   C0205217:Increased [Quantitative Concept]
  1000   C0442805:Increased [Functional Concept]
   928 E C1517378:Gain [Quantitative Concept]
   907 E C0439661:Acquired [Temporal Concept]
   907 E C0442808:Increasing [Functional Concept]
   907 E C1301820:Obtain [Functional Concept]
   907 E C1706701:Acquire [Activity]
   907 E C3245488:acquired [Intellectual Product]

Phrase: "significantly in the renal cortex of diabetic rats"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   770   C0022655:Renal cortex [Body Part, Organ, or Organ Component]
   744   C0007776:Cortex [Body Part, Organ, or Organ Component]
   744   C0022646:Renal [Body Part, Organ, or Organ Component]
   744   C0034693:rats [Mammal]
   744   C0034721:Rats [Mammal]
   744   C0241863:DIABETIC [Finding]
   744   C1176472:Cortex [Body Part, Organ, or Organ Component]
   744   C2700441:Cortex [Plant]

Phrase: "compared with the control value"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   760   C0243148:control [Qualitative Concept]
   760   C1522609:Value [Quantitative Concept]
   760   C1550141:Control [Substance]
   760   C1707455:Compared [Activity]
   760   C1882979:Control [Conceptual Entity]
   760   C2587213:Control [Functional Concept]
   760   C3274648:Control [Qualitative Concept]

Phrase: "(60.5  13.5"

Phrase: "vs. 44.5  11.6 AU/mg collagen"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   793   C0009325:Collagen [Amino Acid, Peptide, or Protein,Biologically Active Substance,Biomedical or Dental Material]
   793   C1167364:collagen [Cell Component]
   721 E C0439689:Collagenous [Qualitative Concept]

Phrase: "; P < 0.01"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C2603361:P' [Clinical Attribute]

Phrase: "; Fig. 3"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0349966:Fig [Food]
   861   C1337208:FIG [Food]

Phrase: ")."
Processing 00000000.tx.171: Concerning this type of fluorescence, the preventive action of tenilsetam against the increase in fluorescence intensity was similar to that observed in conventional fluorescence described above, so that the fluorescence intensity was not different from the control value (40.7  9.9 AU/mg collagen). 

Phrase: "Concerning"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C2699424:Concern [Idea or Concept]

Phrase: "this type of fluorescence,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0332307:Type [Qualitative Concept]
   770   C1547052:*Type [Quantitative Concept]

Phrase: "the preventive action of tenilsetam"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   806   C1456501:Preventive action [Qualitative Concept]
   760   C0441472:Action [Functional Concept]
   760   C3266814:Action [Activity]

Phrase: "against the increase"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0442805:Increase [Functional Concept]

Phrase: "in fluorescence intensity"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   861   C0016315:Fluorescence [Natural Phenomenon or Process]
   861   C0522510:Intensity [Qualitative Concept]
   789 E C0303920:Fluorescent [Indicator, Reagent, or Diagnostic Aid,Organic Chemical]

Phrase: "was"

Phrase: "similar to that"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C2348205:Similar [Qualitative Concept]

Phrase: "observed in conventional fluorescence"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0016315:Fluorescence [Natural Phenomenon or Process]
   770   C0439858:Conventional [Qualitative Concept]
   770   C1441672:Observed [Functional Concept]

Phrase: "described"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1552738:described [Idea or Concept]

Phrase: "above, so"

Phrase: "that"

Phrase: "the fluorescence intensity"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   861   C0016315:Fluorescence [Natural Phenomenon or Process]
   861   C0522510:Intensity [Qualitative Concept]
   789 E C0303920:Fluorescent [Indicator, Reagent, or Diagnostic Aid,Organic Chemical]

Phrase: "was"

Phrase: "not different from the control value"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C1705242:Different [Qualitative Concept]

Phrase: "(40.7  9.9 AU/mg collagen"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   793   C0009325:Collagen [Amino Acid, Peptide, or Protein,Biologically Active Substance,Biomedical or Dental Material]
   793   C1167364:collagen [Cell Component]
   721 E C0439689:Collagenous [Qualitative Concept]

Phrase: ")."
Processing 00000000.tx.172: View larger version (23K): [in this window] [in a new window]  Figure 3. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "larger version"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0333052:Version [Functional Concept]
   861   C2607870:Version [Spatial Concept]

Phrase: "(23K"

Phrase: ")"

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  Figure 3."
Processing 00000000.tx.173: Fluorescence intensity in the collagenase-soluble fraction of renal cortex measured at 370/440 and 328/378 nm excitation/emission. 

Phrase: "Fluorescence intensity in the collagenase-soluble fraction of renal cortex"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   739   C0016315:Fluorescence [Natural Phenomenon or Process]
   739   C0522510:Intensity [Qualitative Concept]

Phrase: "measured at 370/440"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   770   C0444706:Measured [Qualitative Concept]
   770   C3541902:MEASURED [Diagnostic Procedure]
   737 E C0079809:Measure [Quantitative Concept]
   737 E C0242485:Measure [Functional Concept]

Phrase: "and"

Phrase: "328/378 nm excitation/emission."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   804   C0233929:Emission [Body Substance]
   804   C2349995:Emission [Substance]
Processing 00000000.tx.174: After 16 weeks of STZ treatment, the renal cortex of each animal was extracted and solubilized with collagenase. 

Phrase: "After 16 weeks"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0439230:weeks [Temporal Concept]
   827 E C0332174:/week [Temporal Concept]

Phrase: "of STZ treatment,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   861   C0039798:treatment [Functional Concept]
   861   C0087111:Treatment [Therapeutic or Preventive Procedure]
   861   C1522326:Treatment [Functional Concept]
   861   C1533734:Treatment [Therapeutic or Preventive Procedure]
   861   C1705169:Treatment [Conceptual Entity]
   861   C3538994:TREATMENT [Research Activity]

Phrase: "the renal cortex of each animal"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   790   C0022655:Renal cortex [Body Part, Organ, or Organ Component]
   753   C0007776:Cortex [Body Part, Organ, or Organ Component]
   753   C0022646:Renal [Body Part, Organ, or Organ Component]
   753   C1176472:Cortex [Body Part, Organ, or Organ Component]
   753   C2700441:Cortex [Plant]

Phrase: "was"

Phrase: "extracted"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0185115:Extracted [Therapeutic or Preventive Procedure]
  1000   C3541890:EXTRACTED [Finding]
   966 E C2828366:Extract [Substance]

Phrase: "and"

Phrase: "solubilized with collagenase."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0162745:COLLAGENASE [Amino Acid, Peptide, or Protein,Enzyme,Pharmacologic Substance]
Processing 00000000.tx.175: Fluorescence intensities in the soluble fraction of renal cortex were measured and corrected by collagen content. 

Phrase: "Fluorescence intensities in the soluble fraction of renal cortex"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   742   C0522510:intensities [Qualitative Concept]

Phrase: "were"

Phrase: "measured"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C0444706:Measured [Qualitative Concept]
  1000   C3541902:MEASURED [Diagnostic Procedure]
   966 E C0079809:Measure [Quantitative Concept]
   966 E C0242485:Measure [Functional Concept]

Phrase: "and"

Phrase: "corrected by collagen content."
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   770   C0009325:Collagen [Amino Acid, Peptide, or Protein,Biologically Active Substance,Biomedical or Dental Material]
   770   C0205202:Corrected [Qualitative Concept]
   770   C0423896:Content [Mental Process]
   770   C0456205:Content [Conceptual Entity]
   770   C1167364:collagen [Cell Component]
   737 E C2349182:Correct [Qualitative Concept]
Processing 00000000.tx.176: The fluorescence intensity was elevated in diabetic rats compared with that in controls and was suppressed in diabetics administered tenilsetam. 

Phrase: "The fluorescence intensity"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   861   C0016315:Fluorescence [Natural Phenomenon or Process]
   861   C0522510:Intensity [Qualitative Concept]
   789 E C0303920:Fluorescent [Indicator, Reagent, or Diagnostic Aid,Organic Chemical]

Phrase: "was"

Phrase: "elevated in diabetic rats"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   770   C0034693:rats [Mammal]
   770   C0034721:Rats [Mammal]
   770   C0205250:Elevated [Qualitative Concept]
   770   C0241863:DIABETIC [Finding]
   770   C3163633:Elevated [Qualitative Concept]

Phrase: "compared with that"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C1707455:Compared [Activity]

Phrase: "in controls"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   966   C0243148:control [Qualitative Concept]
   966   C1550141:Control [Substance]
   966   C1882979:Control [Conceptual Entity]
   966   C2587213:Control [Functional Concept]
   966   C3274648:Control [Qualitative Concept]

Phrase: "and"

Phrase: "was"

Phrase: "suppressed in diabetics"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0241863:diabetics [Finding]
   790   C1260953:Suppressed [Functional Concept]

Phrase: "administered"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1521801:Administered [Functional Concept]
   966 E C1621583:Administer [Functional Concept]

Phrase: "tenilsetam."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0076093:tenilsetam [Organic Chemical,Pharmacologic Substance]
Processing 00000000.tx.177: *, P < 0.01 vs. control rats; 

Phrase: "*,"

Phrase: "P < 0.01"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C2603361:P' [Clinical Attribute]

Phrase: "vs. control rats"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   861   C0034693:rats [Mammal]
   861   C0034721:Rats [Mammal]
   861   C0243148:control [Qualitative Concept]
   861   C1550141:Control [Substance]
   861   C1882979:Control [Conceptual Entity]
   861   C2587213:Control [Functional Concept]
   861   C3274648:Control [Qualitative Concept]

Phrase: ";"
Processing 00000000.tx.178: **, P < 0.01 vs. untreated diabetic rats.  

Phrase: "*"

Phrase: "*,"

Phrase: "P < 0.01"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C2603361:P' [Clinical Attribute]

Phrase: "vs. untreated diabetic rats."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0034693:rats [Mammal]
   827   C0034721:Rats [Mammal]
   827   C0241863:DIABETIC [Finding]
Processing 00000000.tx.179: These inhibitory effects of tenilsetam were confirmed by investigating the fluorescence intensity of aortas in the same animals (Fig. 4). 

Phrase: "These inhibitory effects of tenilsetam"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   760   C1280500:effects [Qualitative Concept]
   726 E C2348382:Effect [Qualitative Concept]

Phrase: "were"

Phrase: "confirmed by investigating"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   882   C0521093:Confirmed by [Qualitative Concept]
           confirmed
   790   C0750484:Confirmed [Idea or Concept]
   790   C1292732:investigating [Functional Concept]
   756 E C1456348:Confirm [Qualitative Concept]

Phrase: "the fluorescence intensity of aortas"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0016315:Fluorescence [Natural Phenomenon or Process]
   760   C0522510:Intensity [Qualitative Concept]

Phrase: "in the same animals"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0003062:Animals [Animal]

Phrase: "(Fig. 4"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0349966:Fig [Food]
   861   C1337208:FIG [Food]

Phrase: ")."
Processing 00000000.tx.180: The fluorescence intensity (excitation, 370 nm; emission, 440 nm) of the aorta in diabetic rat was significantly higher than that in the control group (21.4  9.9 vs. 10.2  2.7 AU/mg collagen; P < 0.01). 

Phrase: "The fluorescence intensity"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   861   C0016315:Fluorescence [Natural Phenomenon or Process]
   861   C0522510:Intensity [Qualitative Concept]
   789 E C0303920:Fluorescent [Indicator, Reagent, or Diagnostic Aid,Organic Chemical]

Phrase: "(excitation,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0549255:Excitation [Activity]

Phrase: "370 nm"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0312860:NM [Cell Function]

Phrase: "; emission,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0233929:Emission [Body Substance]
  1000   C2349995:Emission [Substance]

Phrase: "440 nm) of the aorta"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0312860:NM [Cell Function]

Phrase: "in diabetic rat"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0034693:Rat, NOS [Mammal]
   861   C0034721:Rat [Mammal]
   861   C0241863:DIABETIC [Finding]

Phrase: "was"

Phrase: "significantly higher than that"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   737   C0205250:High [Qualitative Concept]
   737   C1299351:High [Qualitative Concept]
   737   C2700149:HIGH [Intellectual Product]

Phrase: "in the control group"
Meta Candidates (Total=12; Excluded=0; Pruned=0; Remaining=12)
  1000   C0009932:Control Group [Group]
   861   C0243148:control [Qualitative Concept]
   861   C0441833:Group [Idea or Concept]
   861   C0687744:group [Population Group]
   861   C1257890:Group [Population Group]
   861   C1550141:Control [Substance]
   861   C1552516:Group [Health Care Related Organization]
   861   C1705428:Group [Conceptual Entity]
   861   C1705429:Group [Population Group]
   861   C1882979:Control [Conceptual Entity]
   861   C2587213:Control [Functional Concept]
   861   C3274648:Control [Qualitative Concept]

Phrase: "(21.4  9.9"

Phrase: "vs. 10.2  2.7 AU/mg collagen"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   793   C0009325:Collagen [Amino Acid, Peptide, or Protein,Biologically Active Substance,Biomedical or Dental Material]
   793   C1167364:collagen [Cell Component]
   721 E C0439689:Collagenous [Qualitative Concept]

Phrase: "; P < 0.01"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C2603361:P' [Clinical Attribute]

Phrase: ")."
Processing 00000000.tx.181: The fluorescence intensity returned to the control level with tenilsetam treatment (8.1  1.4 AU/mg collagen). 

Phrase: "The fluorescence intensity"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   861   C0016315:Fluorescence [Natural Phenomenon or Process]
   861   C0522510:Intensity [Qualitative Concept]
   789 E C0303920:Fluorescent [Indicator, Reagent, or Diagnostic Aid,Organic Chemical]

Phrase: "returned to the control level"
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
   790   C0332156:Return to [Qualitative Concept]
           Return
   760   C0243148:control [Qualitative Concept]
   760   C0441889:Level [Qualitative Concept]
   760   C0456079:Level [Classification]
   760   C1547707:Level [Geographic Area]
   760   C1550141:Control [Substance]
   760   C1882979:Control [Conceptual Entity]
   760   C2587213:Control [Functional Concept]
   760   C2946261:Level [Pharmacologic Substance]
   760   C3274648:Control [Qualitative Concept]

Phrase: "with tenilsetam treatment"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   861   C0039798:treatment [Functional Concept]
   861   C0087111:Treatment [Therapeutic or Preventive Procedure]
   861   C1522326:Treatment [Functional Concept]
   861   C1533734:Treatment [Therapeutic or Preventive Procedure]
   861   C1705169:Treatment [Conceptual Entity]
   861   C3538994:TREATMENT [Research Activity]

Phrase: "(8.1  1.4 AU/mg collagen"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   793   C0009325:Collagen [Amino Acid, Peptide, or Protein,Biologically Active Substance,Biomedical or Dental Material]
   793   C1167364:collagen [Cell Component]
   721 E C0439689:Collagenous [Qualitative Concept]

Phrase: ")."
Processing 00000000.tx.182: The other fluorescence intensity (excitation, 328 nm; emission, 378 nm) also increased significantly in aortas of diabetic rats compared with that in the controls (64.3  22.0 vs. 25.3  4.4 AU/mg collagen; P < 0.01; Fig. 4). 

Phrase: "The"

Phrase: "other fluorescence intensity"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   861   C0016315:Fluorescence [Natural Phenomenon or Process]
   861   C0522510:Intensity [Qualitative Concept]
   789 E C0303920:Fluorescent [Indicator, Reagent, or Diagnostic Aid,Organic Chemical]

Phrase: "(excitation,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0549255:Excitation [Activity]

Phrase: "328 nm"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0312860:NM [Cell Function]

Phrase: "; emission,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0233929:Emission [Body Substance]
  1000   C2349995:Emission [Substance]

Phrase: "378 nm) also"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0312860:NM [Cell Function]

Phrase: "increased"
Meta Candidates (Total=8; Excluded=6; Pruned=0; Remaining=2)
  1000   C0205217:Increased [Quantitative Concept]
  1000   C0442805:Increased [Functional Concept]
   928 E C1517378:Gain [Quantitative Concept]
   907 E C0439661:Acquired [Temporal Concept]
   907 E C0442808:Increasing [Functional Concept]
   907 E C1301820:Obtain [Functional Concept]
   907 E C1706701:Acquire [Activity]
   907 E C3245488:acquired [Intellectual Product]

Phrase: "significantly in aortas of diabetic rats"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   753   C0003483:Aortas [Body Part, Organ, or Organ Component]
   753   C0034693:rats [Mammal]
   753   C0034721:Rats [Mammal]
   753   C0241863:DIABETIC [Finding]
   750   C1882561:Rat Aorta [Body Part, Organ, or Organ Component]
   719 E C1278934:Aorta [Body Part, Organ, or Organ Component]

Phrase: "compared with that"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C1707455:Compared [Activity]

Phrase: "in the controls"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   966   C0243148:control [Qualitative Concept]
   966   C1550141:Control [Substance]
   966   C1882979:Control [Conceptual Entity]
   966   C2587213:Control [Functional Concept]
   966   C3274648:Control [Qualitative Concept]

Phrase: "(64.3  22.0"

Phrase: "vs. 25.3  4.4 AU/mg collagen"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   793   C0009325:Collagen [Amino Acid, Peptide, or Protein,Biologically Active Substance,Biomedical or Dental Material]
   793   C1167364:collagen [Cell Component]
   721 E C0439689:Collagenous [Qualitative Concept]

Phrase: "; P < 0.01"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C2603361:P' [Clinical Attribute]

Phrase: "; Fig. 4"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0349966:Fig [Food]
   861   C1337208:FIG [Food]

Phrase: ")."
Processing 00000000.tx.183: Fluorescence intensity was restored to the control level with tenilsetam treatment (27.5  3.1 AU/mg collagen). 

Phrase: "Fluorescence intensity"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   861   C0016315:Fluorescence [Natural Phenomenon or Process]
   861   C0522510:Intensity [Qualitative Concept]
   789 E C0303920:Fluorescent [Indicator, Reagent, or Diagnostic Aid,Organic Chemical]

Phrase: "was"

Phrase: "restored to the control level"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   760   C0243148:control [Qualitative Concept]
   760   C0441889:Level [Qualitative Concept]
   760   C0456079:Level [Classification]
   760   C1547707:Level [Geographic Area]
   760   C1550141:Control [Substance]
   760   C1882979:Control [Conceptual Entity]
   760   C2587213:Control [Functional Concept]
   760   C2946261:Level [Pharmacologic Substance]
   760   C3274648:Control [Qualitative Concept]

Phrase: "with tenilsetam treatment"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   861   C0039798:treatment [Functional Concept]
   861   C0087111:Treatment [Therapeutic or Preventive Procedure]
   861   C1522326:Treatment [Functional Concept]
   861   C1533734:Treatment [Therapeutic or Preventive Procedure]
   861   C1705169:Treatment [Conceptual Entity]
   861   C3538994:TREATMENT [Research Activity]

Phrase: "(27.5  3.1 AU/mg collagen"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   793   C0009325:Collagen [Amino Acid, Peptide, or Protein,Biologically Active Substance,Biomedical or Dental Material]
   793   C1167364:collagen [Cell Component]
   721 E C0439689:Collagenous [Qualitative Concept]

Phrase: ")."
Processing 00000000.tx.184: View larger version (21K): [in this window] [in a new window]  Figure 4. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "larger version"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0333052:Version [Functional Concept]
   861   C2607870:Version [Spatial Concept]

Phrase: "(21K"

Phrase: ")"

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  Figure 4."
Processing 00000000.tx.185: Fluorescence intensity in the collagenase-soluble fraction of aorta measured at 370/440 and 328/378 nm excitation/emission. 

Phrase: "Fluorescence intensity in the collagenase-soluble fraction of aorta"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   742   C0016315:Fluorescence [Natural Phenomenon or Process]
   742   C0522510:Intensity [Qualitative Concept]

Phrase: "measured at 370/440"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   770   C0444706:Measured [Qualitative Concept]
   770   C3541902:MEASURED [Diagnostic Procedure]
   737 E C0079809:Measure [Quantitative Concept]
   737 E C0242485:Measure [Functional Concept]

Phrase: "and"

Phrase: "328/378 nm excitation/emission."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   804   C0233929:Emission [Body Substance]
   804   C2349995:Emission [Substance]
Processing 00000000.tx.186: Fluorescence intensities of solubilized aorta were corrected by collagen content measured by hydroxyproline assay. 

Phrase: "Fluorescence intensities of solubilized aorta"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0522510:intensities [Qualitative Concept]

Phrase: "were"

Phrase: "corrected by collagen content"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   770   C0009325:Collagen [Amino Acid, Peptide, or Protein,Biologically Active Substance,Biomedical or Dental Material]
   770   C0205202:Corrected [Qualitative Concept]
   770   C0423896:Content [Mental Process]
   770   C0456205:Content [Conceptual Entity]
   770   C1167364:collagen [Cell Component]
   737 E C2349182:Correct [Qualitative Concept]

Phrase: "measured by hydroxyproline assay."
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
   770   C0005507:Assay [Laboratory Procedure]
   770   C0020388:Hydroxyproline [Amino Acid, Peptide, or Protein,Biologically Active Substance,Pharmacologic Substance]
   770   C0243073:assay [Qualitative Concept]
   770   C0444706:Measured [Qualitative Concept]
   770   C1510438:Assay [Laboratory Procedure]
   770   C3541902:MEASURED [Diagnostic Procedure]
   737 E C0079809:Measure [Quantitative Concept]
   737 E C0242485:Measure [Functional Concept]
Processing 00000000.tx.187: The fluorescence intensity was elevated in diabetic rats compared with that in controls and was suppressed in diabetics administered tenilsetam. 

Phrase: "The fluorescence intensity"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   861   C0016315:Fluorescence [Natural Phenomenon or Process]
   861   C0522510:Intensity [Qualitative Concept]
   789 E C0303920:Fluorescent [Indicator, Reagent, or Diagnostic Aid,Organic Chemical]

Phrase: "was"

Phrase: "elevated in diabetic rats"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   770   C0034693:rats [Mammal]
   770   C0034721:Rats [Mammal]
   770   C0205250:Elevated [Qualitative Concept]
   770   C0241863:DIABETIC [Finding]
   770   C3163633:Elevated [Qualitative Concept]

Phrase: "compared with that"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C1707455:Compared [Activity]

Phrase: "in controls"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   966   C0243148:control [Qualitative Concept]
   966   C1550141:Control [Substance]
   966   C1882979:Control [Conceptual Entity]
   966   C2587213:Control [Functional Concept]
   966   C3274648:Control [Qualitative Concept]

Phrase: "and"

Phrase: "was"

Phrase: "suppressed in diabetics"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0241863:diabetics [Finding]
   790   C1260953:Suppressed [Functional Concept]

Phrase: "administered"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1521801:Administered [Functional Concept]
   966 E C1621583:Administer [Functional Concept]

Phrase: "tenilsetam."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0076093:tenilsetam [Organic Chemical,Pharmacologic Substance]
Processing 00000000.tx.188: *, P < 0.01 vs. control rats; 

Phrase: "*,"

Phrase: "P < 0.01"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C2603361:P' [Clinical Attribute]

Phrase: "vs. control rats"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   861   C0034693:rats [Mammal]
   861   C0034721:Rats [Mammal]
   861   C0243148:control [Qualitative Concept]
   861   C1550141:Control [Substance]
   861   C1882979:Control [Conceptual Entity]
   861   C2587213:Control [Functional Concept]
   861   C3274648:Control [Qualitative Concept]

Phrase: ";"
Processing 00000000.tx.189: **, P < 0.01 vs. untreated diabetic rats.  

Phrase: "*"

Phrase: "*,"

Phrase: "P < 0.01"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C2603361:P' [Clinical Attribute]

Phrase: "vs. untreated diabetic rats."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0034693:rats [Mammal]
   827   C0034721:Rats [Mammal]
   827   C0241863:DIABETIC [Finding]
Processing 00000000.tx.190: Pyrraline level in the rat renal cortex and aorta As shown in Fig. 

Phrase: "Pyrraline level in the rat renal cortex"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   748   C0441889:Level [Qualitative Concept]
   748   C0456079:Level [Classification]
   748   C1547707:Level [Geographic Area]
   748   C2946261:Level [Pharmacologic Substance]

Phrase: "and"

Phrase: "aorta"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0003483:Aorta [Body Part, Organ, or Organ Component]
  1000   C1278934:Aorta [Body Part, Organ, or Organ Component]

Phrase: "As"

Phrase: "shown in Fig."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0349966:Fig [Food]
   790   C1337208:FIG [Food]
   756   C1547282:Show [Intellectual Product]
Processing 00000000.tx.191: 5, the level of pyrraline in the collagenase digest of renal cortex increased significantly in diabetic rats 16 weeks after the induction of diabetes compared with that in control rats (24.7  2.4 vs. 19.7  2.1 nmol/mg collagen; P < 0.01). 

Phrase: "5,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0439084:>5 [Quantitative Concept]
  1000   C0728893:+5 [Quantitative Concept]

Phrase: "the level of pyrraline"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0441889:Level [Qualitative Concept]
   770   C0456079:Level [Classification]
   770   C1547707:Level [Geographic Area]
   770   C2946261:Level [Pharmacologic Substance]

Phrase: "in the collagenase"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0162745:COLLAGENASE [Amino Acid, Peptide, or Protein,Enzyme,Pharmacologic Substance]

Phrase: "digest of renal cortex"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   833   C0022655:Renal cortex [Body Part, Organ, or Organ Component]
   770   C0007776:Cortex [Body Part, Organ, or Organ Component]
   770   C0022646:Renal [Body Part, Organ, or Organ Component]
   770   C0868946:digest [Physiologic Function]
   770   C1176472:Cortex [Body Part, Organ, or Organ Component]
   770   C2700441:Cortex [Plant]

Phrase: "increased"
Meta Candidates (Total=8; Excluded=6; Pruned=0; Remaining=2)
  1000   C0205217:Increased [Quantitative Concept]
  1000   C0442805:Increased [Functional Concept]
   928 E C1517378:Gain [Quantitative Concept]
   907 E C0439661:Acquired [Temporal Concept]
   907 E C0442808:Increasing [Functional Concept]
   907 E C1301820:Obtain [Functional Concept]
   907 E C1706701:Acquire [Activity]
   907 E C3245488:acquired [Intellectual Product]

Phrase: "significantly in diabetic rats 16 weeks"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   753   C0034693:rats [Mammal]
   753   C0034721:Rats [Mammal]
   753   C0241863:DIABETIC [Finding]
   753   C0439230:weeks [Temporal Concept]
   719 E C0332174:/week [Temporal Concept]

Phrase: "after the induction"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0205263:Induction [Functional Concept]
  1000   C0857127:induction [Therapeutic or Preventive Procedure]

Phrase: "of diabetes"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0011847:Diabetes [Disease or Syndrome]
  1000   C0011849:Diabetes [Disease or Syndrome]

Phrase: "compared with that"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C1707455:Compared [Activity]

Phrase: "in control rats"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   861   C0034693:rats [Mammal]
   861   C0034721:Rats [Mammal]
   861   C0243148:control [Qualitative Concept]
   861   C1550141:Control [Substance]
   861   C1882979:Control [Conceptual Entity]
   861   C2587213:Control [Functional Concept]
   861   C3274648:Control [Qualitative Concept]

Phrase: "(24.7  2.4"

Phrase: "vs. 19.7  2.1 nmol/mg collagen"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   795   C0009325:Collagen [Amino Acid, Peptide, or Protein,Biologically Active Substance,Biomedical or Dental Material]
   795   C1167364:collagen [Cell Component]
   724 E C0439689:Collagenous [Qualitative Concept]

Phrase: "; P < 0.01"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C2603361:P' [Clinical Attribute]

Phrase: ")."
Processing 00000000.tx.192: Tenilsetam significantly prevented the increase in pyrraline (20.2  3.3 nmol/mg collagen; P < 0.01 vs. untreated diabetic rats). 

Phrase: "Tenilsetam significantly"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0076093:tenilsetam [Organic Chemical,Pharmacologic Substance]

Phrase: "prevented"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0309872:PREVENT [Pharmacologic Substance]

Phrase: "the increase in pyrraline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0442805:Increase [Functional Concept]

Phrase: "(20.2  3.3 nmol/mg collagen"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   795   C0009325:Collagen [Amino Acid, Peptide, or Protein,Biologically Active Substance,Biomedical or Dental Material]
   795   C1167364:collagen [Cell Component]
   724 E C0439689:Collagenous [Qualitative Concept]

Phrase: "; P < 0.01"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C2603361:P' [Clinical Attribute]

Phrase: "vs. untreated diabetic rats"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0034693:rats [Mammal]
   827   C0034721:Rats [Mammal]
   827   C0241863:DIABETIC [Finding]

Phrase: ")."
Processing 00000000.tx.193: The pyrraline level in the collagenase digest of aorta also significantly increased in diabetic rats compared with that in control rats (4.3  1.8 vs. 0.3  0.4 nmol/mg collagen; P < 0.01; Fig. 6). 

Phrase: "The pyrraline level in the collagenase"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   753   C0441889:Level [Qualitative Concept]
   753   C0456079:Level [Classification]
   753   C1547707:Level [Geographic Area]
   753   C2946261:Level [Pharmacologic Substance]

Phrase: "digest of aorta also significantly"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0003483:Aorta [Body Part, Organ, or Organ Component]
   760   C0868946:digest [Physiologic Function]
   760   C1278934:Aorta [Body Part, Organ, or Organ Component]

Phrase: "increased in diabetic rats"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   770   C0034693:rats [Mammal]
   770   C0034721:Rats [Mammal]
   770   C0205217:Increased [Quantitative Concept]
   770   C0241863:DIABETIC [Finding]
   770   C0442805:Increased [Functional Concept]

Phrase: "compared with that"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C1707455:Compared [Activity]

Phrase: "in control rats"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   861   C0034693:rats [Mammal]
   861   C0034721:Rats [Mammal]
   861   C0243148:control [Qualitative Concept]
   861   C1550141:Control [Substance]
   861   C1882979:Control [Conceptual Entity]
   861   C2587213:Control [Functional Concept]
   861   C3274648:Control [Qualitative Concept]

Phrase: "(4.3  1.8"

Phrase: "vs. 0.3  0.4 nmol/mg collagen"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   795   C0009325:Collagen [Amino Acid, Peptide, or Protein,Biologically Active Substance,Biomedical or Dental Material]
   795   C1167364:collagen [Cell Component]
   724 E C0439689:Collagenous [Qualitative Concept]

Phrase: "; P < 0.01"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C2603361:P' [Clinical Attribute]

Phrase: "; Fig. 6"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0349966:Fig [Food]
   861   C1337208:FIG [Food]

Phrase: ")."
Processing 00000000.tx.194: The administration of tenilsetam in diabetic rats significantly suppressed the increase in the pyrraline level of aorta (2.3  1.1 nmol/mg collagen; P < 0.05). 

Phrase: "The administration of tenilsetam"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0001554:Administration [Occupational Activity]
   770   C1533734:Administration [Therapeutic or Preventive Procedure]

Phrase: "in diabetic rats significantly"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0034693:rats [Mammal]
   827   C0034721:Rats [Mammal]
   827   C0241863:DIABETIC [Finding]

Phrase: "suppressed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1260953:Suppressed [Functional Concept]

Phrase: "the increase in the pyrraline level of aorta"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   744   C0442805:Increase [Functional Concept]

Phrase: "(2.3  1.1 nmol/mg collagen"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   795   C0009325:Collagen [Amino Acid, Peptide, or Protein,Biologically Active Substance,Biomedical or Dental Material]
   795   C1167364:collagen [Cell Component]
   724 E C0439689:Collagenous [Qualitative Concept]

Phrase: "; P < 0.05"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C2603361:P' [Clinical Attribute]

Phrase: ")."
Processing 00000000.tx.195: View larger version (19K): [in this window] [in a new window]  Figure 5. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "larger version"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0333052:Version [Functional Concept]
   861   C2607870:Version [Spatial Concept]

Phrase: "(19K"

Phrase: ")"

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  Figure 5."
Processing 00000000.tx.196: Pyrraline level in the collagenase-soluble fraction of renal cortex. 

Phrase: "Pyrraline level in the collagenase-soluble fraction of renal cortex."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   739   C0441889:Level [Qualitative Concept]
   739   C0456079:Level [Classification]
   739   C1547707:Level [Geographic Area]
   739   C2946261:Level [Pharmacologic Substance]
Processing 00000000.tx.197: The pyrraline level in the renal cortex of diabetic rats, determined by ELISA using monoclonal antibody to pyrraline, was significantly elevated compared with that in control rats. 

Phrase: "The pyrraline level in the renal cortex of diabetic rats,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   739   C0441889:Level [Qualitative Concept]
   739   C0456079:Level [Classification]
   739   C1547707:Level [Geographic Area]
   739   C2946261:Level [Pharmacologic Substance]

Phrase: "determined by ELISA"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   882   C0014441:Enzyme-Linked Immunosorbent Assay [Laboratory Procedure]
   783   C2717977:Enzyme Assay [Laboratory Procedure]
   753   C0005507:Assay [Laboratory Procedure]
   753   C0014442:Enzyme [Enzyme,Organic Chemical]
   753   C0021075:immunosorbent [Indicator, Reagent, or Diagnostic Aid]
   753   C0243073:assay [Qualitative Concept]
   753   C1510438:Assay [Laboratory Procedure]
   719   C1517892:Link [Intellectual Product]
   719   C1704666:Link [Intellectual Product]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "monoclonal antibody to pyrraline,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   833   C0003250:Monoclonal antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   770   C0003241:Antibody [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   770   C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   770   C0746619:monoclonal [Finding]

Phrase: "was"

Phrase: "significantly"

Phrase: "elevated"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0205250:Elevated [Qualitative Concept]
  1000   C3163633:Elevated [Qualitative Concept]

Phrase: "compared with that"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C1707455:Compared [Activity]

Phrase: "in control rats."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   861   C0034693:rats [Mammal]
   861   C0034721:Rats [Mammal]
   861   C0243148:control [Qualitative Concept]
   861   C1550141:Control [Substance]
   861   C1882979:Control [Conceptual Entity]
   861   C2587213:Control [Functional Concept]
   861   C3274648:Control [Qualitative Concept]
Processing 00000000.tx.198: The elevated level was suppressed to the control level by the oral administration of tenilsetam. 

Phrase: "The elevated level"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0441889:Level [Qualitative Concept]
   861   C0456079:Level [Classification]
   861   C1547707:Level [Geographic Area]
   861   C2946261:Level [Pharmacologic Substance]

Phrase: "was"

Phrase: "suppressed to the control level"
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   760   C0243148:control [Qualitative Concept]
   760   C0441889:Level [Qualitative Concept]
   760   C0456079:Level [Classification]
   760   C1260953:Suppressed [Functional Concept]
   760   C1547707:Level [Geographic Area]
   760   C1550141:Control [Substance]
   760   C1882979:Control [Conceptual Entity]
   760   C2587213:Control [Functional Concept]
   760   C2946261:Level [Pharmacologic Substance]
   760   C3274648:Control [Qualitative Concept]

Phrase: "by the oral administration"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0001563:Administration, Oral [Therapeutic or Preventive Procedure]
   861   C0001554:Administration [Occupational Activity]
   861   C0442027:Oral [Spatial Concept]
   861   C1533734:Administration [Therapeutic or Preventive Procedure]

Phrase: "of tenilsetam."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0076093:tenilsetam [Organic Chemical,Pharmacologic Substance]
Processing 00000000.tx.199: *, P < 0.01 vs. control rats; 

Phrase: "*,"

Phrase: "P < 0.01"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C2603361:P' [Clinical Attribute]

Phrase: "vs. control rats"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   861   C0034693:rats [Mammal]
   861   C0034721:Rats [Mammal]
   861   C0243148:control [Qualitative Concept]
   861   C1550141:Control [Substance]
   861   C1882979:Control [Conceptual Entity]
   861   C2587213:Control [Functional Concept]
   861   C3274648:Control [Qualitative Concept]

Phrase: ";"
Processing 00000000.tx.200: **, P < 0.01 vs. untreated diabetic rats.  

Phrase: "*"

Phrase: "*,"

Phrase: "P < 0.01"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C2603361:P' [Clinical Attribute]

Phrase: "vs. untreated diabetic rats."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0034693:rats [Mammal]
   827   C0034721:Rats [Mammal]
   827   C0241863:DIABETIC [Finding]
Processing 00000000.tx.201: View larger version (16K): [in this window] [in a new window]  Figure 6. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "larger version"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0333052:Version [Functional Concept]
   861   C2607870:Version [Spatial Concept]

Phrase: "(16K"

Phrase: ")"

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  Figure 6."
Processing 00000000.tx.202: Pyrraline level in the collagenase-soluble fraction of aorta. 

Phrase: "Pyrraline level in the collagenase-soluble fraction of aorta."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   742   C0441889:Level [Qualitative Concept]
   742   C0456079:Level [Classification]
   742   C1547707:Level [Geographic Area]
   742   C2946261:Level [Pharmacologic Substance]
Processing 00000000.tx.203: The pyrraline level in the soluble fraction of aorta from diabetic rats was significantly elevated compared with that in control rats, as determined by ELISA. 

Phrase: "The pyrraline level in the soluble fraction of aorta"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   742   C0441889:Level [Qualitative Concept]
   742   C0456079:Level [Classification]
   742   C1547707:Level [Geographic Area]
   742   C2946261:Level [Pharmacologic Substance]

Phrase: "from diabetic rats"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0034693:rats [Mammal]
   861   C0034721:Rats [Mammal]
   861   C0241863:DIABETIC [Finding]

Phrase: "was"

Phrase: "significantly"

Phrase: "elevated"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0205250:Elevated [Qualitative Concept]
  1000   C3163633:Elevated [Qualitative Concept]

Phrase: "compared with that"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C1707455:Compared [Activity]

Phrase: "in control rats,"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   861   C0034693:rats [Mammal]
   861   C0034721:Rats [Mammal]
   861   C0243148:control [Qualitative Concept]
   861   C1550141:Control [Substance]
   861   C1882979:Control [Conceptual Entity]
   861   C2587213:Control [Functional Concept]
   861   C3274648:Control [Qualitative Concept]

Phrase: "as"

Phrase: "determined by ELISA."
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   882   C0014441:Enzyme-Linked Immunosorbent Assay [Laboratory Procedure]
   783   C2717977:Enzyme Assay [Laboratory Procedure]
   753   C0005507:Assay [Laboratory Procedure]
   753   C0014442:Enzyme [Enzyme,Organic Chemical]
   753   C0021075:immunosorbent [Indicator, Reagent, or Diagnostic Aid]
   753   C0243073:assay [Qualitative Concept]
   753   C1510438:Assay [Laboratory Procedure]
   719   C1517892:Link [Intellectual Product]
   719   C1704666:Link [Intellectual Product]
Processing 00000000.tx.204: It was suppressed to the control level by oral administration of tenilsetam. 

Phrase: "It"

Phrase: "was"

Phrase: "suppressed to the control level"
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   760   C0243148:control [Qualitative Concept]
   760   C0441889:Level [Qualitative Concept]
   760   C0456079:Level [Classification]
   760   C1260953:Suppressed [Functional Concept]
   760   C1547707:Level [Geographic Area]
   760   C1550141:Control [Substance]
   760   C1882979:Control [Conceptual Entity]
   760   C2587213:Control [Functional Concept]
   760   C2946261:Level [Pharmacologic Substance]
   760   C3274648:Control [Qualitative Concept]

Phrase: "by oral administration"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0001563:Administration, Oral [Therapeutic or Preventive Procedure]
   861   C0001554:Administration [Occupational Activity]
   861   C0442027:Oral [Spatial Concept]
   861   C1533734:Administration [Therapeutic or Preventive Procedure]

Phrase: "of tenilsetam."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0076093:tenilsetam [Organic Chemical,Pharmacologic Substance]
Processing 00000000.tx.205: *, P < 0.01 vs. control rats; 

Phrase: "*,"

Phrase: "P < 0.01"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C2603361:P' [Clinical Attribute]

Phrase: "vs. control rats"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   861   C0034693:rats [Mammal]
   861   C0034721:Rats [Mammal]
   861   C0243148:control [Qualitative Concept]
   861   C1550141:Control [Substance]
   861   C1882979:Control [Conceptual Entity]
   861   C2587213:Control [Functional Concept]
   861   C3274648:Control [Qualitative Concept]

Phrase: ";"
Processing 00000000.tx.206: **, P < 0.05 vs. untreated diabetic rats.  

Phrase: "*"

Phrase: "*,"

Phrase: "P < 0.05"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C2603361:P' [Clinical Attribute]

Phrase: "vs. untreated diabetic rats."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0034693:rats [Mammal]
   827   C0034721:Rats [Mammal]
   827   C0241863:DIABETIC [Finding]
Processing 00000000.tx.207: In vitro direct reactivity of tenilsetam to 3-DG A 50-M concentration of 3-DG solution incubated with PB alone showed a negligible change in 3-DG concentration throughout the incubation period. 

Phrase: "In vitro direct reactivity of tenilsetam"

Phrase: "to 3-DG"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0047359:3-deoxyglucosone [Carbohydrate]

Phrase: "A 50-M concentration of 3-DG solution"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   744   C0086045:Concentration [Mental Process]
   744   C1446561:Concentration [Quantitative Concept]
   731   C1707468:Concentrated Solution [Biomedical or Dental Material]

Phrase: "incubated with PB"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C1439852:Incubated [Laboratory Procedure]

Phrase: "alone"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205171:Alone [Quantitative Concept]
  1000   C0439044:alone [Finding]
  1000   C0679994:alone [Group Attribute]

Phrase: "showed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "a negligible change in 3-DG concentration"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   748   C0392747:Change [Functional Concept]
   748   C0443172:change [Quantitative Concept]
   748   C1705241:Change [Quantitative Concept]

Phrase: "throughout the incubation period."
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
  1000   C1320226:Incubation period [Finding]
   861   C0439531:/period [Temporal Concept]
   861   C1948053:Period [Temporal Concept]
   789 E C0332182:Periodic [Temporal Concept]
   789 E C1706381:PERIODIC [Intellectual Product]
   761 E C0031084:Periodicities [Temporal Concept]
Processing 00000000.tx.208: The level of 3-DG was 42.4  2.0 M 72 h after incubation with the buffer (Fig. 7). 

Phrase: "The level of 3-DG"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   797   C0456949:Level 3 [Intellectual Product]
   760   C0441889:Level [Qualitative Concept]
   760   C0456079:Level [Classification]
   760   C1547707:Level [Geographic Area]
   760   C2946261:Level [Pharmacologic Substance]

Phrase: "was"

Phrase: "42.4  2.0 M 72 h after incubation"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   762   C0011744:h 2 [Element, Ion, or Isotope]
   762   C2348952:H/m [Quantitative Concept]
   742   C0033727:H+ [Element, Ion, or Isotope]
   742   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   742   C0441932:H+ [Classification]
   742   C0564385:/h [Quantitative Concept]

Phrase: "with the buffer"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0006353:Buffer [Indicator, Reagent, or Diagnostic Aid,Pharmacologic Substance]

Phrase: "(Fig. 7"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0349966:Fig [Food]
   861   C1337208:FIG [Food]

Phrase: ")."
Processing 00000000.tx.209: Incubation with 5 mM tenilsetam also did not produce a significant change in the 3-DG concentration. 

Phrase: "Incubation with 5 mM tenilsetam also"

Phrase: "did"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "produce"

Phrase: "a significant change in the 3-DG concentration."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   744   C0392747:Change [Functional Concept]
   744   C0443172:change [Quantitative Concept]
   744   C1705241:Change [Quantitative Concept]
Processing 00000000.tx.210: Even after 72 h of incubation with tenilsetam, the concentration of free 3-DG was still 40.9  1.0 M. 

Phrase: "Even after 72 h of incubation"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   753   C0033727:H+ [Element, Ion, or Isotope]
   753   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   753   C0441932:H+ [Classification]
   753   C0564385:/h [Quantitative Concept]

Phrase: "with tenilsetam,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0076093:tenilsetam [Organic Chemical,Pharmacologic Substance]

Phrase: "the concentration of free 3-DG"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0086045:Concentration [Mental Process]
   753   C1446561:Concentration [Quantitative Concept]

Phrase: "was"

Phrase: "still 40.9  1.0 M."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   799   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   799   C0441923:M+ [Intellectual Product]
Processing 00000000.tx.211: In contrast, 50 M 3-DG solution incubated with 5 mM AG decreased the concentration of 3-DG to 24.1  8.8 M after 6 h of incubation and to an undetectable level after 24 h of incubation. 

Phrase: "In contrast,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1979874:Contrast [Qualitative Concept]

Phrase: "50 M 3-DG solution"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   804   C0037633:Solution [Substance]
   804   C0525069:Solution [Biomedical or Dental Material]

Phrase: "incubated with 5 mM AG"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0282774:aminoguanidine [Organic Chemical,Pharmacologic Substance]
   760   C1439852:Incubated [Laboratory Procedure]

Phrase: "decreased"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0205216:Decreased [Quantitative Concept]
  1000   C0392756:Decreased [Qualitative Concept]
  1000   C0442797:decreased [Qualitative Concept]
   966 E C0547047:Decrease [Quantitative Concept]

Phrase: "the concentration of 3-DG"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0086045:Concentration [Mental Process]
   760   C1446561:Concentration [Quantitative Concept]

Phrase: "to 24.1  8.8 M"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   804   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   804   C0441923:M+ [Intellectual Product]

Phrase: "after 6 h"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "of incubation"

Phrase: "and to an undetectable level"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   760   C0441889:Level [Qualitative Concept]
   760   C0456079:Level [Classification]
   760   C1515981:And [Idea or Concept]
   760   C1547707:Level [Geographic Area]
   760   C2946261:Level [Pharmacologic Substance]

Phrase: "after 24 h"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "of incubation."
Processing 00000000.tx.212: View larger version (37K): [in this window] [in a new window]  Figure 7. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "larger version"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0333052:Version [Functional Concept]
   861   C2607870:Version [Spatial Concept]

Phrase: "(37K"

Phrase: ")"

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  Figure 7."
Processing 00000000.tx.213: Reactivity of tenilsetam to 3-DG. 

Phrase: "Reactivity of tenilsetam"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   718   C0205332:Reactive [Qualitative Concept]

Phrase: "to 3-DG."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0047359:3-deoxyglucosone [Carbohydrate]
Processing 00000000.tx.214: 3-DG solution (50 M in PB, pH 7.4) was incubated in the presence and absence of 5 mM tenilsetam at 37 C. 

Phrase: "3-DG solution"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0037633:Solution [Substance]
   827   C0525069:Solution [Biomedical or Dental Material]
   734   C0047359:3-deoxyglucosone [Carbohydrate]

Phrase: "(50 M in PB,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   770   C0441923:M+ [Intellectual Product]

Phrase: "pH 7.4"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   913   C2678549:PH-4 [Gene or Genome]
   901   C1882074:pH 7 [Qualitative Concept]
   827   C0020283:[pH] [Quantitative Concept]
   827   C0450407:ph+ [Finding]
   827   C0450408:ph++ [Finding]
   827   C0450409:ph+++ [Finding]

Phrase: ")"

Phrase: "was"

Phrase: "incubated in the presence"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0392148:Presence [Therapeutic or Preventive Procedure]
   770   C1439852:Incubated [Laboratory Procedure]

Phrase: "and"

Phrase: "absence of 5 mM tenilsetam"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0332197:absence [Quantitative Concept]
   760   C1689985:Absence [Anatomical Abnormality]

Phrase: "at 37 C."
Processing 00000000.tx.215: AG (5 mM) was also incubated with 3-DG under the same conditions as those used for tenilsetam. 

Phrase: "AG"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0282774:aminoguanidine [Organic Chemical,Pharmacologic Substance]

Phrase: "(5 mM)"

Phrase: "was"

Phrase: "also"

Phrase: "incubated with 3-DG"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1439852:Incubated [Laboratory Procedure]

Phrase: "under the same conditions"
Meta Candidates (Total=7; Excluded=4; Pruned=0; Remaining=3)
   827   C0012634:condition [Disease or Syndrome]
   827   C0348080:Condition [Qualitative Concept]
   827   C1705253:Condition [Conceptual Entity]
   777 E C0009647:Conditioned [Mental Process]
   777 E C1701901:Conditional [Qualitative Concept]
   777 E C1963686:Conditional [Functional Concept]
   755 E C1519605:Conditionality [Conceptual Entity]

Phrase: "as those"

Phrase: "used for tenilsetam."
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   790   C0076093:tenilsetam [Organic Chemical,Pharmacologic Substance]
   790   C1273517:used [Finding]
   756 E C0042153:use [Functional Concept]
   756 E C0457083:Use [Functional Concept]
   756 E C1947944:Use [Intellectual Product]
Processing 00000000.tx.216: The remaining free 3-DG levels in the reaction mixtures were assayed periodically by HPLC. 

Phrase: "The remaining free 3-DG levels in the reaction mixtures"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   741   C0456949:Level 3 [Intellectual Product]
   739   C0441889:Levels [Qualitative Concept]
   706 E C0456079:Level [Classification]
   706 E C1547707:Level [Geographic Area]
   706 E C2946261:Level [Pharmacologic Substance]

Phrase: "were"

Phrase: "assayed"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C0005507:Assay [Laboratory Procedure]
   966   C0243073:assay [Qualitative Concept]
   966   C1510438:Assay [Laboratory Procedure]

Phrase: "periodically by HPLC."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0008562:HPLC [Laboratory Procedure]
   790   C0332182:Periodically [Temporal Concept]
Processing 00000000.tx.217: Tenilsetam did not significantly react with 3-DG, whereas AG directly trapped 3-DG.   

Phrase: "Tenilsetam"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0076093:tenilsetam [Organic Chemical,Pharmacologic Substance]

Phrase: "did"

Phrase: "not significantly"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1518422:Not [Functional Concept]

Phrase: "react with 3-DG,"

Phrase: "whereas"

Phrase: "AG directly"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0282774:aminoguanidine [Organic Chemical,Pharmacologic Substance]

Phrase: "trapped"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0184047:Trapped [Medical Device]

Phrase: "3-DG."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0047359:3-deoxyglucosone [Carbohydrate]
Processing 00000000.tx.218: Discussion Top Abstract Introduction Materials and Methods Results Discussion References  Since the first description of the inhibitory effect of AG on the Maillard reaction, several other suppressive effects of the agent on the progression of diabetic complications have been reported (22, 23, 24, 25, 26). 

Phrase: "Discussion Top Abstract Introduction Materials"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   804   C0520510:Materials [Substance]

Phrase: "and"

Phrase: "Methods Results Discussion References"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   779   C1514811:Reference [Idea or Concept]
   779   C1706462:Reference [Conceptual Entity]

Phrase: "Since"

Phrase: "the first description of the inhibitory effect of AG"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   742   C0678257:Description [Idea or Concept]

Phrase: "on the Maillard reaction,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0024495:Maillard Reaction [Natural Phenomenon or Process]
   861   C0443286:Reaction [Functional Concept]
   861   C1114821:Reaction [Clinical Attribute]

Phrase: "several"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0439064:Several [Quantitative Concept]
  1000   C0443302:Several [Quantitative Concept]

Phrase: "other suppressive effects of the agent"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   753   C1280500:effects [Qualitative Concept]
   719 E C2348382:Effect [Qualitative Concept]

Phrase: "on the progression"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0242656:progression [Pathologic Function]
  1000   C0449258:Progression [Functional Concept]

Phrase: "of diabetic complications"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
  1000   C0342257:Diabetic Complications [Pathologic Function]
   861   C0009566:Complications [Pathologic Function]
   861   C1171258:complications [Pathologic Function]
   827 E C2362589:Complication [Idea or Concept]
   777 E C0231242:Complicated [Functional Concept]

Phrase: "have"

Phrase: "been"

Phrase: "reported"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0684224:Reported [Intellectual Product]
  1000   C0700287:Reported [Health Care Activity]
  1000   C3496591:Reported [Clinical Attribute]
   966 E C3273238:Report [Intellectual Product]

Phrase: "(22,"

Phrase: "23,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0450348:23 [Quantitative Concept]

Phrase: "24,"

Phrase: "25,"

Phrase: "26"

Phrase: ")."
Processing 00000000.tx.219: The present study focused on another agent, tenilsetam, previously used in human volunteers and patients with dementia of the Alzheimer type (29, 30, 31, 32). 

Phrase: "The present study"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0150312:Present [Quantitative Concept]
   861   C0449450:Present [Idea or Concept]
   861   C0557651:Study [Manufactured Object]
   861   C2603343:Study [Research Activity]

Phrase: "focused on another agent,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   770   C0205234:Focused [Spatial Concept]
   770   C0450442:Agent [Chemical Viewed Functionally]
   770   C1254351:Agent [Pharmacologic Substance]
   770   C1285542:focused [Functional Concept]
   770   C1521826:Agent [Intellectual Product]

Phrase: "tenilsetam,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0076093:tenilsetam [Organic Chemical,Pharmacologic Substance]

Phrase: "previously"

Phrase: "used in human volunteers"
Meta Candidates (Total=9; Excluded=5; Pruned=0; Remaining=4)
   833   C0020155:Human Volunteers [Population Group]
   770   C0042960:Volunteers [Professional or Occupational Group]
   770   C0086418:Human [Human]
   770   C1273517:used [Finding]
   737 E C0042153:use [Functional Concept]
   737 E C0457083:Use [Functional Concept]
   737 E C1549078:Volunteer [Idea or Concept]
   737 E C1947944:Use [Intellectual Product]
   737 E C1997894:volunteer [Population Group]

Phrase: "and"

Phrase: "patients with dementia of the Alzheimer type"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   757   C1550335:Patient type [Classification]
   748   C0030705:Patients [Patient or Disabled Group]
   731   C0002395:DEMENTIA OF THE ALZHEIMER TYPE [Disease or Syndrome]

Phrase: "(29,"

Phrase: "30,"

Phrase: "31,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0450355:31 [Intellectual Product]

Phrase: "32"

Phrase: ")."
Processing 00000000.tx.220: Our results indicated that tenilsetam suppressed protein polymerization due to an in vitro glycation. 

Phrase: "Our results"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C1274040:Result [Functional Concept]
   966   C1546471:Result [Idea or Concept]
   966   C2825142:Result [Finding]

Phrase: "indicated"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1444656:Indicated [Finding]

Phrase: "that tenilsetam suppressed protein polymerization due to an in vitro glycation."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   756   C1523272:protein polymerization [Molecular Function]
   738   C0314672:Polymerisation [Phenomenon or Process]
Processing 00000000.tx.221: Enzymatic collagen digestion is known to decrease after advanced glycation (43, 44). 

Phrase: "Enzymatic collagen digestion"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   827   C0012238:Digestion [Organism Function]
   827   C2349986:Digestion [Research Activity]
   771 E C0443277:Peptic [Functional Concept]

Phrase: "is"

Phrase: "known"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205309:Known [Qualitative Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "decrease after advanced glycation"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0205179:Advanced [Qualitative Concept]
   770   C0392756:Decrease [Qualitative Concept]
   770   C0547047:Decrease [Quantitative Concept]
   770   C0598528:glycation [Phenomenon or Process]

Phrase: "(43,"

Phrase: "44"

Phrase: ")."
Processing 00000000.tx.222: Tenilsetam prevented the reduction of collagen digestibility in a dose-dependent manner. 

Phrase: "Tenilsetam"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0076093:tenilsetam [Organic Chemical,Pharmacologic Substance]

Phrase: "prevented"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0309872:PREVENT [Pharmacologic Substance]

Phrase: "the reduction of collagen digestibility"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0301630:Reduction [Natural Phenomenon or Process]
   760   C0392756:Reduction [Qualitative Concept]
   760   C0441610:Reduction [Therapeutic or Preventive Procedure]

Phrase: "in a dose-dependent manner."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   734   C1512045:Dose-dependent [Quantitative Concept]
Processing 00000000.tx.223: Our results also demonstrated an inhibitory effect of tenilsetam on fructosylation of proteins. 

Phrase: "Our results also"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C1274040:Result [Functional Concept]
   827   C1546471:Result [Idea or Concept]
   827   C2825142:Result [Finding]

Phrase: "demonstrated"

Phrase: "an inhibitory effect of tenilsetam"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C1280500:Effect [Qualitative Concept]
   760   C2348382:Effect [Qualitative Concept]

Phrase: "on fructosylation"

Phrase: "of proteins."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0033684:Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]
Processing 00000000.tx.224: Fructose is known to react with proteins more efficiently than glucose (45). 

Phrase: "Fructose"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0016745:Fructose [Carbohydrate,Pharmacologic Substance]

Phrase: "is"

Phrase: "known"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205309:Known [Qualitative Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "react with proteins more efficiently"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0033684:Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "than glucose"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]

Phrase: "(45"

Phrase: ")."
Processing 00000000.tx.225: Our in vitro observations showed that the rate of polymerization of lysozyme incubated with fructose was greater than that with glucose, and digestibility of collagen declined after incubation with fructose more than after incubation with glucose. 

Phrase: "Our in vitro observations"
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
   827   C0302523:observations [Research Activity]
   827   C0700325:observations [Health Care Activity]
   827   C3244290:observations [Functional Concept]
   793 E C1964257:Observation [Diagnostic Procedure]
   743 E C1518527:OBSERVATIONAL [Research Activity]
   734   C0021135:In Vitro [Intellectual Product]
   734   C1533691:in vitro [Qualitative Concept]
   734   C2827718:In Vitro [Functional Concept]

Phrase: "showed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "that"

Phrase: "the rate of polymerization of lysozyme"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0871208:Rate [Activity]
   753   C1521828:Rate [Quantitative Concept]

Phrase: "incubated with fructose"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0016745:Fructose [Carbohydrate,Pharmacologic Substance]
   790   C1439852:Incubated [Laboratory Procedure]

Phrase: "was"

Phrase: "greater than that"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   882   C0439093:Greater Than [Quantitative Concept]
   790   C0443228:greater [Quantitative Concept]
   790   C1704243:Greater [Quantitative Concept]
   756 E C0549177:Great [Quantitative Concept]

Phrase: "with glucose,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]

Phrase: "and"

Phrase: "digestibility of collagen"

Phrase: "declined after incubation"

Phrase: "with fructose more"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0016745:Fructose [Carbohydrate,Pharmacologic Substance]

Phrase: "than"

Phrase: "after incubation"

Phrase: "with glucose."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
Processing 00000000.tx.226: Tenilsetam also inhibited these fructosylations of proteins in a dose-dependent manner. 

Phrase: "Tenilsetam also"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0076093:tenilsetam [Organic Chemical,Pharmacologic Substance]

Phrase: "inhibited"
Meta Candidates (Total=6; Excluded=5; Pruned=0; Remaining=1)
  1000   C0311403:Inhibited [Qualitative Concept]
   928 E C0018790:arrested [Disease or Syndrome]
   928 E C0237477:Arrest [Temporal Concept]
   928 E C0392351:arrest [Governmental or Regulatory Activity]
   928 E C0521111:Retarded [Qualitative Concept]
   907 E C3463820:Inhibiting [Activity]

Phrase: "these fructosylations of proteins"

Phrase: "in a dose-dependent manner."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   734   C1512045:Dose-dependent [Quantitative Concept]
Processing 00000000.tx.227: Furthermore, even 30 mM glucose, comparable to diabetic blood sugar level, showed a suppressive effect on collagen digestibility in vitro, although it was not as much as 100 mM glucose. 

Phrase: "Furthermore,"

Phrase: "even 30 mM glucose,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]

Phrase: "comparable to diabetic blood sugar level,"

Phrase: "showed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "a suppressive effect on collagen digestibility"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C1280500:Effect [Qualitative Concept]
   753   C2348382:Effect [Qualitative Concept]

Phrase: "in vitro,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0021135:In Vitro [Intellectual Product]
  1000   C1533691:in vitro [Qualitative Concept]
           vitro
  1000   C2827718:In Vitro [Functional Concept]

Phrase: "although"

Phrase: "it"

Phrase: "was"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "as"

Phrase: "much as 100 mM glucose."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
Processing 00000000.tx.228: This effect of 30 mM glucose was very efficiently inhibited by tenilsetam. 

Phrase: "This effect of 30 mM glucose"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   783   C1158774:glucose effect [Genetic Function]
   753   C1280500:Effect [Qualitative Concept]
   753   C2348382:Effect [Qualitative Concept]

Phrase: "was"

Phrase: "very efficiently"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0442824:Very [Qualitative Concept]

Phrase: "inhibited by tenilsetam."
Meta Candidates (Total=6; Excluded=4; Pruned=0; Remaining=2)
   790   C0076093:tenilsetam [Organic Chemical,Pharmacologic Substance]
   790   C0311403:Inhibited [Qualitative Concept]
   718 E C0018790:arrested [Disease or Syndrome]
   718 E C0237477:Arrest [Temporal Concept]
   718 E C0392351:arrest [Governmental or Regulatory Activity]
   718 E C0521111:Retarded [Qualitative Concept]
Processing 00000000.tx.229: It would be conceivable that longer exposure to high blood glucose in vivo would lead to more remarkable AGE formation on tissue collagen due to the time-dependent reaction, so that the effect of tenilsetam might become more noticeable. 

Phrase: "It"

Phrase: "would"

Phrase: "be"

Phrase: "conceivable"

Phrase: "that longer exposure to high blood glucose"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   778   C0332157:Exposure to [Clinical Attribute]
           Exposure
   748   C0274281:Exposure, NOS [Injury or Poisoning]

Phrase: "in vivo"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1515655:In Vivo [Spatial Concept]
           vivo

Phrase: "would"

Phrase: "lead"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0023175:???lead [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
  1000   C1442948:lead [Inorganic Chemical,Pharmacologic Substance]
  1000   C1522538:Lead [Functional Concept]
  1000   C2348269:Lead [Element, Ion, or Isotope]
  1000   C3275067:LEAD [Therapeutic or Preventive Procedure]

Phrase: "to more remarkable AGE formation on tissue collagen"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   767   C2246343:collagen formation [Molecular Function]
   744   C0220781:formation [Biologic Function]
   744   C0439634:formation [Spatial Concept]
   744   C1522492:Formation [Functional Concept]

Phrase: "due to the time-dependent reaction,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   913   C0034746:time reaction [Temporal Concept]
   827   C0443286:Reaction [Functional Concept]
   827   C1114821:Reaction [Clinical Attribute]

Phrase: "so"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0037640:SO [Geographic Area]

Phrase: "that"

Phrase: "the effect of tenilsetam"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C1280500:Effect [Qualitative Concept]
   770   C2348382:Effect [Qualitative Concept]

Phrase: "might"

Phrase: "become"

Phrase: "more noticeable."
Processing 00000000.tx.230: Our following in vivo studies actually indicated that AGE formation in tissues occurred predominantly in diabetic rats and was inhibited by the administration of tenilsetam. 

Phrase: "Our"

Phrase: "following"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332282:Following [Temporal Concept]
   966 E C0332283:follow [Temporal Concept]
   966 E C1719822:Follow [Intellectual Product]

Phrase: "in vivo"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1515655:In Vivo [Spatial Concept]
           vivo

Phrase: "studies"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557651:Study [Manufactured Object]
  1000   C0947630:studies [Laboratory Procedure]
  1000   C2603343:Study [Research Activity]

Phrase: "actually"

Phrase: "indicated"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1444656:Indicated [Finding]

Phrase: "that AGE formation in tissues"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0220781:formation [Biologic Function]
   760   C0439634:formation [Spatial Concept]
   760   C1522492:Formation [Functional Concept]

Phrase: "occurred"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1709305:Occurred [Activity]
   966 E C2745955:OCCUR [Temporal Concept]

Phrase: "predominantly in diabetic rats"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0034693:rats [Mammal]
   770   C0034721:Rats [Mammal]
   770   C0241863:DIABETIC [Finding]

Phrase: "and"

Phrase: "was"

Phrase: "inhibited by the administration of tenilsetam."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   753   C0001554:Administration [Occupational Activity]
   753   C0076093:tenilsetam [Organic Chemical,Pharmacologic Substance]
   753   C0311403:Inhibited [Qualitative Concept]
   753   C1533734:Administration [Therapeutic or Preventive Procedure]
Processing 00000000.tx.231: The results demonstrated that tenilsetam suppressed to control levels the formation of two different types of fluorescence characteristic of AGEs in the renal cortex and aorta of diabetic rats. 

Phrase: "The results"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C1274040:Result [Functional Concept]
   966   C1546471:Result [Idea or Concept]
   966   C2825142:Result [Finding]

Phrase: "demonstrated"

Phrase: "that tenilsetam"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0076093:tenilsetam [Organic Chemical,Pharmacologic Substance]

Phrase: "suppressed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1260953:Suppressed [Functional Concept]

Phrase: "to control levels"
Meta Candidates (Total=9; Excluded=3; Pruned=0; Remaining=6)
   827   C0243148:control [Qualitative Concept]
   827   C0441889:Levels [Qualitative Concept]
   827   C1550141:Control [Substance]
   827   C1882979:Control [Conceptual Entity]
   827   C2587213:Control [Functional Concept]
   827   C3274648:Control [Qualitative Concept]
   793 E C0456079:Level [Classification]
   793 E C1547707:Level [Geographic Area]
   793 E C2946261:Level [Pharmacologic Substance]

Phrase: "the formation of two different types of fluorescence"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   744   C0220781:formation [Biologic Function]
   744   C0439634:formation [Spatial Concept]
   744   C1522492:Formation [Functional Concept]

Phrase: "characteristic of AGEs"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C1521970:Characteristic [Qualitative Concept]
   716   C0162574:Glycation End Products, Advanced [Biologically Active Substance,Organic Chemical]

Phrase: "in the renal cortex"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0022655:Renal cortex [Body Part, Organ, or Organ Component]
   861   C0007776:Cortex [Body Part, Organ, or Organ Component]
   861   C0022646:Renal [Body Part, Organ, or Organ Component]
   861   C1176472:Cortex [Body Part, Organ, or Organ Component]
   861   C2700441:Cortex [Plant]

Phrase: "and"

Phrase: "aorta of diabetic rats."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   802   C1882561:Rat Aorta [Body Part, Organ, or Organ Component]
   770   C0003483:Aorta [Body Part, Organ, or Organ Component]
   770   C1278934:Aorta [Body Part, Organ, or Organ Component]
Processing 00000000.tx.232: One type of fluorescence (excitation/emission = 370/440 nm) has been conventionally used as a marker of AGEs (19). 

Phrase: "One type of fluorescence"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0332307:Type [Qualitative Concept]
   770   C1547052:*Type [Quantitative Concept]

Phrase: "(excitation/emission"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0233929:Emission [Body Substance]
   861   C2349995:Emission [Substance]

Phrase: "= 370/440 nm)"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0312860:NM [Cell Function]

Phrase: "has"

Phrase: "been"

Phrase: "conventionally"

Phrase: "used as a marker of AGEs"
Meta Candidates (Total=14; Excluded=5; Pruned=0; Remaining=9)
   818   C0162574:Glycation End Products, Advanced [Biologically Active Substance,Organic Chemical]
   745   C1524063:Use of [Functional Concept]
   742   C0005516:Marker [Clinical Attribute]
   742   C0205179:Advanced [Qualitative Concept]
   742   C0444930:End [Spatial Concept]
   742   C0598528:glycation [Phenomenon or Process]
   742   C1273517:used [Finding]
   742   C1514468:Products [Entity]
   742   C2746065:End [Temporal Concept]
   708 E C0042153:use [Functional Concept]
   708 E C0457083:Use [Functional Concept]
   708 E C0725066:Advance [Medical Device]
   708 E C1704444:Product [Quantitative Concept]
   708 E C1947944:Use [Intellectual Product]

Phrase: "(19"

Phrase: ")."
Processing 00000000.tx.233: The other fluorescence (excitation/emission = 328/378 nm) was recently demonstrated by analysis of three-dimensional fluorescence spectra to represent fluorescence in glycated proteins (20). 

Phrase: "The"

Phrase: "other fluorescence"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0016315:Fluorescence [Natural Phenomenon or Process]
   928 E C0303920:Fluorescent [Indicator, Reagent, or Diagnostic Aid,Organic Chemical]

Phrase: "(excitation/emission"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0233929:Emission [Body Substance]
   861   C2349995:Emission [Substance]

Phrase: "= 328/378 nm)"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0312860:NM [Cell Function]

Phrase: "was"

Phrase: "recently"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0332185:Recently [Temporal Concept]

Phrase: "demonstrated by analysis of three-dimensional fluorescence spectra to"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   764   C0450363:3-Dimensional [Spatial Concept]
   745   C0037812:Spectrum Analysis [Laboratory Procedure]
   742   C0002778:Analysis [Laboratory Procedure]
   742   C0016315:Fluorescence [Natural Phenomenon or Process]
   742   C0205449:Three [Quantitative Concept]
   742   C0936012:Analysis [Research Activity]
   742   C1524024:analysis [Functional Concept]
   708   C1883073:Spectrum [Quantitative Concept]
   708   C2827424:Spectrum [Conceptual Entity]

Phrase: "represent"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1882932:Represent [Activity]

Phrase: "fluorescence in glycated proteins"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0016315:Fluorescence [Natural Phenomenon or Process]

Phrase: "(20"

Phrase: ")."
Processing 00000000.tx.234: Furthermore, the latter fluorescence is similar to the maximum fluorescence characteristic of pentosidine, one of the fluorophores formed in advanced Maillard reaction (13, 46). 

Phrase: "Furthermore,"

Phrase: "the latter fluorescence"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0016315:Fluorescence [Natural Phenomenon or Process]
   789 E C0303920:Fluorescent [Indicator, Reagent, or Diagnostic Aid,Organic Chemical]

Phrase: "is"

Phrase: "similar to the maximum fluorescence"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C2348205:Similar [Qualitative Concept]

Phrase: "characteristic of pentosidine,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C1521970:Characteristic [Qualitative Concept]

Phrase: "one of the fluorophores"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0205447:One [Quantitative Concept]

Phrase: "formed in advanced Maillard reaction"
Meta Candidates (Total=8; Excluded=3; Pruned=0; Remaining=5)
   806   C0024495:Maillard Reaction [Natural Phenomenon or Process]
   760   C0205179:Advanced [Qualitative Concept]
   760   C0205431:Formed [Functional Concept]
   760   C0443286:Reaction [Functional Concept]
   760   C1114821:Reaction [Clinical Attribute]
   726 E C0348078:Form [Qualitative Concept]
   726 E C0376315:Form [Manufactured Object]
   726 E C1522492:Form [Functional Concept]

Phrase: "(13,"

Phrase: "46"

Phrase: ")."
Processing 00000000.tx.235: Our results were consistent with those of Dyer et al. 

Phrase: "Our results"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C1274040:Result [Functional Concept]
   966   C1546471:Result [Idea or Concept]
   966   C2825142:Result [Finding]

Phrase: "were"

Phrase: "consistent with those of Dyer et al."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   778   C0332290:Consistent with [Idea or Concept]
           Consistent
Processing 00000000.tx.236: (47), confirming that the fluorescence intensity in tissues at an excitation/emission = 328/378 nm was twice as much as that at an excitation/emission = 370/440 nm. 

Phrase: "(47"

Phrase: ")"

Phrase: ","

Phrase: "confirming"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0521093:confirming [Qualitative Concept]
  1000   C0750484:confirming [Idea or Concept]
   966 E C1456348:Confirm [Qualitative Concept]

Phrase: "that"

Phrase: "the fluorescence intensity in tissues"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0016315:Fluorescence [Natural Phenomenon or Process]
   760   C0522510:Intensity [Qualitative Concept]

Phrase: "at an excitation/emission"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0233929:Emission [Body Substance]
   861   C2349995:Emission [Substance]

Phrase: "= 328/378 nm"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0312860:NM [Cell Function]

Phrase: "was"

Phrase: "twice"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1720725:Twice [Intellectual Product]
  1000   C1948050:Twice [Quantitative Concept]

Phrase: "as"

Phrase: "much"

Phrase: "as"

Phrase: "that at an excitation/emission"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0233929:Emission [Body Substance]
   760   C0549255:Excitation [Activity]
   760   C2349995:Emission [Substance]

Phrase: "= 370/440 nm."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0312860:NM [Cell Function]
Processing 00000000.tx.237: Furthermore, our results revealed an inhibitory effect of tenilsetam on the formation of pyrraline in the collagenase-soluble fraction of diabetic renal cortex and aorta. 

Phrase: "Furthermore,"

Phrase: "our results"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C1274040:Result [Functional Concept]
   966   C1546471:Result [Idea or Concept]
   966   C2825142:Result [Finding]

Phrase: "revealed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0443289:Revealed [Qualitative Concept]

Phrase: "an inhibitory effect of tenilsetam"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C1280500:Effect [Qualitative Concept]
   760   C2348382:Effect [Qualitative Concept]

Phrase: "on the formation"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0220781:formation [Biologic Function]
  1000   C0439634:formation [Spatial Concept]
  1000   C1522492:Formation [Functional Concept]

Phrase: "of pyrraline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0209143:pyrraline [Biologically Active Substance,Organic Chemical]

Phrase: "in the collagenase-soluble fraction"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C1264633:Fraction [Quantitative Concept]
   827   C1554103:Fraction [Idea or Concept]

Phrase: "of diabetic renal cortex"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   901   C0022655:Renal cortex [Body Part, Organ, or Organ Component]
   827   C0007776:Cortex [Body Part, Organ, or Organ Component]
   827   C0022646:Renal [Body Part, Organ, or Organ Component]
   827   C1176472:Cortex [Body Part, Organ, or Organ Component]
   827   C2700441:Cortex [Plant]

Phrase: "and"

Phrase: "aorta."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0003483:Aorta [Body Part, Organ, or Organ Component]
  1000   C1278934:Aorta [Body Part, Organ, or Organ Component]
Processing 00000000.tx.238: Using immunohistochemical techniques with monoclonal antibody to pyrraline, Miyata and Monnier (41) recently described the presence of pyrraline, a nonfluorescent product in advanced Maillard reaction, in a glomerular lesion and an arteriosclerotic lesion of a diabetic patient. 

Phrase: "Using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "immunohistochemical techniques with monoclonal antibody"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0025664:techniques [Intellectual Product]
   760   C0449851:Techniques [Functional Concept]

Phrase: "to pyrraline,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0209143:pyrraline [Biologically Active Substance,Organic Chemical]

Phrase: "Miyata"

Phrase: "and"

Phrase: "Monnier"

Phrase: "(41"

Phrase: ")"

Phrase: "recently"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0332185:Recently [Temporal Concept]

Phrase: "described"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1552738:described [Idea or Concept]

Phrase: "the presence of pyrraline,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0392148:Presence [Therapeutic or Preventive Procedure]

Phrase: "a nonfluorescent product in advanced Maillard reaction,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C1514468:product [Entity]
   748   C1704444:Product [Quantitative Concept]

Phrase: "in a glomerular lesion"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0221198:Lesion [Finding]
   861   C1546698:Lesion [Intellectual Product]

Phrase: "and"

Phrase: "an arteriosclerotic lesion of a diabetic patient."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C0221198:Lesion [Finding]
   748   C1546698:Lesion [Intellectual Product]
Processing 00000000.tx.239: In this regard, tenilsetam may be able to inhibit the formation of nonfluorescent advanced glycation products as well as fluorescent products, thus having a potential role in arresting or preventing the pathological process of diabetic angiopathy. 

Phrase: "In this regard,"

Phrase: "tenilsetam"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0076093:tenilsetam [Organic Chemical,Pharmacologic Substance]

Phrase: "may"

Phrase: "be"

Phrase: "able to"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0085732:Able [Organism Attribute]
   861   C1299581:Able [Finding]

Phrase: "inhibit"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   944   C0018790:arrested [Disease or Syndrome]
   944   C0237477:Arrest [Temporal Concept]
   944   C0392351:arrest [Governmental or Regulatory Activity]
   944   C0521111:Retarded [Qualitative Concept]
   916 E C0311403:Inhibited [Qualitative Concept]
   916 E C3463820:Inhibiting [Activity]

Phrase: "the formation of nonfluorescent advanced glycation products"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   748   C0220781:formation [Biologic Function]
   748   C0439634:formation [Spatial Concept]
   748   C1522492:Formation [Functional Concept]

Phrase: "as well as"

Phrase: "fluorescent products,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C1514468:Products [Entity]
   827 E C1704444:Product [Quantitative Concept]

Phrase: "thus"

Phrase: "having"

Phrase: "a potential role in arresting"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0035820:Role [Social Behavior]
   760   C1705810:Role [Conceptual Entity]

Phrase: "or"

Phrase: "preventing"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0309872:PREVENT [Pharmacologic Substance]

Phrase: "the pathological process of diabetic angiopathy."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0030660:Pathological process [Pathologic Function]
   753   C1184743:Process [Body Part, Organ, or Organ Component]
   753   C1522240:Process [Phenomenon or Process]
Processing 00000000.tx.240: Another observation on the cataract suggests that tenilsetam not only reduces the Maillard reaction in renal cortex and aorta of diabetic rats, but also influences diabetic-induced abnormalities in the lens, probably by inhibiting the Maillard reaction in the eye. 

Phrase: "Another observation on the cataract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0302523:Observation [Research Activity]
   760   C0700325:observation [Health Care Activity]
   760   C1964257:Observation [Diagnostic Procedure]

Phrase: "suggests"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1705535:Suggest [Idea or Concept]

Phrase: "that tenilsetam"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0076093:tenilsetam [Organic Chemical,Pharmacologic Substance]

Phrase: "not only"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205171:Only [Quantitative Concept]
   861   C1518422:Not [Functional Concept]
   861   C1720467:Only [Intellectual Product]

Phrase: "reduces"

Phrase: "the Maillard reaction in renal cortex"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0024495:Maillard Reaction [Natural Phenomenon or Process]
   753   C0443286:Reaction [Functional Concept]
   753   C1114821:Reaction [Clinical Attribute]

Phrase: "and"

Phrase: "aorta of diabetic rats,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   802   C1882561:Rat Aorta [Body Part, Organ, or Organ Component]
   770   C0003483:Aorta [Body Part, Organ, or Organ Component]
   770   C1278934:Aorta [Body Part, Organ, or Organ Component]

Phrase: "but"

Phrase: "also"

Phrase: "influences"

Phrase: "diabetic-induced abnormalities in the lens,"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   783   C0549651:LENSE ABNORMALITIES [Pathologic Function]
   753   C0000768:Abnormalities [Congenital Abnormality]
   753   C0000769:abnormalities [Functional Concept]
   719 E C1704258:Abnormality [Finding]

Phrase: "probably by inhibiting"
Meta Candidates (Total=6; Excluded=4; Pruned=0; Remaining=2)
   790   C0750492:Probably [Idea or Concept]
   790   C3463820:Inhibiting [Activity]
   718 E C0018790:arrested [Disease or Syndrome]
   718 E C0237477:Arrest [Temporal Concept]
   718 E C0392351:arrest [Governmental or Regulatory Activity]
   718 E C0521111:Retarded [Qualitative Concept]

Phrase: "the Maillard reaction in the eye."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0024495:Maillard Reaction [Natural Phenomenon or Process]
   753   C0443286:Reaction [Functional Concept]
   753   C1114821:Reaction [Clinical Attribute]
Processing 00000000.tx.241: Several investigators reported that tenilsetam improved impaired cognitive functions in animal models (28) and in geriatric and Alzheimers patients (29, 30, 31, 32). 

Phrase: "Several investigators"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0035173:Investigators [Professional or Occupational Group]

Phrase: "reported"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0684224:Reported [Intellectual Product]
  1000   C0700287:Reported [Health Care Activity]
  1000   C3496591:Reported [Clinical Attribute]
   966 E C3273238:Report [Intellectual Product]

Phrase: "that tenilsetam"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0076093:tenilsetam [Organic Chemical,Pharmacologic Substance]

Phrase: "improved"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0184511:Improved [Qualitative Concept]
  1000   C0332272:Improved [Qualitative Concept]
  1000   C1561611:Improved [Intellectual Product]

Phrase: "impaired cognitive functions in animal models"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   790   C0392335:Cognitive functions [Mental Process]
   753   C0542341:Functions [Functional Concept]
   753   C1516691:Cognitive [Functional Concept]
   719 E C0031843:function [Physiologic Function]
   719 E C0700205:FUNCTION [Classification]
   719 E C1705273:Function [Intellectual Product]

Phrase: "(28"

Phrase: ")"

Phrase: "and in geriatric"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C1515981:And [Idea or Concept]
   790   C1704440:Geriatric [Qualitative Concept]
   790   C1999167:geriatric [Population Group]

Phrase: "and"

Phrase: "Alzheimers patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "(29,"

Phrase: "30,"

Phrase: "31,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0450355:31 [Intellectual Product]

Phrase: "32"

Phrase: ")."
Processing 00000000.tx.242: As the Maillard reaction may play a role in normal aging and in Alzheimers disease, it is conceivable that tenilsetam may also inhibit the Maillard reaction in this process. 

Phrase: "As the Maillard reaction"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0024495:Maillard Reaction [Natural Phenomenon or Process]
   861   C0443286:Reaction [Functional Concept]
   861   C1114821:Reaction [Clinical Attribute]

Phrase: "may"

Phrase: "play"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0032214:Play [Daily or Recreational Activity]
  1000   C0600138:play [Finding]

Phrase: "a role in normal aging"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0035820:Role [Social Behavior]
   760   C1705810:Role [Conceptual Entity]

Phrase: "and in Alzheimers disease,"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   833   C0002395:Alzheimers disease [Disease or Syndrome]
   770   C0012634:Disease [Disease or Syndrome]
   770   C1515981:And [Idea or Concept]
   715 E C1836721:MALS [Finding]
   715 E C3538764:MALS [Gene or Genome]
   715 E C3540595:MAL [Gene or Genome]

Phrase: "it"

Phrase: "is"

Phrase: "conceivable"

Phrase: "that tenilsetam"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0076093:tenilsetam [Organic Chemical,Pharmacologic Substance]

Phrase: "may"

Phrase: "also"

Phrase: "inhibit"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   944   C0018790:arrested [Disease or Syndrome]
   944   C0237477:Arrest [Temporal Concept]
   944   C0392351:arrest [Governmental or Regulatory Activity]
   944   C0521111:Retarded [Qualitative Concept]
   916 E C0311403:Inhibited [Qualitative Concept]
   916 E C3463820:Inhibiting [Activity]

Phrase: "the Maillard reaction in this process."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0024495:Maillard Reaction [Natural Phenomenon or Process]
   753   C0443286:Reaction [Functional Concept]
   753   C1114821:Reaction [Clinical Attribute]
Processing 00000000.tx.243: Although the precise mechanism of tenilsetam to inhibit AGE formation is not fully elucidated, the finding by Munch et al. 

Phrase: "Although"

Phrase: "the precise mechanism of tenilsetam to"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0441712:Mechanism [Functional Concept]
   753   C1706376:Mechanism [Manufactured Object]

Phrase: "inhibit"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   944   C0018790:arrested [Disease or Syndrome]
   944   C0237477:Arrest [Temporal Concept]
   944   C0392351:arrest [Governmental or Regulatory Activity]
   944   C0521111:Retarded [Qualitative Concept]
   916 E C0311403:Inhibited [Qualitative Concept]
   916 E C3463820:Inhibiting [Activity]

Phrase: "AGE formation"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0220781:formation [Biologic Function]
   861   C0439634:formation [Spatial Concept]
   861   C1522492:Formation [Functional Concept]

Phrase: "is"

Phrase: "not fully"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1518422:Not [Functional Concept]

Phrase: "elucidated"

Phrase: ","

Phrase: "the finding by"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0037088:Finding [Sign or Symptom]
   790   C0243095:Finding [Finding]
   790   C2825141:Finding [Finding]

Phrase: "Munch"

Phrase: "et al."
Processing 00000000.tx.244: (48) that radiolabeled tenilsetam was incorporated into glycated proteins may provide a potential mechanism. 

Phrase: "(48"

Phrase: ")"

Phrase: "that radiolabeled tenilsetam"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0076093:tenilsetam [Organic Chemical,Pharmacologic Substance]

Phrase: "was"

Phrase: "incorporated into glycated proteins"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   816   C0373629:Glycated protein [Laboratory Procedure]
   770   C0033684:Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "may"

Phrase: "provide"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1999230:Provide [Activity]

Phrase: "a potential mechanism."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0441712:Mechanism [Functional Concept]
   861   C1706376:Mechanism [Manufactured Object]
Processing 00000000.tx.245: They suggested that the beneficial effect of tenilsetam was due to a covalent attachment to sugar-derived moieties of glycated proteins, thereby blocking the reactive sites for further polymerization reactions. 

Phrase: "They"

Phrase: "suggested"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1705535:Suggest [Idea or Concept]

Phrase: "that"

Phrase: "the beneficial effect of tenilsetam"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C1280500:Effect [Qualitative Concept]
   760   C2348382:Effect [Qualitative Concept]

Phrase: "was due to a covalent attachment"
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   790   C0678226:Due to [Functional Concept]
           due
   753   C0043194:WAS [Disease or Syndrome]
   753   C0185023:Attachment [Therapeutic or Preventive Procedure]
   753   C0258432:WAS [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   753   C1421478:WAS [Gene or Genome]
   753   C1511539:Covalent [Molecular Function]
   753   C1947904:Attachment [Activity]
   753   C1999228:Attachment [Intellectual Product]
   753   C3146286:Due [Idea or Concept]

Phrase: "to sugar-derived moieties"

Phrase: "of glycated proteins,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   983   C0373629:Glycated protein [Laboratory Procedure]
   861   C0033684:Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "thereby"

Phrase: "blocking"
Meta Candidates (Total=6; Excluded=4; Pruned=0; Remaining=2)
  1000   C0233660:Blocking [Mental or Behavioral Dysfunction]
  1000   C0332206:Blocking [Functional Concept]
   966 E C0028778:Block [Pathologic Function]
   966 E C1533157:Block [Substance]
   966 E C1706084:Block [Geographic Area]
   966 E C2828370:Block [Quantitative Concept]

Phrase: "the reactive sites for further polymerization reactions."
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   778   C0205681:Sites, Reactive [Functional Concept]
   762 E C0005456:reactive site [Receptor]
   748   C0205145:Sites [Spatial Concept]
   714 E C1515974:Site [Body Location or Region]
   714 E C2825164:Site [Spatial Concept]
Processing 00000000.tx.246: With regard to the action site of AG, dicarbonyl compounds such as 3-DG have been suggested to be one of the major targets (27). 

Phrase: "With regard to the action site"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0581718:action site [Intellectual Product]
   861   C0205145:Site [Spatial Concept]
   861   C1515974:Site [Body Location or Region]
   861   C2825164:Site [Spatial Concept]

Phrase: "of AG,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0282774:aminoguanidine [Organic Chemical,Pharmacologic Substance]

Phrase: "dicarbonyl compounds such as 3-DG"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   719   C0205198:Compound [Qualitative Concept]
   719   C1706082:Compound [Chemical]

Phrase: "have"

Phrase: "been"

Phrase: "suggested"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1705535:Suggest [Idea or Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "be"

Phrase: "one of the major targets"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0205447:One [Quantitative Concept]

Phrase: "(27"

Phrase: ")."
Processing 00000000.tx.247: Our in vitro investigation using a specific assay for 3-DG also showed that AG trapped 3-DG with time. 

Phrase: "Our in vitro investigation"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   827   C1261322:Investigation [Health Care Activity]
   827   C1552578:investigation [Idea or Concept]
   755 E C1517586:Investigational [Qualitative Concept]
   755 E C3245491:investigational [Intellectual Product]
   734   C0021135:In Vitro [Intellectual Product]
   734   C1533691:in vitro [Qualitative Concept]
   734   C2827718:In Vitro [Functional Concept]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "a specific assay for 3-DG also"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   748   C0005507:Assay [Laboratory Procedure]
   748   C0243073:assay [Qualitative Concept]
   748   C1510438:Assay [Laboratory Procedure]

Phrase: "showed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "that AG"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0282774:aminoguanidine [Organic Chemical,Pharmacologic Substance]

Phrase: "trapped"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0184047:Trapped [Medical Device]

Phrase: "3-DG with time."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   833   C0047359:3-deoxyglucosone [Carbohydrate]
Processing 00000000.tx.248: On the other hand, there was little direct reaction between tenilsetam and 3-DG. 

Phrase: "On the"

Phrase: "other hand,"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
  1000   C0018563:Hand [Body Part, Organ, or Organ Component]
  1000   C1281583:Hand [Body Part, Organ, or Organ Component]
  1000   C1552914:hand [Quantitative Concept]
   944 E C0024763:Manual [Intellectual Product,Manufactured Object]
   944 E C0175674:Manual [Functional Concept]

Phrase: "there"

Phrase: "was"

Phrase: "little direct reaction between tenilsetam"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0443286:Reaction [Functional Concept]
   760   C1114821:Reaction [Clinical Attribute]

Phrase: "and"

Phrase: "3-DG."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0047359:3-deoxyglucosone [Carbohydrate]
Processing 00000000.tx.249: However, tenilsetam proved to inhibit in vitro polymerization of lysozyme with 3-DG. 

Phrase: "However,"

Phrase: "tenilsetam"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0076093:tenilsetam [Organic Chemical,Pharmacologic Substance]

Phrase: "proved"

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "inhibit"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   944   C0018790:arrested [Disease or Syndrome]
   944   C0237477:Arrest [Temporal Concept]
   944   C0392351:arrest [Governmental or Regulatory Activity]
   944   C0521111:Retarded [Qualitative Concept]
   916 E C0311403:Inhibited [Qualitative Concept]
   916 E C3463820:Inhibiting [Activity]

Phrase: "in vitro polymerization of lysozyme"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0314672:Polymerisation [Phenomenon or Process]

Phrase: "with 3-DG."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0047359:3-deoxyglucosone [Carbohydrate]
Processing 00000000.tx.250: Furthermore, tenilsetam inhibited AGE formation in the renal cortex and aorta, including pyrraline that had been reported to form via 3-DG in part (41, 49). 

Phrase: "Furthermore,"

Phrase: "tenilsetam"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0076093:tenilsetam [Organic Chemical,Pharmacologic Substance]

Phrase: "inhibited"
Meta Candidates (Total=6; Excluded=5; Pruned=0; Remaining=1)
  1000   C0311403:Inhibited [Qualitative Concept]
   928 E C0018790:arrested [Disease or Syndrome]
   928 E C0237477:Arrest [Temporal Concept]
   928 E C0392351:arrest [Governmental or Regulatory Activity]
   928 E C0521111:Retarded [Qualitative Concept]
   907 E C3463820:Inhibiting [Activity]

Phrase: "AGE formation in the renal cortex"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0220781:formation [Biologic Function]
   753   C0439634:formation [Spatial Concept]
   753   C1522492:Formation [Functional Concept]

Phrase: "and"

Phrase: "aorta,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0003483:Aorta [Body Part, Organ, or Organ Component]
  1000   C1278934:Aorta [Body Part, Organ, or Organ Component]

Phrase: "including"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332257:Including [Functional Concept]
   966 E C1552866:include [Idea or Concept]
   966 E C2700399:Include [Activity]

Phrase: "pyrraline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0209143:pyrraline [Biologically Active Substance,Organic Chemical]

Phrase: "that"

Phrase: "had"

Phrase: "been"

Phrase: "reported"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0684224:Reported [Intellectual Product]
  1000   C0700287:Reported [Health Care Activity]
  1000   C3496591:Reported [Clinical Attribute]
   966 E C3273238:Report [Intellectual Product]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "form via 3-DG"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0348078:Form [Qualitative Concept]
   770   C0376315:Form [Manufactured Object]
   770   C1522492:Form [Functional Concept]

Phrase: "in part"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0449719:Part [Spatial Concept]
  1000   C1709471:Part [Quantitative Concept]

Phrase: "(41,"

Phrase: "49"

Phrase: ")."
Processing 00000000.tx.251: The latter is also known to be a potential precursor of pentosidine (46). 

Phrase: "The latter"

Phrase: "is"

Phrase: "also"

Phrase: "known"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205309:Known [Qualitative Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "be"

Phrase: "a potential precursor of pentosidine"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C1709634:Precursor [Idea or Concept]

Phrase: "(46"

Phrase: ")."
Processing 00000000.tx.252: We observed inhibition of the fluorescence characteristic of pentosidine in diabetic renal cortex and aorta by tenilsetam administration. 

Phrase: "We"

Phrase: "observed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1441672:Observed [Functional Concept]

Phrase: "inhibition of the fluorescence"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0021467:Inhibition [Mental Process]
   770   C0021469:Inhibition [Molecular Function]
   770   C1628982:% inhibition [Quantitative Concept]
   770   C3463820:Inhibition [Activity]

Phrase: "characteristic of pentosidine"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C1521970:Characteristic [Qualitative Concept]

Phrase: "in diabetic renal cortex"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   901   C0022655:Renal cortex [Body Part, Organ, or Organ Component]
   827   C0007776:Cortex [Body Part, Organ, or Organ Component]
   827   C0022646:Renal [Body Part, Organ, or Organ Component]
   827   C1176472:Cortex [Body Part, Organ, or Organ Component]
   827   C2700441:Cortex [Plant]

Phrase: "and"

Phrase: "aorta by tenilsetam administration."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0003483:Aorta [Body Part, Organ, or Organ Component]
   770   C1278934:Aorta [Body Part, Organ, or Organ Component]
Processing 00000000.tx.253: Thus, our data suggest that tenilsetam acts on a post-3-DG stage in advanced Maillard reaction to inhibit AGE formation. 

Phrase: "Thus,"

Phrase: "our data"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1511726:Data [Idea or Concept]
  1000   C3245479:data [Medical Device]

Phrase: "suggest"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1705535:Suggest [Idea or Concept]

Phrase: "that tenilsetam acts on a post-3-DG stage"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   708   C0079613:ACT [Therapeutic or Preventive Procedure]

Phrase: "in advanced Maillard reaction to"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0024495:Maillard Reaction [Natural Phenomenon or Process]
   812   C0443286:Reaction [Functional Concept]
   812   C1114821:Reaction [Clinical Attribute]

Phrase: "inhibit"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   944   C0018790:arrested [Disease or Syndrome]
   944   C0237477:Arrest [Temporal Concept]
   944   C0392351:arrest [Governmental or Regulatory Activity]
   944   C0521111:Retarded [Qualitative Concept]
   916 E C0311403:Inhibited [Qualitative Concept]
   916 E C3463820:Inhibiting [Activity]

Phrase: "AGE formation."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0220781:formation [Biologic Function]
   861   C0439634:formation [Spatial Concept]
   861   C1522492:Formation [Functional Concept]
Processing 00000000.tx.254: Considering our previous finding (42) that the plasma 3-DG level was elevated in diabetic rats, it would be effective to inhibit the post-3-DG stage in terms of preventing tissues from accumulating AGEs. 

Phrase: "Considering"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0750591:considering [Idea or Concept]

Phrase: "our previous finding"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0037088:Finding [Sign or Symptom]
   861   C0243095:Finding [Finding]
   861   C2825141:Finding [Finding]

Phrase: "(42"

Phrase: ")"

Phrase: "that"

Phrase: "the plasma 3-DG level"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   812   C0441889:Level [Qualitative Concept]
   812   C0456079:Level [Classification]
   812   C1547707:Level [Geographic Area]
   812   C2946261:Level [Pharmacologic Substance]

Phrase: "was"

Phrase: "elevated in diabetic rats,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   770   C0034693:rats [Mammal]
   770   C0034721:Rats [Mammal]
   770   C0205250:Elevated [Qualitative Concept]
   770   C0241863:DIABETIC [Finding]
   770   C3163633:Elevated [Qualitative Concept]

Phrase: "it"

Phrase: "would"

Phrase: "be"

Phrase: "effective to"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1280519:effective [Qualitative Concept]
   861   C1704419:Effective [Qualitative Concept]

Phrase: "inhibit"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   944   C0018790:arrested [Disease or Syndrome]
   944   C0237477:Arrest [Temporal Concept]
   944   C0392351:arrest [Governmental or Regulatory Activity]
   944   C0521111:Retarded [Qualitative Concept]
   916 E C0311403:Inhibited [Qualitative Concept]
   916 E C3463820:Inhibiting [Activity]

Phrase: "the post-3-DG stage in terms of preventing tissues"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   757   C0441771:Stage 3 [Intellectual Product]
   739   C0205390:Stage [Temporal Concept]
   739   C1300072:Stage [Clinical Attribute]
   739   C1306673:Stage [Qualitative Concept]

Phrase: "from accumulating AGEs."
Meta Candidates (Total=11; Excluded=5; Pruned=0; Remaining=6)
   937   C0162574:Glycation End Products, Advanced [Biologically Active Substance,Organic Chemical]
   804   C0205179:Advanced [Qualitative Concept]
   804   C0444930:End [Spatial Concept]
   804   C0598528:glycation [Phenomenon or Process]
   804   C1514468:Products [Entity]
   804   C2746065:End [Temporal Concept]
   771 E C0725066:Advance [Medical Device]
   771 E C1704444:Product [Quantitative Concept]
   748 E C0205088:Terminal [Temporal Concept]
   748 E C1705314:Terminal [Manufactured Object]
   748 E C1705315:Terminal [Spatial Concept]
Processing 00000000.tx.255: Vasan et al. 

Phrase: "Vasan et al."
Processing 00000000.tx.256: (50) recently showed that a compound, N-phenacylthiazolium bromide, cleaved advanced glycated product at the step after the formation of dicarbonyl intermediate. 

Phrase: "(50"

Phrase: ")"

Phrase: "recently"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0332185:Recently [Temporal Concept]

Phrase: "showed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "that"

Phrase: "a compound,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0205198:Compound [Qualitative Concept]
  1000   C1706082:Compound [Chemical]

Phrase: "N-phenacylthiazolium bromide,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0530353:N-phenacylthiazolium bromide [Organic Chemical]
   827   C0006222:Bromide [Inorganic Chemical]

Phrase: "cleaved"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0205242:Cleaved [Spatial Concept]
  1000   C0333853:Cleaved [Cell]

Phrase: "advanced glycated product at the step"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C1514468:product [Entity]
   753   C1704444:Product [Quantitative Concept]

Phrase: "after the formation"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0220781:formation [Biologic Function]
  1000   C0439634:formation [Spatial Concept]
  1000   C1522492:Formation [Functional Concept]

Phrase: "of dicarbonyl"

Phrase: "intermediate."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205103:Intermediate [Spatial Concept]
  1000   C1550465:intermediate [Idea or Concept]
  1000   C2827755:INTERMEDIATE [Laboratory or Test Result]
Processing 00000000.tx.257: The mechanism of tenilsetam action might be compatible with their potential therapeutic approach, although it remains to be further elucidated. 

Phrase: "The mechanism of tenilsetam action"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   844   C0031327:mechanism of action [Physiologic Function]
   844   C1524059:mechanism of action [Functional Concept]
   760   C0441712:Mechanism [Functional Concept]
   760   C1706376:Mechanism [Manufactured Object]

Phrase: "might"

Phrase: "be"

Phrase: "compatible with their potential therapeutic approach,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0332290:compatible [Idea or Concept]
   753   C1524057:Compatible [Qualitative Concept]

Phrase: "although"

Phrase: "it"

Phrase: "remains"

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "be"

Phrase: "further"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1517331:Further [Spatial Concept]
   966 E C0205108:far [Spatial Concept]

Phrase: "elucidated."
Processing 00000000.tx.258: As the mechanism of action of tenilsetam seems different from that of AG, the combined use of tenilsetam and AG or of tenilsetam alone may prove to be beneficial in diabetic complications in the future.  

Phrase: "As the mechanism"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0441712:Mechanism [Functional Concept]
  1000   C1706376:Mechanism [Manufactured Object]

Phrase: "of action"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0441472:Action [Functional Concept]
  1000   C3266814:Action [Activity]

Phrase: "of tenilsetam"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0076093:tenilsetam [Organic Chemical,Pharmacologic Substance]

Phrase: "seems"

Phrase: "different from that of AG,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C1705242:Different [Qualitative Concept]

Phrase: "the combined use of tenilsetam"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   806   C1524063:Use of [Functional Concept]
   760   C0042153:use [Functional Concept]
   760   C0457083:Use [Functional Concept]
   760   C1947944:Use [Intellectual Product]

Phrase: "and"

Phrase: "AG"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0282774:aminoguanidine [Organic Chemical,Pharmacologic Substance]

Phrase: "or of tenilsetam"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0076093:tenilsetam [Organic Chemical,Pharmacologic Substance]

Phrase: "alone"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205171:Alone [Quantitative Concept]
  1000   C0439044:alone [Finding]
  1000   C0679994:alone [Group Attribute]

Phrase: "may"

Phrase: "prove"

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "be"

Phrase: "beneficial in diabetic complications"

Phrase: "in the future."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0016884:Future [Temporal Concept]
Processing 00000000.tx.259: Acknowledgments  We thank Cassella (Frankfurt, Germany) for the supply of Tenilsetam, and Drs. 

Phrase: "Acknowledgments"

Phrase: "We"

Phrase: "thank"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2986676:THANK [Gene or Genome]

Phrase: "Cassella"

Phrase: "(Frankfurt,"

Phrase: "Germany"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0017480:Germany [Geographic Area]

Phrase: ")"

Phrase: "for the supply"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0243163:supply [Idea or Concept]
  1000   C0699914:supply [Quantitative Concept]
  1000   C1314650:SUPPLY, NOT OTHERWISE SPECIFIED [Medical Device]
  1000   C1561604:supply [Functional Concept]
  1000   C1875802:SUPPLY [Medical Device]
  1000   C1999230:Supply [Activity]

Phrase: "of Tenilsetam,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0076093:tenilsetam [Organic Chemical,Pharmacologic Substance]

Phrase: "and"

Phrase: "Drs."
Processing 00000000.tx.260: Schindler and Schraven for the scientific support and fruitful discussions. 

Phrase: "Schindler"

Phrase: "and"

Phrase: "Schraven for the scientific support"

Phrase: "and"

Phrase: "fruitful discussions."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0557061:discussions [Therapeutic or Preventive Procedure]
   827 E C2584313:Discussion [Social Behavior]
Processing 00000000.tx.261: Received October 21, 1996.  

Phrase: "Received October 21,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C1514756:Received [Qualitative Concept]

Phrase: "1996."
Processing 00000000.tx.262: References Top Abstract Introduction Materials and Methods Results Discussion References  Brownlee M, Cerami A, Vlassara H 1988 Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. 

Phrase: "References"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "Top Abstract Introduction Materials"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0520510:Materials [Substance]

Phrase: "and"

Phrase: "Methods Results Discussion"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0557061:Discussion [Therapeutic or Preventive Procedure]
   827   C2584313:Discussion [Social Behavior]

Phrase: "References"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "Brownlee M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Cerami A,"

Phrase: "Vlassara H 1988 Advanced glycosylation end products in tissue"
Meta Candidates (Total=10; Excluded=2; Pruned=0; Remaining=8)
   818   C0162574:Glycosylation End Products, Advanced [Biologically Active Substance,Organic Chemical]
   742   C0017982:glycosylation [Natural Phenomenon or Process]
   742   C0205179:Advanced [Qualitative Concept]
   742   C0376322:Glycosylation [Molecular Function]
   742   C0444930:End [Spatial Concept]
   742   C1514468:Products [Entity]
   742   C2746065:End [Temporal Concept]
   734   C3158557:terminal glycosylation [Molecular Function]
   708 E C0725066:Advance [Medical Device]
   708 E C1704444:Product [Quantitative Concept]

Phrase: "and"

Phrase: "the biochemical basis of diabetic complications."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C1527178:Basis [Functional Concept]
   753   C1874451:Basis [Pharmacologic Substance]
Processing 00000000.tx.263: N Engl J Med 318:13151321[Medline] Monnier VM, Baynes JW 1989 The Maillard Reaction in Aging, Diabetes and Nutrition. 

Phrase: "N Engl J Med 318"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   804   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   804   C0441922:N+ [Intellectual Product]
   804   C1414400:ENGL [Gene or Genome]
   804   C1553036:[n] [Quantitative Concept]

Phrase: ":"

Phrase: "13151321"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Monnier VM,"

Phrase: "Baynes JW 1989"

Phrase: "The Maillard Reaction in Aging,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   806   C0024495:Maillard Reaction [Natural Phenomenon or Process]
   760   C0443286:Reaction [Functional Concept]
   760   C1114821:Reaction [Clinical Attribute]

Phrase: "Diabetes"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0011847:Diabetes [Disease or Syndrome]
  1000   C0011849:Diabetes [Disease or Syndrome]

Phrase: "and"

Phrase: "Nutrition."
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
  1000   C0028707:Nutrition [Biomedical Occupation or Discipline]
  1000   C0392209:nutrition [Organism Attribute]
  1000   C1442959:Nutrition [Organism Function]
   928 E C1521739:Nutritional [Qualitative Concept]
   928 E C2707262:Nutritional [Clinical Attribute]
Processing 00000000.tx.264: Liss, New York Monnier VM, Kohn RR, Cerami A 1984 Accelerated age related browning of human collagen in diabetes mellitus. 

Phrase: "Liss,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1508741:LISS [Laboratory Procedure]
  1000   C2247545:LIS [Molecular Function]

Phrase: "New York Monnier VM,"

Phrase: "Kohn RR,"

Phrase: "Cerami"

Phrase: "A 1984 Accelerated age related browning of human collagen"

Phrase: "in diabetes mellitus."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0011849:Diabetes Mellitus [Disease or Syndrome]
           Diabetes
   861   C0011847:Diabetes [Disease or Syndrome]
Processing 00000000.tx.265: Proc Natl Acad Sci USA 81:583587[Abstract] Nakayama H, Mitsuhashi T, Kuwajima S, Aoki S, Kuroda Y, Itoh T, Nakagawa S 1993 Immunochemical detection of advanced glycation end products in lens crystallins from streptozocin-induced diabetic rat. 

Phrase: "Proc Natl Acad Sci USA 81"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   799   C0041703:USA [Geographic Area]
   799   C0268596:ACAD [Disease or Syndrome]
   799   C1418943:PROC [Gene or Genome]
   799   C2700624:ACAD [Cell Function]
   799   C3642273:SCI [Professional or Occupational Group]

Phrase: ":"

Phrase: "583587"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] Nakayama H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Mitsuhashi T,"

Phrase: "Kuwajima S,"

Phrase: "Aoki S,"

Phrase: "Kuroda Y,"

Phrase: "Itoh T,"

Phrase: "Nakagawa S 1993 Immunochemical detection of advanced glycation end products in lens crystallins"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   735   C1511790:Detection [Therapeutic or Preventive Procedure]

Phrase: "from streptozocin-induced diabetic rat."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   812   C0034693:Rat, NOS [Mammal]
   812   C0034721:Rat [Mammal]
   812   C0241863:DIABETIC [Finding]
Processing 00000000.tx.266: Diabetes 42:345350[Abstract] Mitsuhashi T, Nakayama H, Itoh T, Kuwajima S, Aoki S, Atsumi T, Koike T 1993 Immunochemical detection of advanced glycation end products in renal cortex from STZ-induced diabetic rat. 

Phrase: "Diabetes 42"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0011847:Diabetes [Disease or Syndrome]
   861   C0011849:Diabetes [Disease or Syndrome]

Phrase: ":"

Phrase: "345350"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] Mitsuhashi T,"

Phrase: "Nakayama H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Itoh T,"

Phrase: "Kuwajima S,"

Phrase: "Aoki S,"

Phrase: "Atsumi T,"

Phrase: "Koike T 1993 Immunochemical detection of advanced glycation end products"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   739   C1511790:Detection [Therapeutic or Preventive Procedure]

Phrase: "in renal cortex"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0022655:Renal cortex [Body Part, Organ, or Organ Component]
   861   C0007776:Cortex [Body Part, Organ, or Organ Component]
   861   C0022646:Renal [Body Part, Organ, or Organ Component]
   861   C1176472:Cortex [Body Part, Organ, or Organ Component]
   861   C2700441:Cortex [Plant]

Phrase: "from STZ-induced diabetic rat."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   812   C0034693:Rat, NOS [Mammal]
   812   C0034721:Rat [Mammal]
   812   C0241863:DIABETIC [Finding]
Processing 00000000.tx.267: Diabetes 42:826832[Abstract] Kume S, Takeya M, Mori T, Araki N, Suzuki H, Horiuchi S, Kodama T, Miyauchi Y, Takahashi K 1995 Immunochemical and ultrastructual detection of advanced glycation end products in atherosclerotic lesions of human aorta with a novel specific monoclonal antibody. 

Phrase: "Diabetes 42"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0011847:Diabetes [Disease or Syndrome]
   861   C0011849:Diabetes [Disease or Syndrome]

Phrase: ":"

Phrase: "826832"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] Kume S,"

Phrase: "Takeya M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Mori T,"

Phrase: "Araki N,"

Phrase: "Suzuki H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Horiuchi S,"

Phrase: "Kodama T,"

Phrase: "Miyauchi Y,"

Phrase: "Takahashi K 1995 Immunochemical"

Phrase: "and"

Phrase: "ultrastructual detection of advanced glycation end products"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C1511790:Detection [Therapeutic or Preventive Procedure]

Phrase: "in atherosclerotic lesions"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   861   C0221198:lesions [Finding]
   861   C0333482:Atherosclerotic [Functional Concept]
   827 E C1546698:Lesion [Intellectual Product]

Phrase: "of human aorta"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0003483:Aorta [Body Part, Organ, or Organ Component]
   861   C1278934:Aorta [Body Part, Organ, or Organ Component]

Phrase: "with a novel specific monoclonal antibody."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   875   C0443640:Specific antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0003250:Monoclonal antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   812   C0003241:Antibody [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   812   C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   812   C0746619:monoclonal [Finding]
Processing 00000000.tx.268: Am J Pathol 147:654667[Abstract] Makita Z, Vlassara H, Cerami A, Bucala R 1992 Immunochemical detection of advanced glycosylation end products in vivo. 

Phrase: "Am"

Phrase: "J Pathol 147"

Phrase: ":"

Phrase: "654667"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] Makita Z,"

Phrase: "Vlassara H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Cerami A,"

Phrase: "Bucala R 1992 Immunochemical detection of advanced glycosylation end products"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   739   C1511790:Detection [Therapeutic or Preventive Procedure]

Phrase: "in vivo."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1515655:In Vivo [Spatial Concept]
           vivo
Processing 00000000.tx.269: J Biol Chem 267:51335138[Abstract/Free FullText] Myint T, Hoshi S, Ookawara T, Miyazawa N, Suzuki K, Taniguchi N 1995 Immunological detection of glycated proteins in normal and streptozotocin-induced diabetic rats using anti hexitol-lysine IgG. 

Phrase: "J Biol Chem 267"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0201682:CHEM [Laboratory Procedure]

Phrase: ":"

Phrase: "51335138"

Phrase: "[Abstract/Free FullText"

Phrase: "] Myint T,"

Phrase: "Hoshi S,"

Phrase: "Ookawara T,"

Phrase: "Miyazawa N,"

Phrase: "Suzuki K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Taniguchi N 1995 Immunological detection of glycated proteins"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   744   C1511790:Detection [Therapeutic or Preventive Procedure]

Phrase: "in normal"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205307:Normal [Qualitative Concept]
  1000   C0439166:% normal [Quantitative Concept]
  1000   C2347086:% Normal [Quantitative Concept]

Phrase: "and"

Phrase: "streptozotocin-induced diabetic rats"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   812   C0034693:rats [Mammal]
   812   C0034721:Rats [Mammal]
   812   C0241863:DIABETIC [Finding]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "anti hexitol-lysine IgG."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   902   C0051979:anti-IgG [Amino Acid, Peptide, or Protein,Immunologic Factor]
Processing 00000000.tx.270: Biochim Biophys Acta 1272:7379[Medline] Kohn RR, Cerami A, Monnier VM 1984 Collagen aging in vitro by non-enzymatic glycosylation and browning. 

Phrase: "Biochim Biophys Acta 1272"

Phrase: ":"

Phrase: "7379"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Kohn RR,"

Phrase: "Cerami A,"

Phrase: "Monnier VM 1984 Collagen"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   812   C0009325:Collagen [Amino Acid, Peptide, or Protein,Biologically Active Substance,Biomedical or Dental Material]
   812   C1167364:collagen [Cell Component]
   741 E C0439689:Collagenous [Qualitative Concept]

Phrase: "aging"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0001811:Aging [Organism Function]
   966 E C0001779:Age [Organism Attribute]

Phrase: "in vitro by non-enzymatic glycosylation"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   790   C0021135:In Vitro [Intellectual Product]
   790   C1533691:in vitro [Qualitative Concept]
           vitro
   790   C2827718:In Vitro [Functional Concept]

Phrase: "and"

Phrase: "browning."
Processing 00000000.tx.271: Diabetes 33:5759[Abstract] Vlassara H, Brownlee M, Cerami A 1983 Excessive nonenzymatic glycosylation of peripheral and central nervous system myelin components in diabetic rats. 

Phrase: "Diabetes 33"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0011847:Diabetes [Disease or Syndrome]
   861   C0011849:Diabetes [Disease or Syndrome]

Phrase: ":"

Phrase: "5759"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] Vlassara H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Brownlee M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Cerami"

Phrase: "A 1983 Excessive nonenzymatic glycosylation of peripheral"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   778   C0598528:nonenzymatic glycosylation [Phenomenon or Process]
   748   C0017982:glycosylation [Natural Phenomenon or Process]
   748   C0376322:Glycosylation [Molecular Function]

Phrase: "and"

Phrase: "central nervous system myelin components in diabetic rats."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   744   C0449432:Components [Manufactured Object]
   711 E C1705248:Component [Conceptual Entity]
Processing 00000000.tx.272: Diabetes 32:670674[Abstract] Oimomi M, Maeda Y, Hata F, Kitamura Y, Matsumoto S, Baba S, Iga T, Yamamoto M 1988 Glycation of cataractous lens in nondiabetic senile subjects and in diabetic patients. 

Phrase: "Diabetes 32"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0011847:Diabetes [Disease or Syndrome]
   861   C0011849:Diabetes [Disease or Syndrome]

Phrase: ":"

Phrase: "670674"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] Oimomi M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Maeda Y,"

Phrase: "Hata F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Kitamura Y,"

Phrase: "Matsumoto S,"

Phrase: "Baba S,"

Phrase: "Iga T,"

Phrase: "Yamamoto M 1988 Glycation of cataractous lens"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0598528:glycation [Phenomenon or Process]

Phrase: "in nondiabetic senile subjects"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   793   C0681850:Subject [Group]
   793   C1550501:{Subject} [Idea or Concept]
   793   C1706203:Subject [Idea or Concept]
   793   C2349001:Subject [Human]
   793   C2697811:Subject [Functional Concept]

Phrase: "and in diabetic patients."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0030705:Patients [Patient or Disabled Group]
   770   C0241863:DIABETIC [Finding]
   770   C1515981:And [Idea or Concept]
Processing 00000000.tx.273: Exp Eye Res 46:41520[Medline] Njoroge FG, Sayer LM, Monnier VM 1987 Detection of D-glucose derived pyrrole compounds during Maillard reaction under physiological conditions. 

Phrase: "Exp Eye Res 46"
Meta Candidates (Total=9; Excluded=5; Pruned=0; Remaining=4)
   812   C0015392:Eye [Body Part, Organ, or Organ Component]
   812   C1280202:Eye [Body Part, Organ, or Organ Component]
   812   C1417055:EXP [Gene or Genome]
   812   C2347379:RES [Finding]
   756 E C0029144:optic [Occupation or Discipline]
   756 E C0042789:Ocular [Organism Function]
   756 E C1299003:Ocular [Spatial Concept]
   719 E C0014236:Ophthalmia [Disease or Syndrome]
   719 E C0700042:Oculus [Body Location or Region]

Phrase: ":"

Phrase: "41520"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Njoroge FG,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0439214:fg [Quantitative Concept]
   861   C2348814:FG [Quantitative Concept]

Phrase: "Sayer LM,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C1261082:LM [Body Part, Organ, or Organ Component]
   861   C1551056:lm [Quantitative Concept]
   861   C2981682:LM [Quantitative Concept]

Phrase: "Monnier VM 1987 Detection of"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C1511790:Detection [Therapeutic or Preventive Procedure]

Phrase: "D-"

Phrase: "glucose"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]

Phrase: "derived"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1441547:Derived [Qualitative Concept]
  1000   C3245521:derived [Idea or Concept]

Phrase: "pyrrole compounds during Maillard reaction"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   726   C0205198:Compound [Qualitative Concept]
   726   C1706082:Compound [Chemical]

Phrase: "under physiological conditions."
Meta Candidates (Total=7; Excluded=4; Pruned=0; Remaining=3)
   827   C0012634:condition [Disease or Syndrome]
   827   C0348080:Condition [Qualitative Concept]
   827   C1705253:Condition [Conceptual Entity]
   777 E C0009647:Conditioned [Mental Process]
   777 E C1701901:Conditional [Qualitative Concept]
   777 E C1963686:Conditional [Functional Concept]
   755 E C1519605:Conditionality [Conceptual Entity]
Processing 00000000.tx.274: Carbohydr Res 167:211220[CrossRef][Medline] Sell DR, Monnier VM 1989 Structural elucidation of a senescence cross-link from human extracellular matrix: implication of pentoses in the aging process. 

Phrase: "Carbohydr Res 167"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C2347379:RES [Finding]

Phrase: ":"

Phrase: "211220"

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Sell DR,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0031831:DR [Professional or Occupational Group]
   861   C1707664:DR [Biomedical or Dental Material]
   861   C2348314:Dr. [Conceptual Entity]
   861   C3540849:DR [Idea or Concept]

Phrase: "Monnier VM 1989 Structural elucidation of a senescence cross-link"

Phrase: "from human extracellular matrix"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   901   C0015350:Extracellular Matrix [Tissue]
   827   C0521119:Extracellular [Cell Component]
   827   C1704640:Matrix [Spatial Concept]
   827   C1706515:Matrix [Body Substance]

Phrase: ":"

Phrase: "implication of pentoses"

Phrase: "in the aging process."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1510835:Aging Process [Organism Function]
   861   C1184743:Process [Body Part, Organ, or Organ Component]
   861   C1522240:Process [Phenomenon or Process]
Processing 00000000.tx.275: J Biol Chem 264:2159721602[Abstract/Free FullText] Nakamura K, Hasegawa T, Fukunaga Y, Ienaga K 1992 Crosslines A and B as candidates for the fluorophores in age-and diabetes-related cross-linked proteins, and their diacetates produced by Maillard reaction of -N-acetyl-L-lysine with D-glucose. 

Phrase: "J Biol Chem 264"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0201682:CHEM [Laboratory Procedure]

Phrase: ":"

Phrase: "2159721602"

Phrase: "[Abstract/Free FullText"

Phrase: "] Nakamura K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Hasegawa T,"

Phrase: "Fukunaga Y,"

Phrase: "Ienaga K 1992 Crosslines"

Phrase: "A"

Phrase: "and"

Phrase: "B as candidates"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C2347469:/B [Quantitative Concept]

Phrase: "for the fluorophores"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0598447:fluorophore [Indicator, Reagent, or Diagnostic Aid,Pharmacologic Substance]

Phrase: "in age-"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0001779:Age [Organism Attribute]

Phrase: "and"

Phrase: "diabetes-related"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   861   C0439849:Related [Qualitative Concept]
   861   C0445223:Related [Finding]
   789 E C0080103:Relation [Family Group]
   789 E C0869014:Relations [Social Behavior]

Phrase: "cross-linked"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0178576:Cross Linked [Natural Phenomenon or Process]
  1000   C0332220:cross linked [Functional Concept]
   861   C2828360:Cross [Conceptual Entity]
   827   C1517892:Link [Intellectual Product]
   827   C1704666:Link [Intellectual Product]

Phrase: "proteins,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0033684:Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "and"

Phrase: "their diacetates"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0369114:Diacetate [Organic Chemical]

Phrase: "produced by Maillard reaction of -N-acetyl-L-lysine"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   764   C0024495:Maillard Reaction [Natural Phenomenon or Process]
   742   C0024337:Lysine [Amino Acid, Peptide, or Protein,Biologically Active Substance,Pharmacologic Substance]
   742   C0443286:Reaction [Functional Concept]
   742   C1114821:Reaction [Clinical Attribute]

Phrase: "with"

Phrase: "D-"

Phrase: "glucose."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
Processing 00000000.tx.276: J Chem Soc Chem Commun 14:992994 Hayase F, Hinuma H, Asano M, Kato H, Arai S 1994 Identification of novel fluorescent pyrrolopyridinium compound formed from Maillard reaction of 3-deoxyglucosone and butylamine. 

Phrase: "J Chem Soc Chem Commun 14"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   799   C0201682:CHEM [Laboratory Procedure]

Phrase: ":"

Phrase: "992994 Hayase F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   827   C0439133:(f) [Intellectual Product]
   827   C1553038:[f] [Quantitative Concept]

Phrase: "Hinuma H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Asano M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Kato H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Arai S 1994 Identification of novel fluorescent pyrrolopyridinium compound"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   742   C0020792:Identification [Mental Process]
   742   C0205396:Identification [Qualitative Concept]

Phrase: "formed from Maillard reaction of 3-deoxyglucosone"
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
   778   C0024495:Maillard Reaction [Natural Phenomenon or Process]
   748   C0205431:Formed [Functional Concept]
   748   C0443286:Reaction [Functional Concept]
   748   C1114821:Reaction [Clinical Attribute]
   714 E C0348078:Form [Qualitative Concept]
   714 E C0376315:Form [Manufactured Object]
   714 E C1522492:Form [Functional Concept]

Phrase: "and"

Phrase: "butylamine."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0303836:Butylamine [Organic Chemical]
Processing 00000000.tx.277: Biosci Biotechnol Biochem 58:19361937 Ahmed MU, Thorpe SR, Baynes JW 1986 Identification of N238-carboxymethyllysine as a degradation product of fructoselysine in glycated protein. 

Phrase: "Biosci Biotechnol Biochem 58"

Phrase: ":"

Phrase: "19361937 Ahmed MU,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0347978:Mu [Intellectual Product]

Phrase: "Thorpe SR,"

Phrase: "Baynes JW 1986 Identification of N238-carboxymethyllysine"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C0020792:Identification [Mental Process]
   748   C0205396:Identification [Qualitative Concept]

Phrase: "as a degradation product"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1514468:product [Entity]
   861   C1704444:Product [Quantitative Concept]

Phrase: "of fructoselysine"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0060780:fructose lysine [Amino Acid, Peptide, or Protein]

Phrase: "in glycated protein."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0373629:Glycated protein [Laboratory Procedure]
   861   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]
Processing 00000000.tx.278: J Biol Chem 261:48894894[Abstract/Free FullText] Kimura T, Takamatsu J, Ikeda K, Kondo A, Miyakawa T, Horiuchi S 1996 Accumulation of advanced glycation end products of the Maillard reaction with age in human hippocampal neurons. 

Phrase: "J Biol Chem 261"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0201682:CHEM [Laboratory Procedure]

Phrase: ":"

Phrase: "48894894"

Phrase: "[Abstract/Free FullText"

Phrase: "] Kimura T,"

Phrase: "Takamatsu J,"

Phrase: "Ikeda K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Kondo A,"

Phrase: "Miyakawa T,"

Phrase: "Horiuchi S 1996 Accumulation of advanced glycation end products of the Maillard reaction"

Phrase: "with age"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0001779:Age [Organism Attribute]

Phrase: "in human hippocampal neurons."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   827   C0027882:Neurons [Cell]
   743 E C0521390:Neuronal [Immunologic Factor]
Processing 00000000.tx.279: Neurosci Lett 208:5356[CrossRef][Medline] Shin D, Hayase F, Kato H 1988 Polymerization of proteins caused by reaction with sugars and the formation of 3-deoxyglucosone under physiological conditions. 

Phrase: "Neurosci Lett 208"

Phrase: ":"

Phrase: "5356"

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Shin D,"

Phrase: "Hayase F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Kato H 1988 Polymerization of proteins"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   767   C1523272:protein polymerization [Molecular Function]
   753   C0314672:Polymerisation [Phenomenon or Process]

Phrase: "caused by reaction"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   790   C0443286:Reaction [Functional Concept]
   790   C1114821:Reaction [Clinical Attribute]
   756   C0015127:cause [Functional Concept]
   756   C1524003:Cause [Conceptual Entity]

Phrase: "with sugars"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0242209:Sugars [Carbohydrate,Pharmacologic Substance]
   966 E C0007004:Sugar [Carbohydrate]

Phrase: "and"

Phrase: "the formation of 3-deoxyglucosone"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0220781:formation [Biologic Function]
   760   C0439634:formation [Spatial Concept]
   760   C1522492:Formation [Functional Concept]

Phrase: "under physiological conditions."
Meta Candidates (Total=7; Excluded=4; Pruned=0; Remaining=3)
   827   C0012634:condition [Disease or Syndrome]
   827   C0348080:Condition [Qualitative Concept]
   827   C1705253:Condition [Conceptual Entity]
   777 E C0009647:Conditioned [Mental Process]
   777 E C1701901:Conditional [Qualitative Concept]
   777 E C1963686:Conditional [Functional Concept]
   755 E C1519605:Conditionality [Conceptual Entity]
Processing 00000000.tx.280: Agric Biol Chem 52:14511458 Monnier VM, Cerami A 1981 Non-enzymatic browning in vivo: possible process for aging of long-lived proteins. 

Phrase: "Agric Biol Chem 52"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0201682:CHEM [Laboratory Procedure]

Phrase: ":"

Phrase: "14511458 Monnier VM,"

Phrase: "Cerami"

Phrase: "A 1981 Non-enzymatic browning"

Phrase: "in vivo"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1515655:In Vivo [Spatial Concept]
           vivo

Phrase: ":"

Phrase: "possible process for aging of long-lived proteins."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   767   C1510835:Aging Process [Organism Function]
   750   C0033666:process protein [Molecular Function]
   744   C1184743:Process [Body Part, Organ, or Organ Component]
   744   C1522240:Process [Phenomenon or Process]
Processing 00000000.tx.281: Science 211:491493[Medline] Baynes JW 1991 Role of oxidative stress in development of complications in diabetes. 

Phrase: "Science 211"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0036397:Science [Occupation or Discipline]

Phrase: ":"

Phrase: "491493"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Baynes JW 1991 Role of oxidative stress"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C0035820:Role [Social Behavior]
   748   C1705810:Role [Conceptual Entity]

Phrase: "in development"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0243107:development [Physiologic Function]
  1000   C0678723:Development [Organism Function]
  1000   C1527148:Development [Functional Concept]
   928 E C0458003:Developmental [Qualitative Concept]

Phrase: "of complications"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C0009566:Complications [Pathologic Function]
  1000   C1171258:complications [Pathologic Function]
   966 E C2362589:Complication [Idea or Concept]
   916 E C0231242:Complicated [Functional Concept]

Phrase: "in diabetes."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0011847:Diabetes [Disease or Syndrome]
  1000   C0011849:Diabetes [Disease or Syndrome]
Processing 00000000.tx.282: Diabetes 40:405412[Abstract] Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A 1986 Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. 

Phrase: "Diabetes 40"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0011847:Diabetes [Disease or Syndrome]
   861   C0011849:Diabetes [Disease or Syndrome]
   861   C0439509:/40 [Temporal Concept]

Phrase: ":"

Phrase: "405412"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] Brownlee M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Vlassara H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Kooney A,"

Phrase: "Ulrich P,"

Phrase: "Cerami"

Phrase: "A 1986 Aminoguanidine"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0282774:aminoguanidine [Organic Chemical,Pharmacologic Substance]

Phrase: "prevents"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0309872:PREVENT [Pharmacologic Substance]
  1000   C1292733:Prevents [Functional Concept]

Phrase: "diabetes-induced arterial wall protein"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   804   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "cross-linking."
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
  1000   C0332220:Cross-linking [Functional Concept]
   983 E C0178576:Cross link [Natural Phenomenon or Process]
   861   C2828360:Cross [Conceptual Entity]
   827   C1517892:Link [Intellectual Product]
   827   C1704666:Link [Intellectual Product]
Processing 00000000.tx.283: Science 232:16291632[Medline] Charonis AS, Reger LA, Dege JE, Kouzi-Koliakos K, Furcht LT, Wohlhueter RM, Tsilibary EC 1990 Laminin alterations after in vitro nonenzymatic glycosylation. 

Phrase: "Science 232"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0036397:Science [Occupation or Discipline]

Phrase: ":"

Phrase: "16291632"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Charonis AS,"

Phrase: "Reger LA,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0023031:La [Element, Ion, or Isotope]

Phrase: "Dege JE,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0454673:JE [Geographic Area]
   861   C1550752:JE [Temporal Concept]

Phrase: "Kouzi-Koliakos K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   827   C1708601:K' [Quantitative Concept]

Phrase: "Furcht LT,"

Phrase: "Wohlhueter RM,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2951520:RM [Body Location or Region]

Phrase: "Tsilibary EC 1990 Laminin alterations after in vitro nonenzymatic glycosylation."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   706   C1515926:Alteration [Idea or Concept]
Processing 00000000.tx.284: Diabetes 39:807814[Abstract] Kumari K, Umar S, Bansal V, Sahib MK 1991 Inhibition of diabetes-associated complications by nucleophilic compounds. 

Phrase: "Diabetes 39"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0011847:Diabetes [Disease or Syndrome]
   861   C0011849:Diabetes [Disease or Syndrome]

Phrase: ":"

Phrase: "807814"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] Kumari K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Umar S,"

Phrase: "Bansal V,"

Phrase: "Sahib MK 1991 Inhibition of diabetes-associated complications"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   744   C0021467:Inhibition [Mental Process]
   744   C0021469:Inhibition [Molecular Function]
   744   C1628982:% inhibition [Quantitative Concept]
   744   C3463820:Inhibition [Activity]

Phrase: "by nucleophilic compounds."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0205198:Compound [Qualitative Concept]
   827   C1706082:Compound [Chemical]
Processing 00000000.tx.285: Diabetes 40:10791084[Abstract] Makita Z, Vlassara H, Cerami A, Bucala R 1992 Immunochemical detection of advanced glycosylation end products in vivo. 

Phrase: "Diabetes 40"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0011847:Diabetes [Disease or Syndrome]
   861   C0011849:Diabetes [Disease or Syndrome]
   861   C0439509:/40 [Temporal Concept]

Phrase: ":"

Phrase: "10791084"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] Makita Z,"

Phrase: "Vlassara H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Cerami A,"

Phrase: "Bucala R 1992 Immunochemical detection of advanced glycosylation end products"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   739   C1511790:Detection [Therapeutic or Preventive Procedure]

Phrase: "in vivo."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1515655:In Vivo [Spatial Concept]
           vivo
Processing 00000000.tx.286: J Biol Chem 267:51335138[Abstract/Free FullText] Hammes HP, Martin S, Federlin K, Geisen K, Brownlee M 1991 Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. 

Phrase: "J Biol Chem 267"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0201682:CHEM [Laboratory Procedure]

Phrase: ":"

Phrase: "51335138"

Phrase: "[Abstract/Free FullText"

Phrase: "] Hammes HP,"

Phrase: "Martin S,"

Phrase: "Federlin K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Geisen K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Brownlee M 1991 Aminoguanidine treatment"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   804   C0039798:treatment [Functional Concept]
   804   C0087111:Treatment [Therapeutic or Preventive Procedure]
   804   C1522326:Treatment [Functional Concept]
   804   C1533734:Treatment [Therapeutic or Preventive Procedure]
   804   C1705169:Treatment [Conceptual Entity]
   804   C3538994:TREATMENT [Research Activity]

Phrase: "inhibits"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   944   C0018790:arrested [Disease or Syndrome]
   944   C0237477:Arrest [Temporal Concept]
   944   C0392351:arrest [Governmental or Regulatory Activity]
   944   C0521111:Retarded [Qualitative Concept]
   916 E C0311403:Inhibited [Qualitative Concept]
   916 E C3463820:Inhibiting [Activity]

Phrase: "the development of experimental diabetic retinopathy."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0243107:development [Physiologic Function]
   753   C0678723:Development [Organism Function]
   753   C1527148:Development [Functional Concept]
Processing 00000000.tx.287: Proc Natl Acad Sci USA 88:1155511558[Abstract] Yagihashi S, Kamijo M, Baba M, Yagihashi N, Nagai K 1992 Effect of aminoguanidine on functional and structural abnormalities in peripheral nerve of STZ-induced diabetic rats. 

Phrase: "Proc Natl Acad Sci USA 88"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   799   C0041703:USA [Geographic Area]
   799   C0268596:ACAD [Disease or Syndrome]
   799   C1418943:PROC [Gene or Genome]
   799   C2700624:ACAD [Cell Function]
   799   C3642273:SCI [Professional or Occupational Group]

Phrase: ":"

Phrase: "1155511558"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] Yagihashi S,"

Phrase: "Kamijo M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Baba M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Yagihashi N,"

Phrase: "Nagai K 1992 Effect of aminoguanidine"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C1280500:Effect [Qualitative Concept]
   753   C2348382:Effect [Qualitative Concept]

Phrase: "on functional"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205245:Functional [Functional Concept]
  1000   C0542341:Functional [Functional Concept]
  1000   C2700217:Functional [Conceptual Entity]

Phrase: "and"

Phrase: "structural abnormalities in peripheral nerve of STZ-induced diabetic rats."
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   739   C0000768:Abnormalities [Congenital Abnormality]
   739   C0000769:abnormalities [Functional Concept]
   706 E C1704258:Abnormality [Finding]
Processing 00000000.tx.288: Diabetes 41:4752[Abstract] Edelstein D, Brownlee M 1992 Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine. 

Phrase: "Diabetes 41"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0011847:Diabetes [Disease or Syndrome]
   861   C0011849:Diabetes [Disease or Syndrome]

Phrase: ":"

Phrase: "4752"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] Edelstein D,"

Phrase: "Brownlee M 1992 Mechanistic studies of advanced glycosylation end product inhibition"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   756   C2698671:MECHANISTIC STUDIES [Regulation or Law]
   738   C0947630:studies [Laboratory Procedure]
   704 E C0557651:Study [Manufactured Object]
   704 E C2603343:Study [Research Activity]

Phrase: "by aminoguanidine."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0282774:aminoguanidine [Organic Chemical,Pharmacologic Substance]
Processing 00000000.tx.289: Diabetes 41:2629[Abstract] Schindler U, Rush DK, Fielding S 1994 Animal models for studying effects on cognition. 

Phrase: "Diabetes 41"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0011847:Diabetes [Disease or Syndrome]
   861   C0011849:Diabetes [Disease or Syndrome]

Phrase: ":"

Phrase: "2629"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] Schindler U,"

Phrase: "Rush DK,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0011318:DK [Geographic Area]

Phrase: "Fielding S 1994 Animal models for studying effects"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   770   C0599779:Models, Animal [Animal]
   750   C0026336:Study models [Intellectual Product,Research Device]
   750   C0683949:Animal Study [Animal]
   744   C0003062:Animal [Animal]
   744   C3161035:Models [Intellectual Product]

Phrase: "on cognition."
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0009240:Cognition [Mental Process]
   916 E C2981149:Intellect [Mental Process]
   907 E C0233698:Noesis [Mental or Behavioral Dysfunction]
Processing 00000000.tx.290: Drug Dev Res 4:567576 Saletu B, Grunberger J, Cepho H 1986 Pharmacokinetic and -dynamic studies in elderlies with a potential antihypoxidotic/nootropic drug tenilsetam utilizing pharmaco-EEG and psychometry. 

Phrase: "Drug Dev Res 4"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   812   C0013227:Drug [Pharmacologic Substance]
   812   C1254351:Drug [Pharmacologic Substance]
   812   C2347379:RES [Finding]
   756 E C0031336:Pharmaceutical [Biomedical Occupation or Discipline]
   756 E C1135440:pharmaceutical [Therapeutic or Preventive Procedure]
   719 E C0456386:Medicament [Pharmacologic Substance]

Phrase: ":"

Phrase: "567576 Saletu B,"

Phrase: "Grunberger J,"

Phrase: "Cepho H 1986 Pharmacokinetic"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0201734:PHARMACOKINETIC [Research Activity]

Phrase: "and -"

Phrase: "dynamic studies in elderlies"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   770   C0947630:studies [Laboratory Procedure]
   737 E C0557651:Study [Manufactured Object]
   737 E C2603343:Study [Research Activity]

Phrase: "with a potential antihypoxidotic/nootropic drug tenilsetam utilizing pharmaco-EEG"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   793   C0013819:EEG, NOS [Diagnostic Procedure]

Phrase: "and"

Phrase: "psychometry."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   928   C0033920:Psychometric [Diagnostic Procedure]
Processing 00000000.tx.291: Drug Dev Res 9:95113 Saletu B, Grunberger J, Andere P 1987 Proof of antihypoxidotic properties of tenilsetam in man by EEG and psychometric analysis under an experimental hypoxic hypoxidosis. 

Phrase: "Drug Dev Res 9"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   812   C0013227:Drug [Pharmacologic Substance]
   812   C1254351:Drug [Pharmacologic Substance]
   812   C2347379:RES [Finding]
   756 E C0031336:Pharmaceutical [Biomedical Occupation or Discipline]
   756 E C1135440:pharmaceutical [Therapeutic or Preventive Procedure]
   719 E C0456386:Medicament [Pharmacologic Substance]

Phrase: ":"

Phrase: "95113 Saletu B,"

Phrase: "Grunberger J,"

Phrase: "Andere P 1987 Proof of antihypoxidotic properties of tenilsetam"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   742   C0556981:% proof [Quantitative Concept]

Phrase: "in man"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0024554:MAN [Finding]
  1000   C0025266:Man [Population Group]
  1000   C0086418:Man [Human]

Phrase: "by EEG"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0013819:EEG, NOS [Diagnostic Procedure]

Phrase: "and"

Phrase: "psychometric analysis under an experimental hypoxic hypoxidosis."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   748   C0002778:Analysis [Laboratory Procedure]
   748   C0936012:Analysis [Research Activity]
   748   C1524024:analysis [Functional Concept]
Processing 00000000.tx.292: Drug Dev Res 10:133155 Dierks T, Maurer K, Ihl R 1989 Influence of tenilsetam on AEP-P300 in Alzheimers disease. 

Phrase: "Drug Dev Res 10"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   812   C0013227:Drug [Pharmacologic Substance]
   812   C1254351:Drug [Pharmacologic Substance]
   812   C2347379:RES [Finding]
   756 E C0031336:Pharmaceutical [Biomedical Occupation or Discipline]
   756 E C1135440:pharmaceutical [Therapeutic or Preventive Procedure]
   719 E C0456386:Medicament [Pharmacologic Substance]

Phrase: ":"

Phrase: "133155 Dierks T,"

Phrase: "Maurer K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Ihl R 1989 Influence of tenilsetam"

Phrase: "on AEP-P300"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C1333336:p300 [Gene or Genome]
   861   C1530358:p300 [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   861   C1705458:p300 [Gene or Genome]

Phrase: "in Alzheimers disease."
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0002395:Alzheimers disease [Disease or Syndrome]
   861   C0012634:Disease [Disease or Syndrome]
   805 E C1836721:MALS [Finding]
   805 E C3538764:MALS [Gene or Genome]
   805 E C3540595:MAL [Gene or Genome]
Processing 00000000.tx.293: J Neural Transm 1:49 Ihl R, Perisic I, Maurer K, Dierks T 1989 Effect of 3 months treatment with tenilsetam in patients suffering from dementia of Alzheimer type (DAT). 

Phrase: "J Neural Transm 1"
Meta Candidates (Total=5; Excluded=4; Pruned=0; Remaining=1)
   812   C0599851:Neural [Functional Concept]
   756 E C0027740:Nerve [Tissue]
   756 E C0027757:NERVE [Tissue]
   756 E C1280541:Nerve [Body Part, Organ, or Organ Component]
   719 E C0027769:nervy [Sign or Symptom]

Phrase: ":"

Phrase: "49 Ihl R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0205090:R- [Spatial Concept]
   827   C0684010:R. [Professional or Occupational Group]
   827   C2603358:R' [Clinical Attribute]

Phrase: "Perisic I,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0021966:I- [Inorganic Chemical]
   861   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "Maurer K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Dierks T 1989 Effect of 3 months treatment"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   767   C1518681:Treatment Effect [Finding]
   744   C1280500:Effect [Qualitative Concept]
   744   C2348382:Effect [Qualitative Concept]

Phrase: "with tenilsetam"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0076093:tenilsetam [Organic Chemical,Pharmacologic Substance]

Phrase: "in patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "suffering from dementia of Alzheimer type (DAT)."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   820   C0002395:Dementia, Alzheimer Type [Disease or Syndrome]
           Alzheimer's Dementia
   753   C0011265:dementia [Mental or Behavioral Dysfunction]
   753   C0332307:Type [Qualitative Concept]
   753   C0497327:Dementia [Mental or Behavioral Dysfunction]
   753   C0683278:Suffering [Mental or Behavioral Dysfunction]
   753   C1547052:*Type [Quantitative Concept]
Processing 00000000.tx.294: J Neural Transm 1:8485 Smith MA, Taneda S, Richey PL, Miyata S, Yan SD, Stern D, Sayre LM, Monnier VM, Perry G 1994 Advanced Maillard reaction end products are associated with Alzheimer disease pathology. 

Phrase: "J Neural Transm 1"
Meta Candidates (Total=5; Excluded=4; Pruned=0; Remaining=1)
   812   C0599851:Neural [Functional Concept]
   756 E C0027740:Nerve [Tissue]
   756 E C0027757:NERVE [Tissue]
   756 E C1280541:Nerve [Body Part, Organ, or Organ Component]
   719 E C0027769:nervy [Sign or Symptom]

Phrase: ":"

Phrase: "8485 Smith MA,"

Phrase: "Taneda S,"

Phrase: "Richey PL,"

Phrase: "Miyata S,"

Phrase: "Yan SD,"

Phrase: "Stern D,"

Phrase: "Sayre LM,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C1261082:LM [Body Part, Organ, or Organ Component]
   861   C1551056:lm [Quantitative Concept]
   861   C2981682:LM [Quantitative Concept]

Phrase: "Monnier VM,"

Phrase: "Perry G 1994 Advanced Maillard reaction end products"
Meta Candidates (Total=7; Excluded=4; Pruned=0; Remaining=3)
   793   C0444930:End [Spatial Concept]
   793   C1514468:Products [Entity]
   793   C2746065:End [Temporal Concept]
   760 E C1704444:Product [Quantitative Concept]
   737 E C0205088:Terminal [Temporal Concept]
   737 E C1705314:Terminal [Manufactured Object]
   737 E C1705315:Terminal [Spatial Concept]

Phrase: "are"

Phrase: "associated with Alzheimer disease pathology."
Meta Candidates (Total=14; Excluded=5; Pruned=0; Remaining=9)
   806   C0002395:Alzheimer's Disease [Disease or Syndrome]
   806   C0332281:Associated with [Qualitative Concept]
           Associated
   806   C1521724:Alzheimer's Disease [Pathologic Function]
   797   C0243083:associated disease [Pathologic Function]
   760   C0012634:Disease [Disease or Syndrome]
   760   C0030664:Pathology [Biomedical Occupation or Discipline]
   760   C0205469:pathology [Functional Concept]
   760   C0677042:pathology [Pathologic Function]
   726 E C0750490:Associate [Idea or Concept]
   726 E C1706221:Associate [Professional or Occupational Group]
   704 E C1836721:MALS [Finding]
   704 E C3538764:MALS [Gene or Genome]
   704 E C3540595:MAL [Gene or Genome]
Processing 00000000.tx.295: Proc Natl Acad Sci USA 91:57105714[Abstract] Vitek MP, Bhattacharya K, Glendening JM, Stopa E, Vlassara H, Bucala R, Manggue K, Cerami A 1994 Advanced glycation end products contribute to amyloidosis in Alzheimer disease. 

Phrase: "Proc Natl Acad Sci USA 91"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   799   C0041703:USA [Geographic Area]
   799   C0268596:ACAD [Disease or Syndrome]
   799   C1418943:PROC [Gene or Genome]
   799   C2700624:ACAD [Cell Function]
   799   C3642273:SCI [Professional or Occupational Group]

Phrase: ":"

Phrase: "57105714"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] Vitek MP,"

Phrase: "Bhattacharya K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Glendening JM,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0022337:JM [Geographic Area]

Phrase: "Stopa E,"

Phrase: "Vlassara H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Bucala R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Manggue K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Cerami"

Phrase: "A 1994 Advanced glycation end products"
Meta Candidates (Total=11; Excluded=5; Pruned=0; Remaining=6)
   937   C0162574:Glycation End Products, Advanced [Biologically Active Substance,Organic Chemical]
   804   C0205179:Advanced [Qualitative Concept]
   804   C0444930:End [Spatial Concept]
   804   C0598528:glycation [Phenomenon or Process]
   804   C1514468:Products [Entity]
   804   C2746065:End [Temporal Concept]
   771 E C0725066:Advance [Medical Device]
   771 E C1704444:Product [Quantitative Concept]
   748 E C0205088:Terminal [Temporal Concept]
   748 E C1705314:Terminal [Manufactured Object]
   748 E C1705315:Terminal [Spatial Concept]

Phrase: "contribute to amyloidosis"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0002726:Amyloidosis [Disease or Syndrome]
   790   C1880177:Contribute [Activity]

Phrase: "in Alzheimer disease."
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
  1000   C0002395:Alzheimer's Disease [Disease or Syndrome]
  1000   C1521724:Alzheimer's Disease [Pathologic Function]
   861   C0012634:Disease [Disease or Syndrome]
   805 E C1836721:MALS [Finding]
   805 E C3538764:MALS [Gene or Genome]
   805 E C3540595:MAL [Gene or Genome]
Processing 00000000.tx.296: Proc Natl Acad Sci USA 91:47664770[Abstract] Khadem HE, Horton D, Meshreki MH, Nahed MA 1971 New route for the synthesis of 3-deoxyaldose-2-uloses. 

Phrase: "Proc Natl Acad Sci USA 91"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   799   C0041703:USA [Geographic Area]
   799   C0268596:ACAD [Disease or Syndrome]
   799   C1418943:PROC [Gene or Genome]
   799   C2700624:ACAD [Cell Function]
   799   C3642273:SCI [Professional or Occupational Group]

Phrase: ":"

Phrase: "47664770"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] Khadem"

Phrase: "HE,"

Phrase: "Horton D,"

Phrase: "Meshreki MH,"

Phrase: "Nahed MA 1971 New route for the synthesis"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   744   C0013153:ROUTE [Functional Concept]
   744   C0449444:Route [Spatial Concept]
   744   C1879941:ROUTE [Intellectual Product]

Phrase: "of 3-deoxyaldose-2-uloses."
Processing 00000000.tx.297: Carbohydr Res 17:183192[CrossRef] Kato H, Chuyen N, Shinoda T, Sekiya F, Hayase F 1990 Metabolism of 3-deoxyglucosone, an intermediate compound in the Maillard reaction, administered orally or intravenously to rats. 

Phrase: "Carbohydr Res 17"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C2347379:RES [Finding]

Phrase: ":"

Phrase: "183192"

Phrase: "[CrossRef"

Phrase: "] Kato H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Chuyen N,"

Phrase: "Shinoda T,"

Phrase: "Sekiya F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Hayase F 1990 Metabolism of 3-deoxyglucosone,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C0025519:Metabolism [Organism Function]
   748   C0025520:metabolism [Functional Concept]

Phrase: "an intermediate compound in the Maillard reaction,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C0205198:Compound [Qualitative Concept]
   748   C1706082:Compound [Chemical]

Phrase: "administered"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1521801:Administered [Functional Concept]
   966 E C1621583:Administer [Functional Concept]

Phrase: "orally"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0442027:Orally [Spatial Concept]

Phrase: "or"

Phrase: "intravenously to rats."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0034693:rats [Mammal]
   790   C0034721:Rats [Mammal]
Processing 00000000.tx.298: Biochim Biophys Acta 1035:7176[Medline] Bradford M 1976 A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. 

Phrase: "Biochim Biophys Acta 1035"

Phrase: ":"

Phrase: "7176"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Bradford M 1976"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C0441923:M+ [Intellectual Product]

Phrase: "A rapid"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439831:Rapid [Qualitative Concept]

Phrase: "and"

Phrase: "sensitive method for the quantitation of microgram quantities of protein"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   741   C1547724:Quantity method [Idea or Concept]
   739   C0025663:Method [Intellectual Product]
   739   C0449851:Method [Functional Concept]
   739   C0871511:METHOD [Intellectual Product]

Phrase: "utilizing"

Phrase: "the principle of protein-dye binding."
Processing 00000000.tx.299: Ann Biochem 72:248254[CrossRef] Weber K, Osborn M 1969 The reliability of molecular weight determination by dodecyl sulfate-polyacrylamide gel electrophoresis. 

Phrase: "Ann Biochem 72"

Phrase: ":"

Phrase: "248254"

Phrase: "[CrossRef"

Phrase: "] Weber K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Osborn M 1969"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C0441923:M+ [Intellectual Product]

Phrase: "The reliability of molecular weight determination"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C2347947:Reliability [Quantitative Concept]

Phrase: "by dodecyl sulfate-polyacrylamide gel electrophoresis."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   884   C0013862:Polyacrylamide Gel Electrophoresis [Laboratory Procedure]
   840   C0071500:Polyacrylamide Gel [Biomedical or Dental Material,Pharmacologic Substance]
   840   C0596607:Gel Electrophoresis [Laboratory Procedure]
   804   C0013855:Electrophoresis [Laboratory Procedure]
   804   C0017243:Gel [Biomedical or Dental Material]
   804   C0071499:polyacrylamide [Biomedical or Dental Material,Organic Chemical]
   804   C1382104:Gel [Substance]
Processing 00000000.tx.300: J Biol Chem 244:44064412[Abstract/Free FullText] Stegemann H, Stalder K 1967 Determination of hydroxyproline. 

Phrase: "J Biol Chem 244"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0201682:CHEM [Laboratory Procedure]

Phrase: ":"

Phrase: "44064412"

Phrase: "[Abstract/Free FullText"

Phrase: "] Stegemann H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Stalder K 1967 Determination of hydroxyproline."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C1148554:determination [Laboratory Procedure]
Processing 00000000.tx.301: Clin Chim Acta 18:267273[CrossRef][Medline] Raabo E, Terkildsen TC 1960 On the enzymatic determination of blood glucose. 

Phrase: "Clin Chim Acta 18"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C1315013:CLIN [Intellectual Product]

Phrase: ":"

Phrase: "267273"

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Raabo E,"

Phrase: "Terkildsen TC 1960 On the enzymatic determination of blood glucose."
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   760   C0005802:Blood Glucose [Carbohydrate]
   739   C0005767:Blood [Tissue]
   739   C0005768:blood [Body Substance]
   739   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
   739   C0041405:TC [Geographic Area]
   739   C0229664:Blood [Body Substance]
   739   C1148554:determination [Laboratory Procedure]
   739   C1824670:TC [Gene or Genome]
   739   C3272447:TC [Gene or Genome]
Processing 00000000.tx.302: Scand J Clin Lab Invest 12:402407 Miyata S, Monnier VM 1992 Immunohistochemical detection of advanced glycosylation end products in diabetic tissues using monoclonal antibody to pyrraline. 

Phrase: "Scand J Clin Lab"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   812   C0022877:Lab [Manufactured Object,Organization]
   756 E C0035100:Rennin [Amino Acid, Peptide, or Protein,Enzyme,Pharmacologic Substance]
   729 E C0587081:Labs [Finding]

Phrase: "Invest"

Phrase: "12"

Phrase: ":"

Phrase: "402407 Miyata S,"

Phrase: "Monnier VM 1992 Immunohistochemical detection of advanced glycosylation end products"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   739   C1511790:Detection [Therapeutic or Preventive Procedure]

Phrase: "in diabetic tissues"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0040300:Tissues [Tissue]
   827 E C1547928:Tissue [Intellectual Product]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "monoclonal antibody to pyrraline."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   833   C0003250:Monoclonal antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   770   C0003241:Antibody [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   770   C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   770   C0746619:monoclonal [Finding]
Processing 00000000.tx.303: J Clin Invest 89:11021112[Medline] Yamada H, Miyata S, Igaki N, Yatabe H, Miyauchi Y, Ohara T, Sakai M, Shoda H, Oimomi M, Kasuga M 1994 Increase in 3-deoxyglucosone levels in diabetic rat plasma. 

Phrase: "J"

Phrase: "Clin"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1315013:CLIN [Intellectual Product]

Phrase: "Invest"

Phrase: "89"

Phrase: ":"

Phrase: "11021112"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Yamada H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Miyata S,"

Phrase: "Igaki N,"

Phrase: "Yatabe H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Miyauchi Y,"

Phrase: "Ohara T,"

Phrase: "Sakai M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Shoda H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Oimomi M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Kasuga M 1994 Increase in 3-deoxyglucosone levels"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   744   C0442805:Increase [Functional Concept]

Phrase: "in diabetic rat plasma."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0032105:Plasma [Body Substance]
   827   C1550098:Plasma, NOS (not otherwise specified) [Body Substance]
Processing 00000000.tx.304: J Biol Chem 269:2027520280[Abstract/Free FullText] Schnider SL, Kohn RR 1981 Effect of age and diabetes mellitus on the solubility and nonenzymatic glucosylation of human skin collagen. 

Phrase: "J Biol Chem 269"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0201682:CHEM [Laboratory Procedure]

Phrase: ":"

Phrase: "2027520280"

Phrase: "[Abstract/Free FullText"

Phrase: "] Schnider SL,"

Phrase: "Kohn RR 1981 Effect of age"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C1280500:Effect [Qualitative Concept]
   753   C2348382:Effect [Qualitative Concept]

Phrase: "and"

Phrase: "diabetes mellitus on the solubility"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   806   C0011849:Diabetes Mellitus [Disease or Syndrome]
           Diabetes
   760   C0011847:Diabetes [Disease or Syndrome]

Phrase: "and"

Phrase: "nonenzymatic glucosylation of human skin collagen."
Processing 00000000.tx.305: J Clin Invest 67:16301635[Medline] Brennan M 1989 Changes in solubility, non-enzymatic glycation and fluorescence of collagen in tail tendons from diabetic rats. 

Phrase: "J"

Phrase: "Clin"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1315013:CLIN [Intellectual Product]

Phrase: "Invest"

Phrase: "67"

Phrase: ":"

Phrase: "16301635"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Brennan M 1989 Changes in solubility,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   753   C0392747:changes [Functional Concept]
   753   C0443172:changes [Quantitative Concept]
   719 E C1705241:Change [Quantitative Concept]

Phrase: "non-enzymatic glycation"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0598528:glycation [Phenomenon or Process]

Phrase: "and"

Phrase: "fluorescence of collagen"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   790   C0016315:Fluorescence [Natural Phenomenon or Process]
   718 E C0303920:Fluorescent [Indicator, Reagent, or Diagnostic Aid,Organic Chemical]

Phrase: "in tail tendons"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0039508:Tendons [Body Part, Organ, or Organ Component]
   827 E C1280538:Tendon [Body Part, Organ, or Organ Component]

Phrase: "from diabetic rats."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0034693:rats [Mammal]
   861   C0034721:Rats [Mammal]
   861   C0241863:DIABETIC [Finding]
Processing 00000000.tx.306: J Biol Chem 264:2094720952[Abstract/Free FullText] McPherson JD, Shilton BH, Walton DJ 1988 Role of fructose in glycation and crosslinking of proteins. 

Phrase: "J Biol Chem 264"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0201682:CHEM [Laboratory Procedure]

Phrase: ":"

Phrase: "2094720952"

Phrase: "[Abstract/Free FullText"

Phrase: "] McPherson JD,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1549972:JD [Intellectual Product]

Phrase: "Shilton BH,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0004684:BH [Geographic Area]
   861   C1412800:BH [Gene or Genome]
   861   C2986890:BH [Idea or Concept]

Phrase: "Walton DJ 1988 Role of fructose"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0035820:Role [Social Behavior]
   753   C1705810:Role [Conceptual Entity]

Phrase: "in glycation"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0598528:glycation [Phenomenon or Process]

Phrase: "and"

Phrase: "crosslinking of proteins."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0178576:crosslinking [Natural Phenomenon or Process]
Processing 00000000.tx.307: Biochemistry 27:19011907[Medline] Dyer DG, Blackledge JA, Thorpe SR, Baynes JW 1991 Formation of pentosidine during nonenzymatic browning of proteins by glucose. 

Phrase: "Biochemistry 27"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0005477:Biochemistry [Occupation or Discipline]

Phrase: ":"

Phrase: "19011907"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "] Dyer DG,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1275573:dg [Quantitative Concept]

Phrase: "Blackledge JA,"

Phrase: "Thorpe SR,"

Phrase: "Baynes JW 1991 Formation of pentosidine"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0220781:formation [Biologic Function]
   753   C0439634:formation [Spatial Concept]
   753   C1522492:Formation [Functional Concept]

Phrase: "during nonenzymatic browning"

Phrase: "of proteins"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0033684:Proteins [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "by glucose."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0017725:Glucose [Biologically Active Substance,Carbohydrate,Pharmacologic Substance]
Processing 00000000.tx.308: Identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. 

Phrase: "Identification of glucose"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0020792:Identification [Mental Process]
   790   C0205396:Identification [Qualitative Concept]

Phrase: "and"

Phrase: "other carbohydrates as possible precursors of pentosidine"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0007004:Carbohydrates [Carbohydrate]

Phrase: "in vivo."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1515655:In Vivo [Spatial Concept]
           vivo
Processing 00000000.tx.309: J Biol Chem 266:1165411660[Abstract/Free FullText] Dyer DG, Dunn JA, Thorpe SR, Bailie KE, Lyons TJ, McCance DR, Baynes JW 1993 Accumulation of Maillard reaction products in skin collagen in diabetes and aging. 

Phrase: "J Biol Chem 266"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0201682:CHEM [Laboratory Procedure]

Phrase: ":"

Phrase: "1165411660"

Phrase: "[Abstract/Free FullText"

Phrase: "] Dyer DG,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1275573:dg [Quantitative Concept]

Phrase: "Dunn JA,"

Phrase: "Thorpe SR,"

Phrase: "Bailie KE,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0022558:KE [Geographic Area]

Phrase: "Lyons TJ,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0039247:TJ [Geographic Area]

Phrase: "McCance DR,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0031831:DR [Professional or Occupational Group]
   861   C1707664:DR [Biomedical or Dental Material]
   861   C2348314:Dr. [Conceptual Entity]
   861   C3540849:DR [Idea or Concept]

Phrase: "Baynes JW 1993 Accumulation of Maillard reaction products"

Phrase: "in skin collagen"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   861   C0009325:Collagen [Amino Acid, Peptide, or Protein,Biologically Active Substance,Biomedical or Dental Material]
   861   C1167364:collagen [Cell Component]
   789 E C0439689:Collagenous [Qualitative Concept]

Phrase: "in diabetes"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0011847:Diabetes [Disease or Syndrome]
  1000   C0011849:Diabetes [Disease or Syndrome]

Phrase: "and"

Phrase: "aging."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0001811:Ageing [Organism Function]
Processing 00000000.tx.310: J Clin Invest 91:24632469[Medline] Munch G, Tanell Y, Schraven E, Schindler U, Schinzel R, Palm D, Riederer P 1994 The cognition-enhancing drug tenilsetam is an inhibitor of protein crosslinking by advanced glycosylation. 

Phrase: "J"

Phrase: "Clin"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1315013:CLIN [Intellectual Product]

Phrase: "Invest"

Phrase: "91"

Phrase: ":"

Phrase: "24632469"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "Munch"

Phrase: "G,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439267:g% [Quantitative Concept]

Phrase: "Tanell Y,"

Phrase: "Schraven E,"

Phrase: "Schindler U,"

Phrase: "Schinzel R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Palm D,"

Phrase: "Riederer P 1994"

Phrase: "The cognition-enhancing drug tenilsetam"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0076093:tenilsetam [Organic Chemical,Pharmacologic Substance]

Phrase: "is"

Phrase: "an inhibitor of protein crosslinking"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C1999216:Inhibitor [Qualitative Concept]

Phrase: "by advanced glycosylation."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0017982:glycosylation [Natural Phenomenon or Process]
   861   C0376322:Glycosylation [Molecular Function]
Processing 00000000.tx.311: J Neural Transm 8:193208 Hayase F, Nagaraj RH, Miyata S, Njoroge FG, Monnier VM 1989 Aging of proteins: immunological detection of a glucose-derived pyrrole formed during Maillard reaction in vivo. 

Phrase: "J Neural Transm 8"
Meta Candidates (Total=5; Excluded=4; Pruned=0; Remaining=1)
   812   C0599851:Neural [Functional Concept]
   756 E C0027740:Nerve [Tissue]
   756 E C0027757:NERVE [Tissue]
   756 E C1280541:Nerve [Body Part, Organ, or Organ Component]
   719 E C0027769:nervy [Sign or Symptom]

Phrase: ":"

Phrase: "193208 Hayase F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   827   C0439133:(f) [Intellectual Product]
   827   C1553038:[f] [Quantitative Concept]

Phrase: "Nagaraj RH,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0035493:Rh [Element, Ion, or Isotope]
   861   C2699077:Rh- [Classification]
   861   C2699078:Rh+ [Classification]

Phrase: "Miyata S,"

Phrase: "Njoroge FG,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0439214:fg [Quantitative Concept]
   861   C2348814:FG [Quantitative Concept]

Phrase: "Monnier VM 1989 Aging of proteins"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0001811:Ageing [Organism Function]

Phrase: ":"

Phrase: "immunological detection of a glucose-derived pyrrole"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   804   C1658011:detection of glucose [Cell Function]
           glucose detection
   748   C1511790:Detection [Therapeutic or Preventive Procedure]

Phrase: "formed during Maillard reaction"
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
   833   C0024495:Maillard Reaction [Natural Phenomenon or Process]
   770   C0205431:Formed [Functional Concept]
   770   C0443286:Reaction [Functional Concept]
   770   C1114821:Reaction [Clinical Attribute]
   737 E C0348078:Form [Qualitative Concept]
   737 E C0376315:Form [Manufactured Object]
   737 E C1522492:Form [Functional Concept]

Phrase: "in vivo."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1515655:In Vivo [Spatial Concept]
           vivo
Processing 00000000.tx.312: J Biol Chem 264:37583764[Abstract/Free FullText] Vasan S, Zhang X, Zhang X, Kapurnitou A, Bernhagen J, Teichberg S, Basgen J, Wagle D, Shih D, Terlecky I, Bucala R, Cerami A, Egan J, Ulrich P 1996 An agent cleaving glucose-derived protein crosslinks in vitro and in vivo. 

Phrase: "J Biol Chem 264"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0201682:CHEM [Laboratory Procedure]

Phrase: ":"

Phrase: "37583764"

Phrase: "[Abstract/Free FullText"

Phrase: "] Vasan S,"

Phrase: "Zhang X,"

Phrase: "Zhang X,"

Phrase: "Kapurnitou A,"

Phrase: "Bernhagen J,"

Phrase: "Teichberg S,"

Phrase: "Basgen J,"

Phrase: "Wagle D,"

Phrase: "Shih D,"

Phrase: "Terlecky I,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0021966:I- [Inorganic Chemical]
   861   C0221138:I NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "Bucala R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Cerami A,"

Phrase: "Egan J,"

Phrase: "Ulrich P 1996"

Phrase: "An agent"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0450442:Agent [Chemical Viewed Functionally]
  1000   C1254351:Agent [Pharmacologic Substance]
  1000   C1521826:Agent [Intellectual Product]

Phrase: "cleaving"

Phrase: "glucose-derived protein"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   913   C2599779:Glucose & Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance,Carbohydrate]
   827   C0033684:Protein [Amino Acid, Peptide, or Protein,Biologically Active Substance]

Phrase: "crosslinks"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0178576:crosslink [Natural Phenomenon or Process]

Phrase: "in vitro"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0021135:In Vitro [Intellectual Product]
  1000   C1533691:in vitro [Qualitative Concept]
           vitro
  1000   C2827718:In Vitro [Functional Concept]

Phrase: "and"

Phrase: "in vivo."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1515655:In Vivo [Spatial Concept]
           vivo
Processing 00000000.tx.313: Nature 382:275278[CrossRef][Medline]

Phrase: "Nature 382"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   861   C0349590:Nature [Idea or Concept]
   861   C1262865:Nature [Functional Concept]
   789 E C0205296:Natural [Functional Concept]

Phrase: ":"

Phrase: "275278"

Phrase: "[CrossRef"

Phrase: "]"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

